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SUMMARY 
 
Malaria remains a detrimental tropical disease caused by the protozoan parasites known as Plasmodium and is 
threatening almost half the world's population. Nitric oxide (NO) and NO-derived reactive nitrogen species are 
well-known in vivo effector molecules for controlling the malaria parasites in both mosquito transmitting vectors 
and humans. However, NO targets and the profound mechanism of NO actions in the malaria parasites remain 
largely unexplored. Protein S-nitrosylation (SNO), a protein posttranslational modification induced by NO and 
RNS, has been recognized to substantially mediate diverse biological effects of NO in vivo. In this thesis, we 
describe a comprehensive analysis of protein S-nitrosylation in the most deadly malaria parasite Plasmodium 
falciparum. By using a biotin-switch assay coupled with mass spectrometry, we have identified, for the first time, 
319 potential S-nitrosylation targets in Plasmodium falciparum that are widespread in various cellular pathways. 
Interestingly, some metabolic pathways such as glycolysis show an accumulation of S-nitrosylated proteins, 
indicating a high susceptibility to NO-mediated regulation. A major redox protein, P. falciparum thioredoxin 1 
(PfTrx1) was found to be able to transfer or remove NO to or from other proteins, thus possibly mediating the 
transnitrosylation and denitrosylation in the parasites. We thus propose a redox status-based model of the role of 
PfTrx1 in the regulation of SNO in P. falciparum. The model suggests that PfTrx1 may protect the parasite from 
nitrosative stress via protein denitrosylation, whereas upon intensive nitrosative stress PfTrx1 may switch its role 
to transduce nitrosative stress via protein transnitrosylation. We believe that this study contributes to our 
understanding of how central metabolic processes in malaria parasites are regulated by NO and suggests that P. 
falciparum employs the thioredoxin system to deal with the nitrosative challenge. 
The protein turnover via the ubiquitin-proteasome system (UPS) is well-acknowledged as an essential 
mechanism profoundly involved in many cellular events in eukaryotes. The classical UPS pathway in eukaryotes 
typically consists of polyubiquitination of protein substrates, polyubiquitinylated substrates transportation, and 
substrate recognition by the eukaryotic 26S proteasome, and substrate degradation by the proteasome. Although 
compelling data have indicated the presence of a functional 26S proteasome network in P. falciparum, the 
componential integrity and the functionality of the plasmodial 26S proteasome has not been systematically 
studied so far. In this thesis, we aimed to characterize the mechanism of substrate recognition by the 26S 
proteasome of P. falciparum. By using in silico analysis and biochemical investigations, we have identified three 
ubiquitin receptor domains inherited by two plasmodial proteasome subunits, the Rpn10 and Rpn13 subunits. 
These newly identified plasmodial ubiquitin receptor domains include two putative ubiquitin-interacting motif 
(UIM) domains and a putative Pleckstrin-like receptor for ubiquitin (Pru) domain. The P. falciparum UIM 
domains (PfUIMs) and Pru domain (PfPru) were demonstrated to bind ubiquitin-like domains (UBLs) from the 
plasmodial homologues of Rad23 and Dsk2, which are important UBL-containing proteins involved in the 
transportation of proteasomal substrates to the 26S proteasome. Strikingly, only PfUIM2 domain was found to be 
able to directly bind polyubiquitin chains, indicating that PfUIM2 is the site for the direct recognition of 
polyubiquitinylated substrates for proteasomal degradation. Based on the affinity of PfUIM2 domain to the UBL 
domain of the plasmodial Rad23, we successfully established a simple and efficient affinity purification method 
Summary 
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to isolate the P. falciparum 26S proteasome complex together with a number of putative proteasome-interacting 
proteins (PIPs) directly from the parasite extracts. With this method, we provide the first insight into the 
componential composition of the plasmodial 26S proteasome. More importantly, the co-purification of putative 
PIPs in P. falciparum has allowed us to take a first view of the protein metabolism network orchestrated by the 
plasmodial UPS, and may provide new targets for developing novel antimalarial agents targeting the plasmodial 
UPS or related pathways. 
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ZUSAMMENFASSUNG 
 
Die verheerende tropische Erkrankung Malaria wird durch Protozoen, bekannt als Plasmodien, hervorgerufen 
und bedroht fast die Hälfte der Weltbevölkerung. Stickstoffmonoxid (NO) und die von ihm abgeleiteten 
reaktiven Stickstoffspezies (RNS) sind bekannte in vivo Effektormoleküle, welche den Malariaparasiten sowohl 
im transmittierenden Vektor als auch im Menschen kontrollieren. Jedoch gilt der profunde Mechanismus des 
NO-Einflusses und seine Zielmoleküle im Malariaerreger als weitgehend unerforscht. Die S-Nitrosylierung von 
Proteinen (SNO), eine posttranslationale Modifikation induziert durch NO und RNS, stellt einen substantiellen 
Mediator diverser biologischer Effekte von NO in vivo dar. Mit dieser Arbeit stellen wir eine umfassende 
Analyse der S-Nitrosylierung von Proteinen in dem tödlichsten der Malariaparasiten, Plasmodium falciparum, 
dar. Durch die Anwendung des Biotin Switch Assays gekoppelt mit Massenspektrometrie gelang es uns zum 
ersten Mal 319 potentielle Ziele der S-Nitrosylierung in Plasmodium falciparum darzustellen, die in einer 
Vielzahl von zellulären Abläufen zu finden sind. Interessanterweise zeigen einige Stoffwechselwege, wie die 
Glykolyse, eine Akkumulation von S-nitrosylierten Proteinen, welches eine hohe Empfänglichkeit für 
NO-vermittelte Regulationen vermuten lässt. Das wichtige Redoxprotein Thioredoxin 1 aus P. falciparum 
(PfTrx1) konnte als möglicher Vermittler von Transnitrosylierung oder Denitrosylierung im Parasiten 
identifiziert werden, indem es in der Lage ist, NO zu anderen Proteinen zu transportieren oder diese von ihnen zu 
entfernen. Wir vermuten folglich ein Redoxstatus-basiertes Modell der Rolle von PfTrx1 in der Regulation von 
SNO in P. falciparum. Das Modell weist darauf hin, dass PfTrx1 den Parasiten vor Stickstoffstress durch 
Denitrosylierung von Proteinen schützen kann, wohingegen PfTrx1 bei hohem NO bedingtem Stress seine 
Funktion zur Transnitrosylierung von Proteinen ändert. Wir sind der Meinung, dass diese Arbeit zum 
Verständnis beiträgt, wie zentrale metabolische Prozesse im Malariaparasiten durch NO reguliert werden können 
und vermuten, dass P. falciparum das Thioredoxsystem nutzt, um Stickstoffstress entgegenzuwirken.  
Der Proteinumsatz durch das Ubiquitin-Proteasom-System (UPS) ist als essentieller Mechanismus, der 
tiefgreifend in viele zelluläre Ereignisse in Eukaryoten eingreift, bekannt. Der klassische UPS-Weg in 
Eukaryoten besteht typischerweise aus einer Polyubiquitinylierung von Proteinsubstraten, deren Transport und 
Substraterkennung durch das eukaryotische 26S Proteasom sowie der Degradation dieser Substrate durch das 
Proteasom. Obwohl eindeutige Daten die Präsenz eines funktionellen 26S-Proteasom-Netzwerkes in P. 
falciparum vermuten lassen, wurde die Integrität und Funktionalität des plasmodialen 26S Proteasoms bisher 
nicht systematisch erforscht. Mit der vorliegenden Arbeit adressieren wir eine Charakterisierung des 
Mechanismus der Substraterkennung des 26S Proteasoms von P. falciparum. Durch die Verwendung von in 
silico Analysen und biochemischen Untersuchungen konnten wir drei Ubiquitin-Rezeptoreinheiten auf zwei 
plasmodialen Proteasom-Untereinheiten, Rpn10 und Rpn13, bestimmen. Diese neu identifizierten plasmodialen 
Ubiquitin-Rezeptoreinheiten beinhalten zwei potentielle Ubiquitin-Interaktionsmotive (UIM) und eine 
potentielle Pleckstrin-like Rezeptordomäne für Ubiquitin (Pru). Die P. falciparum UIM-Domänen (PfUIMs) und 
Pru-Domäne (PfPru) können an Ubiquitin-like-Domänen (UBLs) der plasmodialen Homologe von Rad23 und 
Dsk2 binden, welche wichtige UBL-beinhaltende Proteine darstellen, die im Transport zum 26S Proteasom 
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involviert sind. Erstaunlicherweise war nur PfUIM2 in der Lage direkt Ubiquitinketten zu binden, was darauf 
hinweist, dass PfUIM2 zur direkten Erkennung von polyubiquitinylierten Substraten zur proteasomalen 
Degradation dient. Basierend auf der Affinität der PfUIM2-Domäne zur UBL-Domäne der plasmodialen Rad23, 
konnten wir eine einfache und effektive Methode der Affinitätsreinigung zur direkten Isolierung des P. 
falciparum 26S Proteasomskomplexes zusammen mit einer Reihe potentieller Proteasom-interagierender 
Proteine (PIPs) aus dem Parasitenextrakt entwickeln. Mit dieser Methode konnten wir erste Einblicke in die 
Zusammenstellung der Komponenten des plasmodialen 26S Proteasoms liefern. Zudem erlaubte uns die 
Co-Reinigung der potentiellen PIPs aus P. falciparum einen ersten Blick auf das metabolische Proteinnetzwerk 
instrumentalisiert durch das plasmodiale UPS und bietet neue Ziele zur Entwicklung neuartiger 
Antimalariawirkstoffe, welche auf die plasmodiale UPS oder verwandte Stoffwechselwege abzielt.  
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1. INTRODUCTION 
1.1 Malaria 
1.1.1 Malaria 
Malaria is the most serious tropical disease caused by protozoan parasites of the genus Plasmodium, which are 
transmitted to human hosts by the infected Anopheles mosquito. Patients with malaria often experience chills, 
fever, headache, and flu-like illness. Left untreated, they may develop severe complications and die (CDC 
website 2013). 
Historically, the term “Malaria” originates from Medieval Italian “mal’ aria” meaning "bad air" (Tuteja 2007). 
Between 1880 and 1890, the causative agents of malaria – the Plasmodium parasites – were identified, and the 
transmission of the parasites between humans and mosquitoes were also discovered (Chernin 1988; Guillemin 
2002). In 1900, more than 77% of the world’s population in 140 countries was at risk of malaria (Hay et al., 
2004). Malaria used to be widespread in temperate regions until the middle of the 20th century but was wiped 
out after the “Global Malaria Eradication Program” between 1955 and 1969 (Hay et al., 2004). This campaign 
against malaria was successful by relying on malaria treatment with chloroquine-based chemotherapy and 
prevention with DDT-based vector control. In the 1970s, malaria was successfully eradicated from most parts of 
Europe and North America. However, the program was abandoned in 1972 due to the emergence of 
chloroquine-resistant Plasmodium parasites and DDT-resistant Anopheles mosquitoes (Enayati et al., 2010). 
Nowadays, malaria is still endemic in tropical and subtropical regions in Africa, South East Asia, Eastern 
Mediterranean Regions, and parts of Central and South America. It threatens about 40% of the world’s 
population and remains a scourge of poorer countries (Figure 1). The WHO estimates that in 2010 there were 
219 million cases of malaria resulting in 660,000 deaths. About 90% of malaria deaths are in Africa, and most of 
the death cases happen to children under the age of five (WHO 2010). 
 
Figure 1. Percentage of national population at risk of malaria. Taken from http://www.worldmalariareport.org/node/57. 
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In response to this dreadful situation, several programs have been launched to concertedly control malaria, for 
example the Roll Back Malaria, the Malaria Vaccine Initiative and the Medicines for Malaria Venture. The 
artemisinin-based combination therapies (ACTs) are largely involved in the treatment of malaria to overcome 
the chloroquine resistance in malaria parasites (WHO 2010). However, the emergence of multiple drug resistant 
parasites, including suspected artemisinin-resistant Plasmodium parasites in some areas (Phyo et al., 2012), is 
threatening our last line of defense against malaria. New antimalarial agents, effective vaccines and anti-vector 
strategies are urgently required. 
 
1.1.2 Malaria parasites 
1.1.2.1 Life cycle 
The causative agents of malaria are eukaryotic, unicellular organisms of the genus Plasmodium, which belong to 
the phylum Apicomplexa (Tuteja 2007; Kappe et al., 2010). Generally, five species of Plasmodium infect 
humans, including P. falciparum, P. vivax, P. knowlesi, P. ovale and P. malariae (Kappe et al., 2010; Hafalla et 
al., 2011). Among them, P. falciparum and P. vivax are responsible for the most malaria infections worldwide. P. 
vivax is mainly distributed in Asia, America, some parts of Africa and usually causes uncomplicated malaria, 
whereas P. falciparum, the most deadly species of human malaria parasites, is predominant in Africa and 
accounts for most malaria deaths (WHO 2010). 
Human malaria parasites undergo a complex life cycle within the mosquito vector and human hosts (Kappe et 
al., 2010). The life cycle of P. falciparum with several developmental transitions is given in Figure 2. Infection 
with malaria begins following the bite of an infected female mosquito, which transmits the parasite sporozoites 
into the blood stream of human hosts. The sporozoites circulate and invade liver cells, where they undergo 
asexual developments (the pre-erythrocytic stage) and divide into thousands of merozoites within several days. 
Once the hepatocytes rupture, the invading merozoites are released to the blood stream and invade erythrocytes, 
initiating the asexual blood stage development (intraerythrocytic stage). Within about 48 hours of rapid 
multiplication and development, P. falciparum undergoes ring, trophozoite, and schizont stages and finally form 
around 20 merozoites, which further rupture the erythrocyte and invade new erythrocytes. A small portion of 
parasites undergo sexual development and differentiate into male and female forms of gametocytes, the only 
form of the parasite taken up by the mosquito in a blood meal. In the mosquito midgut, the gametocytes develop 
into micro- and macrogametes and further form ookinetes, which invade the mosquito midgut. Within the 
midgut epithelium, the parasites develop into mature oocysts. Sporogony in the oocyst results in the production 
of sporozoites, which further migrate to the salivary gland of the mosquito. When the mosquito bites a new 
individual, the sporozoites are transferred to a new host, and the life cycle of the parasite starts again. 
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Figure 2. Life cycles of human malaria parasites in humans and mosquito vectors. The numbers indicate the size of the 
parasite population during life cycle progression. Taken from Kappe et al., 2010. 
 
1.1.2.2 Redox metabolism of malaria parasites 
During its life cycle, the malaria parasites are exposed to oxidative and nitrosative stresses due to either a high 
metabolic rate of the rapidly growing and multiplying parasites or the host immune responses to Plasmodium 
infection (Becker et al., 2004). Furthermore, the intraerythrocytic Plasmodium constantly digests hemoglobin of 
infected erythrocytes as the major source of amino acids. The digestion of hemoglobin in the parasitic food 
vacuole leads to the formation of toxic free heme (ferri/ferroprotoporphyrin IX; FP IX), which needs to be 
detoxified by sequestration into crystalline hemozoin (Atamna et al., 1993). However, residual heme that 
escapes the detoxification process will lead to a significant induction of oxidative stress, causing protein and 
membrane damages in the parasites (Atamna et al., 1993). Apart from the metabolically derived oxidative stress, 
reactive oxygen and nitrogen species (RONS) generated from the host immune system increase the 
oxidative/nitrosative burden of the parasitized cell (Lim et al., 2005; Molina-Cruz et al., 2008). 
To cope with the deleterious effects of oxidative/nitrosative stresses, malaria parasites are equipped with a 
sophisticated antioxidant network (Muller 2004; Jortzik et al., 2012). Two central components of the antioxidant 
network in Plasmodium are the NADPH-dependent thioredoxin (Trx) and glutathione (GSH) systems (Figure 
3). 
 
 
Introduction 
4 
 
Figure 3. The NADPH-dependent thioredoxin system and GSH system in the antioxidant defense of P. falciparum. 
TrxR, thioredoxin reductase; GR, glutathione reductase; Grx, glutaredoxin; GST, glutathione S-transferase; Glos, glyoxalase; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; FP IX,; OAT, ornithine δ-aminotransferase. 
 
1.1.2.2.1 The thioredoxin system of P. falciparum 
The thioredoxin system, composed of thioredoxin (Trx), thioredoxin reductase (TrxR) and NADPH, plays a 
central role in the redox homeostasis of cells (Muller 2004). P. falciparum possesses three classic Trxs that can 
be reduced by P. falciparum TrxR (PfTrxR) and two Trx-like proteins that cannot be reduced by PfTrxR (Jortzik 
et al., 2012). The cytosolic P. falciparum thioredoxin 1 (PfTrx1) is the best studied Trx in P. falciparum and has 
been shown to be a central player in the antioxidant system of the parasites (Krnajski et al., 2001; Kanzok et al., 
2002). PfTrx1 has an active site motif WCGPC, where the two catalytic cysteine residues are located. PfTrx1 
directly counteracts oxidative stress by reducing oxidized glutathione (GSSG), hydrogen peroxide (H2O2), 
tert-butylhydroperoxide (tBuOOH), and S-nitrosoglutathione (GSNO) (Kanzok et al., 2000; Krnajski et al., 
2001). Besides, PfTrx1 also maintains the reduced status of thioredoxin-dependent peroxidases and 
plasmoredoxin, a Plasmodium-specific oxidoreductase (Becker et al., 2003). Furthermore, PfTrx1 has been 
shown to interact with several plasmodial proteins involved in protein folding, glycolysis, polyamine 
metabolism and redox homeostasis (Sturm et al., 2009). 
PfTrxR is a dimeric flavoenzyme catalyzing the NADPH-dependent reduction of the active site disulfide of 
PfTrx1. The C-terminal redox center of PfTrxR employs two non-adjacent cysteine residues (Cys535 and 
Cys540) to interact with the active site dithiols of PfTrx1, in contrast to the consecutive Cys-Sec pair at the 
C-terminus of mammalian TrxRs (Jortzik et al., 2012). The most striking structural differences between PfTrxR 
and human TrxR are the insertion of a Plasmodium-specific loop at the C-terminus of PfTrxR and the 
architecture of the flexible C-terminal arm. The loop seems to be important for the intermolecular interaction 
between PfTrxR and PfTrx1, as a depletion of parts of the loop leads to a decreased efficiency of PfTrxR in the 
reduction of PfTrx1 (Fritz-Wolf et al., 2013). PfTrxR was demonstrated to be crucial for the erythrocytic stages 
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of P. falciparum (Krnajski et al., 2002). However, a recent knockout study reported that TrxR of the rodent 
malaria parasite P. berghei is not essential for the parasites in the mammalian host and the mosquito vector 
(Buchholz et al., 2010). The dispensable role of TrxR might be explained by compensation for the loss of 
functions by the parasitic glutathione system. 
 
1.1.2.2.2  The glutathione system of P. falciparum 
The tripeptide GSH is the major low-molecular-weight antioxidant in almost all aerobic cells (Sies 1999). GSH 
generally exists at milimolar intracellular concentrations (Monostori et al., 2009). It plays a pivotal role in 
cellular antioxidant defense by counteracting deleterious free radicals and peroxides and maintaining the redox 
status of protein thiols (Frey 1997; Sies 1999). Plasmodium possesses the GSH biosynthesis pathway and a 
functional GSH-dependent antioxidant system, consisting of GSH, glutathione reductase (GR), glutaredoxins 
(Grxs), glyoxalase (Glos), and glutathione S-transferase (GST) (Becker et al., 2003; Muller 2004). GSH 
biosynthesis was demonstrated to be particularly important in the mosquito stages, since genetic disruption of P. 
berghei gamma-glutamylcysteine synthetase (γ-GCS), a critical enzyme in the GSH biosynthesis pathway, 
dramatically inhibits plasmodial sporogony in the mosquito (Buchholz et al., 2010). 
In P. falciparum, the reduced form of GSH is mainly recycled by the P. falciparum glutathione reductase (PfGR), 
which reduces GSSG back to GSH in the presence of NADPH (Becker et al., 2003). The redox potential of 
2GSH/GSSG (EGSH), determined by the intracellular molar ratio of GSH to GSSG, reflects the cellular redox 
status. Probed by a GSH biosensor comprising the human Grx1 linked to a redox-sensitive green fluorescent 
protein, the basal cytosolic EGSH of P. falciparum (3D7 strain) has been recently determined to be -314.2±3.1 
mV, indicating a highly reducing cytosol of the parasites (Kasozi et al., 2014). 
Apart from its role in direct detoxification of oxidizing agents, GSH serves as a cofactor for glutathione 
S-transferase to detoxify electrophilic metabolites (Harwaldt et al., 2002), for glyoxalase to detoxify 
methylglyoxal (Iozef et al., 2003), and for glutaredoxin to regulate the redox status of various proteins (Rahlfs et 
al., 2001). Additionally, GSH/GSSG functions as the major thiol redox buffer in cells. Particularly, protein thiols 
can be reversibly modified by GSSG via S-glutathionylation, which can be further de-glutathionylated by 
reduced GSH and other enzymatic factors (Dalle-Donne et al., 2007). Through this mechanism, GSH protects 
protein thiols from irreversible overoxidations under oxidative stress (Giustarini et al., 2004). Recently, a 
systematic approach identified nearly five hundred endogenously S-glutathionylated proteins in P. falciparum 
(Kehr et al., 2011). PfGrx1, PfTrx1, and plasmoredoxin have been shown to be capable of catalyzing the 
de-glutathionylation process in vitro (Kehr et al., 2011). Besides, a particular role of GSH in Plasmodium is the 
detoxification of free FP IX, which escapes its sequestration in the food vacuole. It has been shown that free FP 
IX is degraded non-enzymatically by GSH, and this mechanism can be inhibited by chloroquine (Atamna et al., 
1995; Zhang et al., 1999). Therefore, a high level of reduced GSH is usually considered to be relevant to the 
chloroquine resistance of malaria parasites (Zhang et al., 1999; Deharo et al., 2003). 
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1.2 Nitric oxide and Plasmodium 
1.2.1 Nitric oxide in biology 
Nitric oxide (NO) is a gaseous signaling molecule involved in various physiological and pathological processes 
(Moncada et al., 1991). The important bioactivity of NO was not recognized per se until the late 1980s when 
researchers identified NO as the endothelium-derived relaxing factor (EDRF), which regulates vasodilation of 
blood vessels (Marsh et al., 2000; Loscalzo 2013). The discovery of the regulatory role of NO in the 
cardiovascular system has led to an explosion in research focusing on signaling functions of NO. To date, NO 
has been shown to participate in a wide range of physiological events such as platelet aggregation and adhesion 
(Kalinowski et al., 2002), smooth muscle cell proliferation (Tsihlis et al., 2011), neurotransmission (Vincent 
2010), and innate immune response to pathogen infections (Wink et al., 2011). Besides, NO is also involved in 
the pathogenesis of a number of diseases, including cancer, arthritis, atherosclerosis, diabetes, and several 
neuronal degenerative diseases (Gross et al., 1995). 
As an uncharged and almost nonpolar molecule, NO is more soluble in hydrophobic solvents than in water 
(Toledo et al., 2012). Therefore NO readily diffuses the hydrophobic double layer of biological membranes 
(Toledo et al., 2012). Despite its molecular simplicity, NO possesses diverse chemical reactivity and reacts with 
a wide range of biological targets, including DNA, protein, metal, low-molecular weight thiols, and reactive 
oxygen intermediates (Figure 4). A striking feature of NO in an aerobic environment is that it undergoes 
autoxidation to form dinitrogen trioxide (N2O3), which strongly reacts with amines and thiols to form 
nitrosamines and S-nitrosothiols, respectively (Gardner et al., 2004; Toledo et al., 2012). The second-order 
autoxidation rate for NO indicates that the half life of NO in the reaction is dependent on the concentration of 
NO (Wink et al., 1998). This further indicates a concentration-dependent atmospheric fate for NO: in low 
concentrations (e.g. under physiological conditions), NO has a relatively long lifetime that allows NO to access 
and interact with biological targets, whereas in high concentrations (e.g. under inflammatory conditions), NO 
may undergo rapid oxidation to form reactive nitrogen species (RNS, e.g. N2O3), thus elevating local nitrosative 
stress. Under oxidative stress, NO reacts with superoxide (O2
-), leading to the generation of peroxynitrite 
(ONOO-), which is a powerful oxidant and nitrating agent that can damage a wide array of biomolecules (Toledo 
et al., 2012). Moreover, NO directly reacts with ferrous to form ferrous-nitrosyl complexes, which are of 
particular importance in the modulation of hemeproteins by NO. For example, NO binds to the heme iron in 
soluble guanylate cyclase (sGC) and releases the heme-bound histidine, resulting in a subsequent conformational 
change of the protein and activation of the enzyme (Stone et al., 1994). Besides sGC, the heme proteins 
hemoglobin and cytochrome c oxidase are important NO targets in cells (Sarti et al., 2012; Helms et al., 2013). 
Introduction 
7 
 
Figure 4. Schematic representation of the biological production and reactivity of nitric oxide. NOS, nitric oxide 
synthase. 
 
The physiological and pathophysiological levels of NO vary significantly depending on the rates of NO 
production and metabolism. A widely accepted range of physiological concentrations of NO is 1 nM to 100 nM, 
although several studies have even observed NO concentrations in the picomolar range (Toledo et al., 2012). 
However under infectious and inflammatory conditions, NO levels can dramatically increase by several orders of 
magnitude. This is mainly due to the elevated expression and activity of inducible NO synthase that produces an 
inflammatory level of NO (see below). 
In mammals, biological NO is mainly produced from the oxidation of the amino acid L-arginine catalyzed by 
specialized nitric oxide synthases (NOSs) (Griffith et al., 1995). NOS typically functions by forming 
homodimers (Figure 5). In eukaryotes, each NOS monomer consists of an N-terminal oxygenase and a 
C-terminal reductase domain. The oxygenase domain is the site for binding arginine, a heme prosthetic group, 
and the cofactor tetrahydrobiopterin (BH4), whereas the reductase domain has binding sites for flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), and NADPH. The interdomain linking the 
oxygenase and reductase domain contains a calmodulin (CaM)-binding motif. Binding calmodulin enables 
electron flow from flavin prosthetic groups in the reductase domain to heme, facilitating the turnover of O2 and 
L-arginine to NO and L-citrulline (Alderton et al., 2001). 
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Figure 5. A model for the generation of NO by the NOS homodimers. BH4, tetrahydrobiopterin; CaM, calmodulin; FAD, 
flavin adenine dinucleotide; FMN, flavin mononucleotide. Modified from (Maron et al., 2012) 
 
There are two classes of NOS that have been found (Knowles et al., 1994). The constitutive NOS (NOS I) 
includes the endothelial NOS (eNOS) and neuronal (nNOS), each of which produces low amounts of NO under 
physiological conditions in a calcium-dependent manner. By contrast, the inducible NOS (iNOS, NOS II) can be 
stimulated to produce large amounts of NO under infectious and inflammatory conditions (Menshikova et al., 
2000). High-output of transcription and expression of iNOS can be induced by several pro-inflammatory 
cytokines, such as interleukin-1, tumor necrosis factor alpha (TNF- and interferon-γ (IFN-) (Green et al., 
1994). High levels of NO generated by iNOS have been shown to have anti-microbial and anti-cancer activities 
in vivo, thereby pinpointing the important role of iNOS in the host immune system (Fang 2004). 
 
1.2.2 Plasmodium encounters nitrosative stress 
1.2.2.1 NO in Plasmodium infections 
Nitric oxide has long been recognized as a potent antiparasitic effector molecule in vivo (Figure 6) (Bogdan 
2001). Compelling evidence has shown that NO derived from NOS is an important component of innate immune 
response against Plasmodium parasites in both mammalian hosts and Anopheles mosquito vectors (Nahrevanian 
2006; Rivero 2006). In mammals, iNOS is ubiquitously present in epithelial cells, hepatocytes, and various 
immune cells, including macrophages, NK cells, and dendritic cells (Bogdan 2001). The expression of iNOS can 
be induced in response to several pro-inflammatory cytokines during Plasmodium infection. It is generally 
accepted that NO derived from host iNOS partially mediates the killing of malaria parasites (Nahrevanian 2006). 
Supporting this concept, it has been found that NO generated by human monocytes can kill P. falciparum in vitro 
(Gyan et al., 1994). Besides, upon the invasion of live cells by sporozoites, induction of NO in mammalian 
hepatocytes has also been reported to have antiplasmodial activity against sporozoites (Klotz et al., 1995). 
Notably, the mechanism of the stimulation of NO production in macrophages by Plasmodium has been 
intensively studied. Malarial antigens, including glycosylphosphatidylinositol (GPI) and hemozoin as well as 
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several pro-inflammatory cytokines (e.g. IFN-and TNF-can induce iNOS expression in macrophages and 
lead to the synthesis of inflammatory levels of NO that damage the erythrocytic Plasmodium (Tachado et al., 
1996; Carney et al., 2006). 
Similarly, the role of NO in the control of Plasmodium is also preserved in mosquito vectors. The Anopheles 
mosquito possesses an invertebrate NOS that is homologous to the characterized mammalian NOSs (Luckhart et 
al., 1998; Akman-Anderson et al., 2007). In response to several parasite-induced pro-inflammatory cytokines 
and parasitic antigens, expression of mosquito NOS is significantly elevated in the midgut lumen by the invasion 
of Plasmodium. Later increases of mosquito NOS expression and enzyme activity have also been observed at the 
beginning of sporozoite release (Luckhart et al., 1998). The induction of mosquito NOS leads to the synthesis of 
inflammatory levels of NO in the blood-filled midgut, adversely impacting Plasmodium development in the 
mosquito (Luckhart et al., 1998; Rivero 2006). Consistently, it was found that the hemolymph level of NO is 
markedly higher in the Plasmodium-infected mosquitoes compared to uninfected mosquitoes (Herrera-Ortiz et 
al., 2011). The mosquito-produced NO has been shown to induce apoptosis of a large fraction of invading 
ookinetes and mediate the killing of young oocysts. Pharmaceutically, inactivation of mosquito NOS results in a 
decreased proportion of apoptotic ookinetes and an increased number of developed oocysts in mosquitoes (Ali et 
al., 2010). More recently, mosquito-produced NO has been shown to impair gametogenesis of male Plasmodium 
parasites and reduce the fertility of both male and female gametes (Ramiro et al., 2011). These important 
observations highlight the important participation of NO in the mosquito’s immune system against Plasmodium. 
In accordance, several in vitro studies have confirmed that a number of NO donors have both cytostatic and 
cytotoxic effects on Plasmodium parasites (Rockett et al., 1991; Taylor-Robinson 1997; Balmer et al., 2000; 
Venturini et al., 2000). Notably, the NO donors are much more potent in inhibiting the Plasmodium parasite than 
NO itself, suggesting that NO impacts the parasites in an indirect way, presumably dependent upon NO-derived 
RNS (Sobolewski et al., 2005). Several parasitic targets have been suggested to be NO targets. Falcipain-1, a key 
plasmodial hemoglobinase, has been suggested to be an NO target. NO donors have been shown to inhibit 
falcipain-1 activity, presumably by targeting its active site cysteine (Venturini et al., 2000). 
Although the generation of NO from host immune defense combats Plasmodium, the parasites facilitate its 
survival by developing strategies to alleviate the insult of NO. Particularly, the erythrocytic Plasmodium is 
surrounded by a large amount of hemoglobin, which is a strong scavenger for NO (Liu et al., 1998; Sobolewski 
et al., 2005). The presence of intraparasitic hemoglobin may thereby reduce the NO burden to which the 
parasites are exposed. Importantly, Plasmodium parasites possess arginase, which catalyzes the conversion of 
L-arginine into L-ornithine and urea. Due to the fact that arginase and NOS share the same substrate (L-arginine), 
the parasite-encoded arginase attenuates the production of parasiticidal NO from host iNOS via arginine 
depletion (Vincendeau et al., 2003). Moreover, the P. falciparum peroxiredoxin 1a (PfPrx1a) has been shown to 
degrade the most harmful reactive nitrogen intermediate, peroxynitrite, thus protecting the parasites from severe 
nitrosative stress (Nickel et al., 2005). 
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Figure 6. NO sources in Plasmodium parasites and the defense mechanism of Plasmodium against nitrosative stress. 
FV, food vacuole; Hb, hemoglobin; Hz, hemozoin; L-Arg, L-arginine; PfGPI, P. falciparum glycosylphosphatidylinositol; 
PfPrx1a, P. falciparum thioredoxin-dependent peroxiredoxin 1a; PfNR, P. falciparum nitrate reductase; PVM, 
parasitophorous vacuole membrane; NOX, NADPH oxidase. 
 
1.2.2.2 NO production in Plasmodium 
Although plasmodial homologs of NOS cannot yet be identified, the endogenous NO and RNS have been clearly 
detected in the erythrocytic stages of Plasmodium as well as in Plasmodium gametocytes (Ostera et al., 2008). A 
strong intraparasitic NO signal was detected around the parasitic food vacuole (FV), where a putative plasmodial 
homolog of plant nitrate reductases (NRs) is localized (Ostera et al., 2008; Ostera et al., 2011). This indicates the 
endogenous NO in Plasmodium might be also derived from the reduction of nitrate/nitrite. The endogenous 
produced NO has been recently suggested to play a role in heme speciation inside the FV (Ostera et al., 2011). 
 
1.3 Protein S-nitrosylation 
Protein thiols are major intracellular targets of NO. Particularly, protein S-nitrosylation (SNO) is an important 
protein posttranslational modification (PTM) induced by NO (Hess et al., 2005). SNO refers to the reversible, 
covalent attachment of a nitroso group (-NO) to a reactive cysteine thiol of a protein to form S-nitrosothiol, 
which modulates conformation, stability, activity, localization, and functions of the respective protein (Hess et 
al., 2005). In the past decade, accumulating evidence indicates that SNO has emerged as the principal 
mechanism in either NO signaling or NO-related toxicity, depending on the targeted pathway. So far, SNO has 
been studied in mammals, plants, and E. coli (Anand et al., 2012; Astier et al., 2012; Seth et al., 2012), and over 
3,000 proteins have been identified as potential targets of SNO (dbSNO website: dbsno.mbc.nctu.edu.tw/ ). In 
recent years, a growing body of research indicates that SNO is a tightly controlled process subjected to 
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spatiotemporal regulations by SNO-promoting and SNO-metabolizing factors (Figure 7). 
 
Figure 7. Catalysis of protein S-nitrosylation and denitrosylation. The figure is taken from (Jortzik et al., 2012). Trx, 
thioredoxin; TrxR, thioredoxin reductase; GSH, reduced glutathione; GSNO, S-nitrosoglutathione; GSNOR, 
S-nitrosoglutathione reductase; PDI, protein disulfide-isomerase; NO, nitric oxide; Cys-NO, S-nitrosocysteine; Trx-SNO, 
S-nitrosylated thioredoxin; GAPDH-SNO, S-nitrosylated glyceraldehyde 3-phosphate dehydrogenase; haemoglobin-SNO, 
S-nitrosylated haemoglobin. 
 
1.3.1 Formation of SNO 
Protein S-nitrosylation can be formed in a direct reaction of protein thiols with higher NO oxides (e.g. N2O3) or 
metal-NO complexes (Hogg 2002). The reaction of thiols with nitrosylating equivalents is particularly relevant 
to SNO formation in the vicinity of a NO-generating source, for example, NOS. More importantly, SNO can be 
formed via transnitrosylation, in which the nitroso group is transferred from an S-nitrosothiol to a protein thiol 
(Hogg 2002; Hess et al., 2005). Both low-molecular-weight S-nitrosothiols and protein S-nitrosothiols can 
transnitrosylate proteins. Notably, S-nitrosoglutathione (GSNO), which is derived from the interaction of 
glutathione with NO derivatives or protein S-nitrosothiols, is the major low-molecular-weight S-nitrosothiol in 
cells (Broniowska et al., 2013). Given a higher cellular concentration of GSNO compared to free NO radicals, 
GSNO is considered an endogenous NO carrier and donor (Broniowska et al., 2013). GSNO can efficiently 
induce SNO by transferring its nitroso group to protein thiols, thus playing an important role in mediating NO 
signaling (Hess et al., 2005). Furthermore, protein-protein transnitrosylation represents another important 
pathway leading to the formation of SNO in cells (Nakamura et al., 2013). Protein transnitrosylation generally 
requires a direct interaction of the two proteins and a spatial closeness of the S-nitrosothiol and the acceptor thiol 
to facilitate NO transfer (Hess et al., 2005; Nakamura et al., 2013). Specifically, the redox potential of the 
respective cysteine is a determinant for transnitrosylation: the S-nitrosylated thiol with a higher redox potential 
tends to lose the nitroso group and transfer it to a free thiol nearby with lower redox potential (Nakamura et al., 
2013). Because of these restrictive parameters, protein-protein transnitrosylation is expected to occur in a 
specific subset of proteins and therefore has a particular role in modulating specific signaling pathways. 
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1.3.2 Removal of SNO-denitrosylation 
SNO is reversible. The reverse process of SNO is termed denitrosylation, which regulates the homeostasis of 
SNO (Benhar et al., 2009). SNO decomposition can be catalyzed by a number of enzymes and transition metals. 
Importantly, recent research has revealed that the biologically relevant denitrosylation is an enzymatically 
controlled process. Particularly, the GSH/GSNO reductase system and thioredoxin system are two major 
denitrosylase systems in mammals and plant (Figure 8). 
 
Figure 8. The schematic diagram of protein denitrosylation catalyzed by the thioredoxin system and GSH/GSNOR 
system. GSNOR, S-nitrosoglutathione reductase; Trx, thioredoxin; TrxR, thioredoxin reductase. Modified from (Benhar et 
al., 2009) 
 
S-nitrosothiols can be reduced to thiols by GSH, leading to the formation of GSNO (Broniowska et al., 2013). 
The enzymatic metabolism of GSNO was not clear until a specialized GSNO-metabolizing enzyme was 
identified as class III alcohol dehydrogenase (ADH3), which has thus been renamed GSNO reductase (GSNOR) 
(Liu et al., 2001). GSNOR plays a key role in decomposing SNO by acting on GSNO but not directly on protein 
S-nitrosothiols (Jensen et al., 1998; Benhar et al., 2009). GSNOR catalyzes the NADH-dependent reduction of 
GSNO to form glutathione sulfonamide, which can be further derived to oxidized glutathione (Benhar et al., 
2009). Through this mechanism, GSNOR governs protein S-nitrosothiols and controls SNO-based NO signaling 
by regulating cellular levels of GSNO. Depletion of GSNOR from yeast or mouse has been shown to result in 
increased cellular levels of GSNO and S-nitrosylated proteins as well as an increased susceptibility of cells to 
nitrosative stress, thus highlighting the important role of GSNOR in regulating the homeostasis of SNO in cells 
(Liu et al., 2001; Liu et al., 2004). 
Another important denitrosylase system is the Trx system, which is composed of Trx, TrxR, and NADPH (Wu et 
al., 2011). Trx is a ubiquitous protein disulfide reductase and a central player in cellular redox metabolism. The 
denitrosylating activity of Trx has been intensively studied in recent years. It has been found that Trx is able to 
denitrosylate a broad spectrum of S-nitrosylated proteins and many low-molecular-weight S-nitrosothiols, 
including GSNO, S-nitrosocysteine (CysNO), and S-nitroso-N-acetylpenicillamine (SNAP) (Stoyanovsky et al., 
2005; Sengupta et al., 2007). The denitrosylating activity of Trx is attributed to the catalytic cysteine residues 
located in the conserved active-site Cys-Gly-Pro-Cys motif (Sengupta et al., 2013). Trx-mediated denitrosylation 
may involve two possible transition states, either by forming an intermolecular disulfide intermediate between 
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Trx and the substrate or by a transnitrosylation of Trx at one active-site cysteine thiol to form a transient 
S-nitroso-monothiol. The denitrosylation reaction leads to the release of HNO and the formation of an active-site 
disulfide in Trx (i.e. the oxidized Trx). Subsequently, TrxR reduces the disulfide of Trx to recycle the reduced 
Trx (Benhar et al., 2009; Sengupta et al., 2013). 
The key role of TrxR/Trx in cellular denitrosylation is highlighted by the fact that the Trx system regulates the 
denitrosylation of caspase-3. It has been shown that in resting human lymphocytes, Trx1 actively denitrosylates 
cytosolic caspase-3 and thereby maintains a low steady-state amount of S-nitrosylated caspase-3. Upon apoptotic 
stimulus, the mitochondrial form of Trx (Trx2) mediates the denitrosylation of mitochondria-associated 
caspase-3, thereby activating caspase-3 and promoting apoptosis (Benhar et al., 2008). 
Besides caspase-3, a wide range of proteins appear to be denitrosylation substrates of the Trx system such as 
albumin, metallothionenin, caspase-8, and caspase-9 (Sengupta et al., 2007; Benhar et al., 2009; Sengupta et al., 
2010). Indeed, it was observed that Trx-catalyzed denitrosylation accounts for a 72% reduction of protein 
S-nitrosothiol levels in isolated liver homogenates (Doulias et al., 2010). Furthermore, an impaired Trx system 
with mutated TrxR in Hela cells has led to a dramatically decreased denitrosylation efficiency and a marked 
accumulation of S-nitrosothiols in cells (Stoyanovsky et al., 2005). Taken together, these studies point out an 
indispensable role of the Trx system in the reversible regulation of SNO. 
 
1.3.3 Biological significance of SNO 
Protein S-nitrosylation serves as a major mode of redox signaling in cells (Nakamura et al., 2013). An early study 
by Jia et al. first reported a physiological transnitrosylation between hemoglobin (Hb) and the anion exchanger 1 
(AE1), an erythrocyte membrane-bound protein (Jia et al., 1996). Hemoglobin auto-catalyzes S-nitrosylation of 
its β-chain at Cys93 by using the heme-bound NO group. The S-nitrosylated Hb then undergoes conformational 
change, allowing the binding to the cytoplasmic tail of AE1 and the subsequent transnitrosylation of AE1. The 
S-nitrosylated AE1 further releases NO out of the erythrocyte, thus mediating the vascular relaxing activity of 
NO (Figure 9A). 
More recently, transnitrosylation by Trx has been shown to regulate cell death. In addition to the active-site 
cysteine, human Trx possesses three additional cysteine residues (Cys62, Cys69, and Cys73). In contrast to the 
active-site cysteine that mediates denitrosylaion, Cys73 of Trx can be S-nitrosylated to form S-nitrosylated Trx 
(Trx-Cys73-NO) and mediate transnitrosylation activity of Trx. The nitrosylation of Cys73 appears to occur 
when the active-site cysteines are oxidized to a disulfide, therefore indicating that Trx may transduce NO stress 
upon oxidative/nitrosative stress via transnitrosylation (Wu et al., 2010). Interestingly, an exemplary 
transnitrosylation substrate of Trx is caspase-3, which is also a denitrosylation substrate of Trx (Mitchell et al., 
2005). The S-nitrosylated caspase-3 can transnitrosylate the X-linked inhibitor of apoptosis (XIAP), which is an 
E3 ubiquitin ligase that prevents apoptosis by binding to caspase-3 and promoting the proteasomal degradation 
of caspase-3 (Nakamura et al., 2010; Nakamura et al., 2013). Nitrsosylation of XIAP inhibits its E3 ubiquitin 
ligase activity, thereby blocking its ability to inhibit apoptosis (Tsang et al., 2009). As such, transnitrosylation of 
XIAP by S-nitrosylated caspase-3 contributes to the preservation of active caspase-3, thereby mediating cell 
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apoptosis under nitrosative stress (Nakamura et al., 2013) (Figure 9B). 
 
Figure 9. Schematic illustration of different cellular pathways regulated by SNO. A) The pathway exporting NO from 
erythrocytes requires transnitrosylation of AE1 by the S-nitrosylated Hb. AE1, anion exchanger 1; Hb, hemoglobin. B) 
Transnitrosylation in Trx-caspase3-XIAP pathway mediates apoptotic cell death. Trx, thioredoxin; XIAP, X-linked inhibitor 
of apoptosis. Ub, ubiquitin C) S-nitrosylation of GAPDH mediates the binding of Siah1, nuclear translocation of the 
GAPDH-Siah1 complex and cell apoptosis. Siah1 is an E3 ubiquitin ligase encoded in humans by the SIAH1 gene. Modified 
from (Nakamura et al., 2013) 
 
Furthermore, S-nitrosylation of GAPDH has been shown to mediate its nuclear translocation and induce 
apoptotic cascades. Hara et al. have found that S-nitrosylation of the catalytic cysteine of GAPDH promotes the 
binding of Siah1, an E3 ubiquitin ligase possessing a nuclear localization signal. Then, the GAPDH/Siah1 
complex is translocated to the nucleus, where GAPDH stabilizes Siah1, promoting the Siah1-mediated 
degradation of nuclear proteins and causing apoptotic cell death (Hara et al., 2005). More recently, Kornberg et 
al. found that nucleus-localized S-nitrosylated GAPDH physiologically transnitrosylates nuclear proteins, 
including the deacetylating enzyme sirtuin-1 (SIRT1), histone deacetylase-2 (HDAC2), and DNA-activated 
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protein kinase (DNA-PK) (Kornberg et al., 2010). They further demonstrated that transnitrosylation of SIRT1 
inhibits the activity of SIRT1 and decreases the transcriptional activity of PGC1α, a downstream effector of 
STRT1 (Kornberg et al., 2010). As such, the GAPDH-mediated transnitrosylation in GAPDH-SIRIT1 pathway 
has been suggested to have pathophysiological relevance in neurodegeneration and metabolic dysfunctions 
(Nakamura et al., 2013) (Figure 9C). 
 
1.4 The ubiquitin-proteasome system 
Intracellular protein degradation is an intricately regulated process that governs protein homeostasis by 
removing damaged or misfolded proteins. In eukaryotic cells, the majority of intracellular proteins are degraded 
by the ubiquitin-proteasome system (UPS) (Glickman et al., 2002). 
 
1.4.1 The ubiquitin system 
Degradation of proteins by the UPS typically involves a covalent attachment of the small protein ubiquitin (Ub) 
to the protein destined to be degraded, the so-called ubiquitination process, a major type of protein 
posttranslational modification (Goldstein et al., 1975; Pickart 2001). The modification process most commonly 
attaches the last amino acid (Gly76) of ubiquitin to a lysine residue on the substrate. Ubiquitination consists of 
three main steps, which are concertedly catalyzed by a cascade of three enzymes, namely ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3) (Glickman et al., 2002). The human 
genome encodes two ubiquitin-specific E1s, about fifty E2s, and hundreds of E3s (Pickart et al., 2004). It is 
generally believed that the specificity of ubiquitination largely depends on the respective E3 that specifically 
catalyzes a certain group of proteins (Glickman et al., 2002). 
Ubiquitination begins with the ATP-dependent activation of Ub catalyzed by an E1, resulting in a thioester 
linkage formed between the C-terminal carboxyl group of Ub and the cysteine sulfhydryl group in the active site 
of E1. Then, an E2 enzyme further catalyzes the transfer of Ub from E1 to the active site cysteine of E2. In the 
final step, by directly binding to both E2 and the specific target protein, an E3 enzyme creates an isopeptide 
bond between the C-terminal glycine of Ub and a lysine of the target protein, thereby adding the Ub molecule to 
the target protein (Figure 10). 
Ubiquitination can be generally divided into two classes: the monoubiquitination and polyubiquitination 
(Komander 2009). Monoubiquitination refers to the addition of one Ub molecule to one site or to multiple sites 
(multi-monoubiquitination) on the substrate protein. Monoubiquitination has been shown to be involved in 
several non-proteolytic events, such as membrane trafficking, endocytosis, and viral budding (Miranda et al., 
2007; Ikeda et al., 2008). In contrast, polyubiquitination is the formation of a polyubiquitin (polyUb) chain on a 
single site on the substrate protein. After the attachment of the first Ub to a target protein, further Ub molecules 
can be added stepwise by linking the glycine residue of a Ub molecule to a lysine residue of another ubiquitin, 
thus forming the polyUb chain on the targeted protein. The Ub molecule possesses seven lysine residues (K6, 
K11, K27, K29, K33, K48, and K63) available for polyUb linkage (Komander 2009). Particularly, the 
K48-linked polyubiquitination, the best characterized type of polyubiquitination, targets proteins for 
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proteasomal degradation (Komander 2009). Notably, at least four Ub molecules must be built up during 
polyubiquitination in order to facilitate recognition of the protein for proteasomal degradation (Hicke 2001). 
After the protein is tagged with the polyUb chain, the protein can either be transported by substrate shuttle 
proteins to the proteasome or directly binds to the proteasome for degradation (Glickman et al., 2002). 
Protein ubiquitination is reversed by the deubiquitination process. Deubiquitination is catalyzed by 
deubiquitylating enzymes (DUBs), which cleave ubiquitin from its target proteins (Wilkinson 1997). DUBs 
represent a large group of proteases that fall into two major classes, cysteine proteases and metalloproteases. 
Most DUBs are cytsteine proteases, which can be subdivided into four classes, the ubiquitin-specific proteases 
(USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumor proteases (OTU), and Machado-Josephin 
domain proteases (MJDs). The metalloprotease group contains only the Jab1/Mov34/MPN+ (JAMM) 
domain-containing proteases (Glickman et al., 2002; Reyes-Turcu et al., 2009). Nearly a hundred DUBs are 
encoded in the human genome, whereas twenty DUBs have been found in yeast, implying the importance of 
deubiquitination and the diverse substrate specificity of DUBs in cells (Amerik et al., 2000; Reyes-Turcu et al., 
2009). While most DUBs are free enzymes, three DUBs have been found to be physiologically associated with 
the 26S proteasome, indicating the importance of deubiquitination for proteasomal functions (Finley et al., 
2012). 
 
Figure 10. A schematic overview of protein degradation by the UPS system. E1, ubiquitin-activating enzyme; E2, 
ubiquitin-conjugating enzyme; E3, ubiquitin ligase. DUB, deubiquitinase. Ub, ubiquitin. 
 
1.4.2 The 26S proteasome 
1.4.2.1 The structure of the 26S proteasome 
The proteasome holoenzyme (known as the 26S proteasome) is a ~2.5 MD ATP-dependent chambered protease 
present in the nucleus and cytoplasm of eukaryotes (Tomko et al., 2013). The main function of the proteasome is 
to degrade damaged or misfolded proteins via proteolysis (Tomko et al., 2013). The 26S proteasome is a 
barrel-shaped complex composed of a 20S core particle (CP) and two 19S regulatory particles (RP) that stack to 
both ends of the 20S CP  (Peters et al., 1994) (Figure 11). Purified proteasomes usually contain a mixture of 
free 20S CP (i.e. the 20S proteasome), single or double 19S RP-capped 20S CP. The structure of 20S CP is built 
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up with four stacked heptameric rings (Tanahashi et al., 2000; Tomko et al., 2013). In mammals, each of the two 
identical outer rings consists of seven different alpha-subunits (α1-α7) and each of the two identical inner rings 
contains seven different beta-subunits (β1-β7). The proteolytic activity of the proteasome is found in three 20 CP 
beta-subunits: β1, β2, and β5, which possess peptidylglutamyl-peptide hydrolytic (PGPH) activity, trypsin-like 
activity, and chymotrypsin-like activity, respectively (Tomko et al., 2013). Free 20S CP found in cells usually 
has a low proteolytic activity by itself, at least against folded proteins (Coux et al., 1996). This is due to the fact 
that entry into the inner proteolytic chamber is generally occluded by the outer alpha-subunits, of which 
N-termini form a closed “gate” that blocks protein entry (Rabl et al., 2008). However, the binding of 19S RP or 
the proteasome activator PA28 to the 20S CP can mediate the “gate” opening, thus inducing the peptidase 
activity of the 20S CP (Lehmann et al., 2008; Rabl et al., 2008). 
In mammals, alternative forms of β1, β2, and β5 (β1i, β2i, and β5i) can be expressed in response to 
pro-inflammatory cytokines, especially in hematopoietic cells (Haorah et al., 2004). They can be incorporated 
into the 20S CP by replacing the corresponding beta-subunits, thereby altering the proteolytic specificity of the 
20S CP. The proteasome assembled with these alternative subunits is known as the immunoproteasome, which 
has important functions in antigen presentation and the defense of pathogens (Angeles et al., 2012). 
The 19S RP functions as a highly regulated keeper that responsible for the binding, deubiquitylation, unfolding, 
and translocation of substrates into the 20S CP as well as regulating the gating of the 20S CP (Tomko et al., 
2013). The 19S complex is an asymmetric particle composed of at least 19 different subunits. It can be divided 
into two subassemblies, the base and lid. The base contains six regulatory particle triple-A ATPases (Rpts) and 
four regulatory particle non-ATPases (Rpns). The ATPase subunits form a heterohexameric ring in the order of 
Rpt1/Rpt2/Rpt6/Rpt3/Rpt4/Rpt5 and directly contact with the 20S alpha-ring (Beckwith et al., 2013). 
Importantly, these ATPase subunits function in unfolding and translocation of the substrates as well as mediating 
the gate opening of 20S CP, thereby facilitating the entry of substrate proteins into the 20S catalytic chamber 
(Beckwith et al., 2013). The Rpn1 and 2 are the two largest subunits in the proteasome. They form scaffolds for 
the docking of substrates and other proteasome-interacting partners (Tomko et al., 2013). Particularly, Rpn10 and 
13 function as intrinsic ubiquitin receptors of the proteasome, thereby mediating the recognition of ubiquitinated 
substrate by the proteasome (Sakata et al., 2012). The lid is composed of nine non-ATPase subunits covering the 
base (Sharon et al., 2006). One best known function of the lid is the substrate deubiquitination, which is 
attributed to the Rpn11 subunit (Verma et al., 2002). The Rpn11 subunit contains a highly conserved Jab1/MPN 
domain-associated metalloisopeptidase (JAMM) motif as a zinc-binding site serving for the hydrolysis of 
ubiquitin from a ubiquitinated protein. This deubiquitination process plays important roles in recycling ubiquitin 
and facilitating the substrate degradation by the proteasome. 
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Figure 11. The structure of the eukaryotic 26S proteasome. A) The 26S proteasome is composed of a 20S core particle 
capped with two 19S regulatory particles, which can be divided into the 19S lid and the 19S base. B) The arrangement 
(top-view) of ATPase subunits in forming the 19S ATPase-ring (left) and the complex structure of the ATPase-ring in side- 
and top-view. C) The 20S CP consists of two heptameric alpha-rings and two heptameric beta-rings, in which three 
beta-subunits with different proteolytic activities are located. Modified from (Jung et al., 2013; Tomko et al., 2013). The 26S 
proteasome image was downloaded from http://www.rcsb.org (October 2013 Molecule of the Month by David Goodsell). 
 
1.4.2.2 The mechanism of action of the 26S proteasome 
Protein degradation by the 26S proteasome is a highly controlled process that involves substrate recognition and 
processing, unfolding, translocation and proteolysis, which will be described in the following paragraphs 
(Glickman et al., 2002). 
 
1.4.2.2.1  Substrate recognition 
Over the past decades, structural and mechanistic studies of the 19S RP have provided significant insights into 
the specialized roles of 19S RP components in regulating proteasomal function. Of particular importance, two 
19S RP subunits, Rpn10 and Rpn13, have been identified as intrinsic ubiquitin receptors of the proteasome for 
substrate recognition (Mueller et al., 2003; Fujiwara et al., 2004; Husnjak et al., 2008). Rpn10 (in human termed 
S5a) was the first identified ubiquitin receptor in the 19S RP. It has a von Willebrand factor A (vWA) domain at 
the N-terminal region, and one or more ubiquitin-interacting motifs (UIMs) in the carboxyl-terminal half of the 
protein, depending on the species (Tomko et al., 2013). For example, human S5a contains two UIMs: UIM1 and 
UIM2, whereas the Saccharomyces cerevisiae homolog of human S5a (Rpn10) contains only UIM1 (Young et 
al., 1998). In human S5a, the two UIMs are approximately 30-amino acids long and are separated by 50 
intervening residues. The UIMs form an α-helical structure and possess a special amino acid sequence containing 
5 hydrophobic residues Leu-Ala-Leu-Ala-Leu (LALAL), which has been demonstrated to be essential for 
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binding the K-48-linked polyubiquitin chain. Each UIM has been shown to have greater affinity to bind the 
longer polyubiquitin chain, and UIM2 appears to have a higher affinity than UIM1. The selectivity of binding the 
polyubiquitin chain most likely arises from the hydrophobic interaction between the UIM helix with the 
hydrophobic patch of ubiquitin and the association of the helix with the opposing ubiquitin present at an 
interface among two ubiquitins (Fisher et al., 2003) (Figure 12). Indeed, the human S5a accordingly has much 
stronger binding affinity for polyubiquitinated protein than for mono- and di-ubiquitinated proteins, which may 
be responsible for the preferential recognition of polyubiquitinated proteins as proteasome substrate (Young et 
al., 1998). 
A recent study screening additional ubiquitin receptors identified Rpn13 as another important intrinsic ubiquitin 
receptor in the proteasome (Husnjak et al., 2008; Schreiner et al., 2008). Rpn13 docks at the 19S RP by binding 
to Rpn2 and has a C-terminal region that binds a deubiquitinase Uch37/UCHL5. Importantly, it was found that 
Rpn13 binds ubiquitin and a subset of ubiquitin-like proteins via a conserved N-terminal region termed the 
Pleckstrin-like receptor for ubiquitin (Pru) domain, which has been shown to bind K48-linked diubiquitin with 
an affinity of approximately 90 nM (Schreiner et al., 2008). The Pru domain contains two β-sheets orthogonally 
packed against each other and a C-terminal α-helix, which is located in the crevice of a β-sandwich. The 
ubiquitin binding entities of Rpn13 are distributed into three non-contiguous loops within the Pru domain, 
significantly differing from those of Rpn10 (Figure 12). Sequence analysis reveals that the Pru domain is highly 
conserved in eukaryotic organisms from yeast to mammals, indicating that the Pru domain of Rpn13 is indeed an 
inhered ubiquitin receptor of the 26S proteasome (Husnjak et al., 2008). 
Besides the intrinsic ubiquitin receptors in the 26S proteasome, several UBL-UBA proteins appear to be 
extrinsic ubiquitin receptors involved in the recognition of proteasome substrates and the delivery of the 
substrates to the proteasome (Winget et al., 2010). These proteins typically have a ubiquitin-like (UBL) domain 
and one or two ubiquitin-associated (UBA) domain(s) (Elsasser et al., 2005). The N-terminal UBL domain 
serves as a docking site for the 19S RP of the proteasome, whereas the UBA domain binds ubiquitin (Elsasser et 
al., 2005). The 19S RP-localized Rpn10 and Rpn1 have been shown to be possible binding sites for the UBL 
domain of the UBL-UBA proteins (Hiyama et al., 1999; Elsasser et al., 2002). The UBA domain forms a large 
hydrophobic surface patch that interacts with the hydrophobic surface on the five-stranded β-sheet of ubiquitin 
(Mueller et al., 2002). As such, the UBL-UBA proteins function as shuttle factors that deliver the ubiquitinated 
substrates to the proteasome for degradation (Elsasser et al., 2005). Three UBL-UBA proteins have been 
identified in yeast, namely Rad23, Dsk2, and Ddi1, which have multiple orthologs in higher eukaryotes (Elsasser 
et al., 2005). The UBL-UBA proteins may have different ubiquitin chain specificities. The UBA domain of 
hRad23A (human Rad23 isoform A) prefers K48-linked chains, whereas the UBA domain in human Dsk2 has no 
notable preference for K48- compared to K63-linked ubiquitin chains (Zhang et al., 2008). 
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Figure 12. Ubiquitin receptors. A) Domain organization of the intrinsic Ub receptors S5a (human) and Rpn13 and the 
extrinsic receptors Rad23 and Dsk2. B) Distinct modes of interaction with Ub are used by different ubiquitin receptors. 
Amino acids of each ubiquitin-interacting domain are highlighted in red. vWA, von Willebrand factor A domain; UIM, 
ubiquitin-interacting motif; Pru, Pleckstrin-like receptor for ubiquitin domain; UBL, ubiquitin-like domain; UBA, 
ubiquitin-associated domain. Modified from (Tomko et al., 2013) 
 
1.4.2.2.2  Deubiquitination at the proteasome 
After binding to the proteasome, the polyubiquitinated substrates undergo deubiquitination at the proteasome 
either prior to or potentially concomitant with substrate unfolding (Tomko et al., 2013). As aforementioned, a lid 
metalloprotease Rpn11 is responsible for the cleavage of the ubiquitin chain off the substrate (Yao et al., 2002). 
Although Rpn11 is unlikely an ATPase, the deubiquitinating activity of Rpn11 appears to be ATP-dependent, 
most likely due to the fact that protein unfolding by the ATPase(Rpt)-ring facilitates the action of Rpn11 (Lee et 
al., 2011). A recent study using electron microscopy reported that the active site of Rpn11 is positioned 10-20 Å 
over the pore of the ATPase-ring. During the protein unfolding process, a conformational change in the protein 
positions the polyubiquitin chain near the pore of the ATPase-ring, bringing it into the position that allows 
Rpn11 to act (Lander et al., 2012). In agreement, Rpn11 preferentially cleaves the ubiquitin proximal to the 
substrate protein’s end, thereby cutting the polyubiquitin chain as a whole. The deubiquitination catalyzed by 
Rpn11 may further promote protein unfolding and threading through the ATPase-ring (Verma et al., 2002). 
In addition to Rpn11, the 26S proteasome harbors two extrinsic DUBs associated with the 19S RP, the ubiquitin 
carboxy-terminal hydrolase-37 (Uch37) and the ubiquitin-specific protease-6 (Ubp6, in human USP14) (Lee et 
al., 2011). Both of them are cysteine proteases, which are different from the Zn2+-dependent metalloprotease 
Rpn11. Uch37 binds the 19S RP by docking to the C-terminal domain of Rpn13, whereas Ubp6 principally binds 
to Rpn1 via its N-terminal ubiquitin-like domain. Interestingly, both enzymes must be activated via 
incorporation into the 19S complex, indicating that their ubiquitin chaining-trimming role is important and 
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restricted at the proteasome (Leggett et al., 2002; Hu et al., 2005). In contrast to Rpn11, Uch37 and Ubp6 trim 
ubiquitin chains from the distal end, thereby editing the length of the polyubiquitin chain of substrate proteins 
(Kim et al., 2011). More strikingly, the removal of ubiquitin catalyzed by the two DUBs appears to antagonize 
the protein degradation by the proteasome (Hanna et al., 2006). A commonly accepted view is that trimming the 
ubiquitin chain with the two DUBs provides a quality control mechanism, allowing poorly ubiquitinated or 
unproductively bound substrates to escape the proteasomal degradation (Ehlinger et al., 2013). Therefore, the 
deubiquitination concertedly operated by Rpn11, Uch37 and Ubp6 at the proteasome plays important decisive 
roles in initiating the proteasomal degradation. 
 
1.4.2.2.3  Substrate unfolding and translocation 
In order to be degraded, the substrate protein must enter the 20S CP and come in contact with the proteolytic 
beta-subunits. Unfolding of protein substrates is therefore necessary in order for the protein to enter into the 
narrow channel of the 20S CP (Finley et al., 2012). Substrate unfolding has been demonstrated to be a strictly 
ATP-dependent process, which is catalyzed by the heterohexameric ATPase-ring in the 19S base (Rabl et al., 
2008). The studies on the archaeal ATPase complex PAN (Proteasome-Activating Nucleotidase), the homolog of 
eukaryotic ATPase ring complex, have advanced our knowledge in understanding the protein unfolding process. 
It was proposed that a conserved aromatic hydrophobic (Ar-Φ) loop protrudes from every ATPase subunit into 
the pore of the ATPase ring. Upon ATP hydrolysis, conformational changes of the ATPase domains move the 
pore loops along the axis of the channel, providing the driving force for substrate unfolding and translocation 
(Sauer et al., 2011). 
 
1.4.2.2.4  Proteolysis 
Once the unfolded substrates thread into the 20S catalytic chamber, they are subjected to proteolysis by the 
proteolytic beta-subunits, β1, β2 and β5 (Finley et al., 2012). All the catalytic β subunits belong to the family of 
threonine proteases, which harbor an active-site threonine residue (Tomko et al., 2013). The mechanism of 
proteolysis involves a threonine-dependent nucleophilic attack of the substrate. The three catalytic subunits 
differ in their catalytic preference: β1 cleaves after acidic or small hydrophobic amino acids, β2 cuts after basic or 
small hydrophobic amino acids, while β5 hydrolyzes the peptide bond after hydrophobic residues regardless of 
whether they are bulky or not (Dick et al., 1998). In most cases, the proteasome cleaves protein substrates into 
small peptides with lengths of 3 and 23 amino acids (Kisselev et al., 1999), and the peptides can be further 
hydrolyzed by downstream proteases and aminopeptidases (Glickman et al., 2002). The products of proteasomal 
degradation can be utilized as amino acid sources for protein biosynthesis or for antigen presentation by major 
histocompatibility complex (MHC) class I molecules (Glickman et al., 2002; Warnatsch et al., 2013). 
Notably, although the proteasome mainly breaks down the ubiubiquitinated protein substrates, it may also 
degrade a number of non-ubiquitinated substrates, i.e. ubiquitin-independent degradation by the proteasome. An 
exemplary non-ubiquitinated proteasome substrate is ornithine decarboxylase (ODC), a key enzyme in 
polyamine biosynthesis (Zhang et al., 2003). It has been revealed that the proteasomal degradation of ODC is 
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mediated by its inhibitory partner, the antizyme (AZ) (Coffino 2001). Antizyme physiologically binds ODC and 
promotes its association with the proteasome, where the exposure of an unstructured region of ODC provides the 
initiation site for protein unfolding at the 19S RP, thereby facilitating further degradation by the 20S CP 
(Godderz et al., 2011). In contrast to ODC, some proteins are degraded by the 20S CP without the participation 
of the 19S RP. Blm10, a 246-kDa HEAT-repeat protein, functions as a “CP activator” (Dange et al., 2011). A 
certain amount of 20S CP (20% in yeast) is bound to Blm10 instead of 19S RP (Schmidt et al., 2005). Blm10 
binds to the 20S CP via its C-terminus, by which Blm10 regulates the gate opening of 20S CP. By doing so, 
Blm10 may preferentially mediate the degradation of proteins that can bypass the ATP-dependent unfolding step, 
i.e. the substrate spontaneously unfolds at a high frequency or is constitutively unfolded (Dange et al., 2011). 
 
1.4.3 Proteasome inhibitors 
Because a great diversity of intracelluar proteins is degraded through the proteasome, proteasomal functions are 
profoundly involved in various biological processes, including protein quality control, antigen processing, signal 
transduction, cell cycle control, cell differentiation, and apoptosis (Glickman et al., 2002). Thereby, proteasome 
inhibitors are of great biological significance in intervention of certain cellular pathways via modulating the 
proteasomal activity (Nalepa et al., 2006). So far, five classes of proteasome inhibitors have been found, 
including peptide aldehydes, peptide vinyl sulphones, peptide boronates, peptide epoxiketones and β-lactones 
(Borissenko et al., 2007). Of note, proteasome inhibitors have been found to exhibit potent anticancer efficacy. 
Particularly, bortezomib, a small-molecule inhibitor of the 20S proteasome particle, has been successfully 
developed to become an anti-neoplastic drug for the treatment of relapsed and refractory multiple myeloma 
(Adams 2004). Importantly, bortezomib and other proteasome inhibitors show selective cytotoxicity to 
cancerous cells compared to normal cells in both in vitro and in vivo assays. The selectivity and specificity of 
proteasome inhibitors on cancerous cells may be due to the rapid proliferation rate of many cancerous cells that 
might make these cells more dependent on the proteasome to remove misfolded or damaged proteins, the 
accumulation of which may induce apoptosis (Adams 2004). 
 
1.4.4 The ubiquitin-proteasome system of Plasmodium 
1.4.4.1 The UPS in Plasmodium 
As eukaryotes, Plasmodium parasites are supposed to preserve the UPS as the major machinery for intraparasitic 
protein degradation (Chung et al., 2010). In fact, independent lines of evidence indicate the presence of a 
functional UPS in Plasmodium parasites. Over half of the parasite proteins have been predicted to be targets for 
ubiquitination, especially the proteins found to be present in the trophozoite and schizont stages (Ponts et al., 
2011). Besides, annotation of the genome for P. falciparum has revealed a similar componential profile of the 
plasmodial UPS to those of higher eukaryotic organisms. Notably, the UPS pathway in P. falciparum was 
deduced by Dr. Hagai Ginsburg. (http://sites.huji.ac.il/malaria/maps/proteaUbiqpath.html). Recently, Ponts et al. 
have conducted a comprehensive in silico analysis of proteins predicted to be involved in the apicomplexan 
ubiquitin-mediated pathway. Their study revealed a set of essential components in the ubiquitin pathway of P. 
Introduction 
23 
falciparum, including a plasmodial homolog of ubiquitin and ubiquitin-like molecules, ubiquitination enzymes 
(E1, E2, and E3), and deubiquitinases (Ponts et al., 2008). Consistent to the in silico studies, ubiquitin conjugates 
have been detected abundantly in P. falciparum of all intraerythorytic stages (Ponts et al., 2011). Furthermore, 
purification of ubiquitin conjugates in P. falciparum using anti-conjugated ubiquitin antibody has allowed the 
identification of 437 ubiquitinated proteins in the intraerythrocytic parasites (Ponts et al., 2011). Several 
ubiquitination components in P. falciparum have also been biochemically characterized. Importantly, Chung et 
al. have recently characterized a cascade of fully functional ubiquitination enzymes that are specifically involved 
in the endoplasmic reticulum-associated degradation (ERAD) pathway of P. falciparum (Chung et al., 2012). 
Besides, two putative deubiquitinases of P. falciparum, PfUCH54 and PfUCHL3, have been characterized in 
detail (Artavanis-Tsakonas et al., 2006; Artavanis-Tsakonas et al., 2010). Interestingly, PfUCH54 was 
demonstrated to have an additional deneddylating activity in vitro, which is absent from its human counterpart 
(Artavanis-Tsakonas et al., 2006). 
In addition to the ubiquitination pathway, the eukaryotic 26S proteasome also appears to be present in 
Plasmodium. An in silico search (Basic Local Alignment Search Tool, BLAST) using human 26S proteasome 
components as queries has revealed that the P. falciparum genome encodes all essential 26S proteasome subunits 
sharing high similarities with corresponding counterparts in human 26S proteasome (Aminake et al., 2012). In 
agreement, Sessler and coworkers have managed to separate and detect the 20S CP complex in the schizont stage 
of P. falciparum by using an approach based on the blue native polyacrylamide gel electrophoresis (BN-PAGE) 
(Sessler et al., 2012). Consistently, by using a specific antibody against the P. falciparum β5 subunit, Aminake et 
al. have observed that the β5 subunit is abundantly localized in the cytoplasm and nucleus of parasite 
trophozoites and schizonts as well as in the cytoplasm of gametocytes (Aminake et al., 2011). Interestingly, it 
has been suggested that the P. falciparum proteasome may somewhat differ from the human proteasome in the 
insertion of Plasmodium-specific domains in certain proteasomal subunits, for example the asparagine-rich 
domain found in the plasmodial Rpn6 subunit and a large insert in the plasmodial β1 subunit (Muralidharan et al., 
2011; Sridhar et al., 2013). 
 
1.4.4.2 Inhibition of the plasmodial proteasome 
Due to the essential roles of the UPS in all eukaryotic cells and the successful application of proteasome 
inhibitors in cancer therapeutics, a number of human proteasome inhibitors have been tested for their 
antiparasitic efficacy against Plasmodium (Gantt et al., 1998; Lindenthal et al., 2005; Reynolds et al., 2007; 
Czesny et al., 2009; Aminake et al., 2011). As expected, human proteasome inhibitors have been demonstrated 
to exhibit potent antiplasmodial activities. Their potency is reflected by their efficiency in inhibiting 
Plasmodium in vitro at nanomolar concentrations (Table 1). Accumulation of ubiquitinated protein was 
commonly observed in the parasite lysate after treatment of the parasites with proteasome inhibitors, providing 
indirect evidence that the plasmodial proteasome is affected (Lindenthal et al., 2005; Aminake et al., 2011). 
A remarkable advantage of proteasome inhibitors is their capability to inhibit Plasmodium parasites across 
different life stages. Different proteasome inhibitors have been shown to inhibit parasite growth in erythrocytic 
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stages at low nanomolar concentrations (Table 1). Particularly, the proteasome inhibitors lactacystin and 
MLN273 (a compound related to bortezomib) have been reported to have antiparasitic effects on liver stage 
parasites. Both can block the development of exoerythrocytic forms in liver hepatoma cells in vitro, and 
lactacystin has been shown to inhibit the infectivity of P. berghei in a mouse model (Gantt et al., 1998; 
Lindenthal et al., 2005). Furthermore, MG132 and epoxomicin have been reported to exhibit in vitro 
gametocytocidal effects within nanomolar concentrations, indicating that proteasome inhibitors may be 
applicable in transmission blockage by targeting Plasmodium gametocytes (Czesny et al., 2009; Aminake et al., 
2011). Of particular importance, it has been found that proteasome inhibitors are equipotent against 
chloroquine-resistant Plasmodium parasites, suggesting that targeting the plasmodial proteasome may be a 
promising strategy that may bypass the issue of chloroquine resistance in treating malaria parasites (Reynolds et 
al., 2007; Kreidenweiss et al., 2008; Prudhomme et al., 2008; Aminake et al., 2011). 
 
Table 1. The antimalarial effect of proteasome inhibitors＊. 
 
Liver stages 
100% inhibition [μM] 
Blood stages 
IC50 [μM] 
Gametocytes 
100% elimination [μM] 
Bortezomib n.d. 0.03–0.56 n.d. 
Epoxomicin n.d. 0.002–0.03 0.03 
Lactacystin 9.0 1.2–1.5 n.d. 
MG-132 n.d. 0.04–0.05 0.5 
MLN273 1.0 0.04 n.d. 
Salinosporamide A n.d. 0.01 n.d. 
Thiostrepton n.d. 8.9–16.7 8.9 
＊Modified from (Aminake et al., 2012) 
 
1.5 Aim of the study 
The thesis consists of two parts: the study of protein S-nitrosylation in P. falciparum and the characterization of 
the 26S proteasome network in P. falciparum. The aims of each part are described below. 
1) Protein S-nitrosylation in P. falciparum 
As discussed before, it is evident that during its life cycle in humans and mosquito vectors, P. falciparum is 
exposed to NO and NO-derived reactive nitrogen species, which certainly have impacts on the development of 
the parasites. However, the mode of action of NO and its targets in P. falciparum have hardly been characterized. 
A striking biochemical feature of NO is to induce protein S-nitrosylation, and this protein modification has 
emerged as a principal mechanism by which NO exerts diverse biological effects. We therefore speculate that 
protein S-nitrosylation could also serve as an important mechanism for NO to exert biological functions in P. 
falciparum. In the study, we aimed to globally identify S-nitrosylated proteins in P. falciparum in order to shed 
light on potential NO targets in the parasites. Furthermore, we planned to study how protein S-nitrosylation is 
regulated in the parasites with respect to protein transnitrosylation and denitrosylation. This study should 
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contribute to our knowledge and understanding of how NO acts in malaria parasites and what the mechanism of 
NO toxicity/signaling in the malaria parasite might be. 
2) Characterization of the 26S proteasome network in P. falciparum 
Although compelling data have indicated the presence of a functional 26S proteasome network in P. falciparum, 
the componential integrity and functionality of the plasmodial 26S proteasome has not yet been systematically 
studied in detail. Besides, what might be different in the plasmodial 26S proteasome network compared to that 
of humans remains totally unclear. Therefore, this study aims to characterize (i) important components in the 
plasmodial proteasome system, mainly focusing on the factors that mediate the substrate recognition by the 
plasmodial proteasome, (ii) the componential integrity of the plasmodial 26S proteasome complex, and (iii) to 
identify important proteasome-interacting partners. In order to achieve these goals, we aim to develop an affinity 
purification method to isolate the intact plasmodial 26S proteasome together with proteasome-interacting 
partners from P. falciparum. By doing so, we sought to provide an initial insight into the 26S proteasome 
network in P. falciparum and pave the way for developing novel antimalarial agents targeting the UPS.
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2. MATERIALS 
2.1 Chemicals 
Chemical Company 
1,4-Dithiothreitol (DTT) Roth, Karlsruhe 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth, Karlsruhe 
6-Aminohexanoic acid Roth, Karlsruhe 
7-Amino-4-methylcoumarin (AMC) Enzo life Science, Lörrach 
Acetic acid Acrylamide and bis-acrylamide solution (30/0.8%) Roth, KarlsruheBioRad, München 
Acetonitrile Sigma Aldrich, Steinheim 
Adenosinetriphosphate (ATP) Sigma Aldrich, Steinheim 
Agarose PeqLab, Erlangen 
Albumax Gibco, Karlsruhe 
Alkynyl biotin Invitrogen, USA  
Ammonium acetate Sigma Aldrich, Steinheim 
Ammonium persulfate (APS) Sigma Aldrich, Steinheim 
Ammonium sulfate Roth, Karlsruhe 
Azido myristic acid Invitrogen, USA  
Bacto-Agar Roth, Karlsruhe 
Boric acid Roth, Karlsruhe 
Bovine serum albumin (BSA) Roth, Karlsruhe 
Bradford reagent BioRad, München 
Bromophenol blue Sigma Aldrich, Steinheim 
Bz-Val-Gly-Arg-AMC (Bz-VGR-AMC) Enzo life Science, Lörrach 
Calcium chloride Roth, Karlsruhe 
Carbenicillin Roth, Karlsruhe 
Complete protease inhibitors Roche, Mannheim 
Coomassie brilliant blue R250 Sigma Aldrich, Steinheim 
Coumaric acid Sigma, Steinheim 
Cystatin Roth, Karlsruhe 
Dimethyl sulfoxide (DMSO) Roth, Karlsruhe 
Dipotassium phosphate (K2HPO4) Roth, Karlsruhe 
Disodium hydrogen phosphate (Na2HPO4) Roth, Karlsruhe 
dNTPs Fermentas, St. Leon-Rot 
Ethanol Roth, Karlsruhe 
Ethidium bromide Sigma Aldrich, Steinheim 
Ethylene glycol tetraacetic acid (EGTA) Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Roth, Karlsruhe 
Formic acid Sigma Aldrich, Steinheim 
Gentamycin Invitrogen, Karlsruhe 
Giemsa (0.4%, w/v) Sigma Aldrich, Steinheim 
Glucose Merck, Darmstadt 
Glutathione disulfide (GSSG) Sigma Aldrich, Steinheim 
Glutathione reduced (GSH) Sigma Aldrich, Steinheim 
Glycerol Roth, Karlsruhe 
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Glycin Roth, Karlsruhe 
Hydrochloric acid Roth, Karlsruhe 
Hydrogen peroxide Sigma Aldrich, Steinheim 
Imidazole Roth, Karlsruhe 
Iodoacetamide (IAA) Sigma Aldrich, Steinheim 
Iodoacetyl-PEG2-biotin Thermo Scientific Pierce 
Isopropanol Roth, Karlsruhe 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Roth, Karlsruhe 
Kanamycin Roth, Karlsruhe 
Lactacystin Enzo life Science, Lörrach 
L-Arabinose Sigma Aldrich, Steinheim 
Luminol Sigma Aldrich, Steinheim 
Magnesium chloride Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
Methyl methanethiosulfonate (MMTS) Sigma Aldrich, Steinheim 
MG132 Enzo life Science, Lörrach 
Milk powder Roth, Karlsruhe 
Neocuproine Sigma Aldrich, Steinheim 
Nickel-nitrilotriacetic acid (Ni-NTA) Qiagen, Hilden 
Nicotinamide adenine dinucleotide (NAD+) Sigma Aldrich, Steinheim 
PEG 3350 (Polyethylene glycol) Roth, Karlsruhe 
PEG 6000 Roth, Karlsruhe 
Pepstatin A Sigma Aldrich, Steinheim 
Phenylmethylsulfonylfluoride (PMSF) Sigma Aldrich, Steinheim 
Phosphate buffered saline tablet Sigma Aldrich, Steinheim 
Phosphoenolpyruvate (PEP) Sigma Aldrich, Steinheim 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe 
Potassium hydroxide (KOH) Roth, Karlsruhe 
Potassiumchloride (KCl) Roth, Karlsruhe 
RPMI 1640 Gibco Invitrogen, Karlsruhe 
Saccharose Roth, Karlsruhe 
Saponin Roth, Karlsruhe 
S-nitrosoglutathione (GSNO) Sigma Aldrich, Steinheim 
Sodium acetate Roth, Karlsruhe 
Sodium ascorbate (NaAsc) Sigma Aldrich, Steinheim 
Sodium chloride (NaCl) Roth, Karlsruhe 
Sodium dihydrogen phosphate (NaH2PO4) Roth, Karlsruhe 
Sodium dodecyl sulphate (SDS) Merck, Darmstadt 
Sodium hydrogen carbonate (NaHCO3) Roth, Karlsruhe 
Sodium orthovanadate (Na3VO4) Sigma Aldrich, Steinheim 
SoftLink™ Soft Release avidin Promega, Mannheim 
Sorbitol Sigma Aldrich, Steinheim 
Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC) Enzo life Science, Lörrach 
Tetramethylethylenediamine (TEMED) Sigma Aldrich, Steinheim 
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Tetramethylethylenediamine (TEMED) Sigma Aldrich, Steinheim 
Triethylamine hydrochloride (TEA-HCl) Sigma, Steinheim 
Tris(2-carboxyethyl)phosphine (TCEP) Sigma Aldrich, Steinheim 
Tris(hydroxymethyl)aminomethane (Tris) Roth, Karlsruhe 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) Sigma Aldrich, Steinheim 
Triton X-100 Sigma Aldrich, Steinheim 
Trypton Roth, Karlsruhe 
Tween 20 Merck, Darmstadt 
Urea Roth, Karlsruhe 
Yeast extract Oxoid LTD, U.K 
Z-Leu-Leu-Glu-AMC (Z-LLE-AMC) Enzo life Science, Lörrach 
 
2.2 Biological materials 
2.2.1 Antibodies 
Antibody Source 
Mouse anti-histidine6-tag antibody Dianova, Hamburg 
HRP Anti-mouse IgG antibody Pierce, Rockford 
Anti-biotin antibody Santa Cruz, California 
Anti-ubiquitin antibody Sigma Aldrich, Steinheim 
Anti-GST-HRP conjugates GE Healthcare, Freiburg 
 
2.2.2 Plasmids 
Plasmids Antibiotic resistance Source 
pGEM-T Easy Carbenicillin Promega, Mannheim 
pQE30 Carbenicillin Qiagen, Hilden 
pGEX-4T Carbenicillin GE Healthcare, Freiburg 
pRSET Carbenicillin Invitrogen, USA 
 
2.2.3 E. coli strains 
E. coli strains Usage Source 
XL-1 Blue Cloning and plasmid preparation Stratagene, Amsterdam 
BL21 Overexpression Invitrogen, Karlsruhe 
M15 Overexpression Qiagen, Hilden 
 
2.2.4 Enzymes 
2.2.4.1 DNA polymerase 
Enzyme Company 
AccuPrimeTM Taq DNA polymerase Invitrogen, Karlsruhe 
Pfu DNA polymerase Promega, Mannheim 
RedTaq® DNA polymerase Sigma Aldrich, Steinheim 
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2.2.4.2 Restriction enzymes 
Enzyme Cleavage sequence Source 
BamHI 5'-G↓GATCC-3' Fermentas, St. Leon-Rot 
HindIII 5'-A↓AGCTT-3' Fermentas, St. Leon-Rot 
EcoRI 5'-G↓AATTC-3' Fermentas, St. Leon-Rot 
2.2.4.3 Other enzymes 
Enzyme Function Source 
DNaseI DNA digestion Roche, Mannheim 
Lysozyme Cell lysis Sigma Aldrich, Steinheim 
T4 Ligase Nucleotide fragment ligation Fermentas, St. Leon-Rot 
 
2.2.5 Kits 
Kit Source 
Bradford assay kit Bio-Rad, München 
QIAprep Spin Miniprep kit Qiagen, Hilden 
QIAprep Spin Maxiprep kit Qiagen, Hilden 
QIAquick PCR purification kit Qiagen, Hilden 
Silver staining kit Pierce, Rockford 
 
2.2.6 Materials of affinity chromatography 
Material Source 
Nickel-nitrilotriacetate-agarose (Ni-NTA) Qiagen, Hilden 
GSH-sepharose 4B GE Healthcare, Freiburg 
 
2.2.7 Plasmodium falciparum strain  
Plasmodium falciparum strain                      Source  
3D7 (Chloroquine-sensitive)                         Prof. Lanzer, Heidelberg University 
 
2.2.8 Medium for E. coli culture 
Culture medium Recipe 
Lysogeny broth medium (LB), 1 L 10 g Tryptone 
 5 g Yeast extract 
 10 g NaCl 
Terrific broth medium (TB), 1 L 12 g Tryptone 
 24 g Yeast extract 
 9,4 g K2HPO4 
 2,2 g KH2PO4 
 4 ml Glycerol 
 
2.3 Buffers and solutions 
2.3.1 Buffer for DNA electrophoresis 
DNA Sample buffer 0.1% Bromophenol blue 
 60% Saccharose 
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 1 mM Tris  
 pH 8.3 HCl (adjustment) 
10 X TBE (electrophoresis buffer) 1 M Tris  
 1 M Boric acid 
 20 mM EDTA  
 pH 8.0 Acetic acid (adjustment) 
 
2.3.2 Buffer for isolation of P. falciparum parasites 
Saponin lysis buffer 7 mM K2HPO4 
 1 mM MgCl2 
 1 mM NaH2PO4 
 11 mM NaHCO3 
 58 mM KCl 
 56 mM NaCl 
 14 mM Glucose 
 0.02% Saponin 
 pH 7.4 HCl (adjustment) 
 
2.3.3 Buffer for SDS-PAGE electrophoresis 
Electrophoresis buffer 193 mM Glycine 
 25 mM Tris 
 0.1% (w/v) SDS 
 pH 8.3 HCl (adjustment) 
SDS sample buffer (4X) 240 mM 1 M Tris-HCl, pH 6.8 
 8% (w/v) SDS 
 40% (v/v) Glycerol 
 5% (v/v) 14.7 M β-Mercaptoethanol 
 0.04% (w/v) Bromophenol blue 
Coomassie staining solution 0.2% (w/v) Coomassie brillant blue R250 
 40% (v/v) 2-Propanol 
 10% (v/v) Acetic acid 
Coomassie destaining solution 10% (v/v) Acetic acid 
 40% (v/v) Methanol 
 
2.3.4 Buffer for Western blot  
Trans-blotting buffer 25 mM Tris 
 192 mM Glycerol 
 20% Methanol 
TBS buffer 10 mM Tris 
 155 mM NaCl 
 pH 8.0 HCl (adjustment) 
TBS-Tween (TBST) 0.05% Tween 20 (in TBS buffer) 
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Ponceau S staining solution 1% (w/v) Ponceau S 
 5% (v/v) Acetic acid 
Ponceau S destaining solution 1% (w/v) Acetic acid 
Luminol solution (store in the dark at 4 °C) 1.25 mM Luminol 
 0.0093% (v/v) H2O2 
 0.1 M Tris-HCl, pH 8.6 
 
2.4 Instruments 
Instruments Producer 
Analytical balance Scaltec Instruments, Göttingen 
Autoclave Webeco, Bad Schwartau 
Beckman Optima Max ultracentrifuge Beckmann, Munich 
Bio photometer Eppendorf,Hamburg 
Eppendorf Research® plus pipettes Eppendorf, Hamburg 
Eppendorf thermomixer Eppendorf, Hamburg 
FPLC software Unicorn Amersham Bioscience, Freiburg 
FPLC system ÄKTA-FPLC Amersham Bioscience, Freiburg 
Fraction collector Frac-100 Pharmacia Biotech, Freiburg 
Freezer -86 °C Heraeus Instruments, Hanau 
Gene pulser Xcell Electroporation BioRad, Munich 
GEL DOC 2000 system BioRad, Munich 
HeraCell CO2 incubator for P. falciparum culture Heraeus Instruments, Hanau 
Hitachi U-2001 spectrophotometer Hitachi, Schwäbisch Gmünd 
Magnetic stirrers RCT basic IKA Werke, Staufen 
Mastercycler® thermal cyclers Eppendorf, Hamburg 
Megafuge 1.0R centrifuge Heraeus Instruments, Hanau 
Mini-PROTEAN cell electrophoresis module BioRad, Munich 
Minispin® centrifuge Eppendorf, Hamburg 
Mitsubishi P91 photo printer Mitsubishi, Ratingen 
Neolab heating block NeoLab, Heidelberg 
OptimaTM TLX ultracentrifuge Beckmann, Munich 
OptiMax X-ray film processor Protec, Oberstenfeld 
QuadroMACS® magnetic separator Miltenyi Biotec GmbH, Bergisch Gladbach 
Owl EasyCast B1A mini gel electrophoresis systems Thermo Scientific, Dreieich 
pH meter Beckman, Munich 
Pharmacia LKB Multiphor II NovaBlot Amersham Pharmacia Biotech, Freiburg 
Rotor Sorvall SLA 3000, SS34 Thermo Fisher Scientific, Waltham, USA 
Sonopuls GM 70 ultrasonicator BandelinElectronics, Berlin 
Sorvall® RC5BPlus centrifuge ThermoScientific, Waltham, USA 
Thermomixer comfort Thermo Life Sciences, Egelsbach 
Tecan Infinite M200 PRO Tecan, Switzerland 
Ultra pure water system MembraPure, Bodenheim 
UV/Vis-Spectrophotometer Beckman DU® 650 Beckmann, Munich 
Vortex minishaker MS2 IKA Werke, Staufen 
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3. METHODS 
3.1 General methods 
3.1.1 Preparation of competent E. coli cells 
E. coli cells were inoculated into 3 mL LB medium and grown overnight (~ 15 hours) in a shaking incubator at 
37 °C. Then 150 mL LB medium was inoculated with the overnight culture, and the cells were grown until the 
value of the optical density at a wavelength of 600 nM (OD600) of the culture mixture reached 0.6. The culture 
was then transferred into Falcon tubes and placed on ice for 10 min. After the culture was centrifuged at 4,000 g 
at 4 °C for 10 min, the cell pellet was resuspended in 10 ml ice-cold sterile resuspension buffer containing 0.1 M 
CaCl2 and 10% glycerol and left on ice for 15 min. Then the cell pellet was resuspended with the resuspension 
buffer and the centrifugation was repeated. In the end, the pellet was resuspended in 1.5 ml ice-cold sterile 
resuspension buffer and aliquoted into sterile Eppendorf tubes and frozen in liquid nitrogen for 3 minutes. Then 
the cells were stored at -80 °C. 
 
3.1.2 Cleavage of double strand DNA by restriction endonucleases and ligation 
The DNA fragments of PCR products or plasmids were cleaved by restriction endonucleases, which has the 
function of recognizing and cutting DNA at a specific nucleotide sequence known as the restriction site (Roberts 
1976). The DNA fragments were digested by the respective Fermentas restriction enzymes in an appropriate 
buffer at 37 °C for 1 hour according to the manufacture’s instruction. The cleaved DNA was purified by a 
QIAquick PCR purification kit and further used for ligation. The DNA concentration was determined via 
measuring its absorption at 260 nm. The purity of the DNA sample was examined by the ratio of 
A260nm/A280nm, which normally ranges from 1.8 to 2.0. 
The ligation of cleaved PCR products with plasmid was carried out by using a T4 ligation system. A T4 ligase 
catalyzes the linkage by forming a phosphodiester bond between the 5' phosphate group of one fragment and the 
3' hydroxyl group of the other. Different molar ratios of the plasmid to the DNA fragment (insert) varied from 
1:3 to 1:5 in the ligation system and 1 unit T4 ligase was used. The ligation mixture was left for 1 hour at RT 
(room temperature) or 4 °C overnight to complete the reaction. In some cases, the ligation can be finished within 
10 min by using a quick ligation system. 
 
3.1.3 Transformation of competent E. coli cells 
Transformation was carried out to insert plasmid DNA to competent E. coli cells. For this purpose, about 100 μL 
of competent E. coli cells were completely thawed on ice and 1 μL plasmid DNA was added to the cells and 
carefully mixed. The E. coli cells were placed on ice for 30 min. Then the cells were heated for 90 sec at 42 °C 
to induce a heat shock forcing the E. coli cells to take up plasmid DNA. Afterwards, the cells were placed on ice 
again for 2 min before a 400 μL of LB medium was added. The cells were incubated at 37 °C for one hour. 
Finally, the E. coli cells were plated on agar plates containing the appropriate antibiotics, and incubated at 37 °C 
overnight. Colonies were normally observed after 16-24 hours. 
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3.1.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate protein 
mixtures based on their molecular weights. Under denaturing conditions, SDS renders a negative charge to the 
proteins, resulting in the proteins being negatively charged in proportion to their molecular weights. Thus, within 
an electronic field, the proteins are fractionated by size (Laemmli 1970). Briefly, protein samples are mixed with 
4× reducing SDS sample buffer and boiled at 95 °C for 5 min in order to denature the proteins. A 12% or 15% 
SDS-PAGE gel was placed in an electrophoresis tank, and the electrophoresis buffer was added. Under a 200 
volt voltage, proteins migrated for about 40 min. Then the gel was subjected to Coomassie blue staining or silver 
staining to visualize the proteins in the gel. If western blot analysis was needed, the gel was directly used for 
trans-blotting proteins without staining. 
 
3.1.5 Western blot analysis 
Western blot analysis was generally used to detect either specific proteins or protein modifications with specific 
antibodies (Towbin et al., 1992). Briefly, after proteins were separated in a gel by SDS-PAGE, the gel was 
soaked in the trans-blotting buffer (25 mM Tris, 192 mM glycine, 20% methanol) for 10 min. In parallel, a 
polyvinylidene difluoride (PVDF) membrane was activated with pure methanol. The PVDF membrane and four 
filter papers were equilibrated with the trans-blotting buffer. Then the transfer sandwich was assembled with two 
filter papers, the gel, a PVDF membrane, and another two filter papers in the order from the cathode to the anode. 
For protein transfer, a Mini Trans-Blot® electrophoretic transfer cell (Bio-Rad) was used. The transfer cassette 
was placed in a tank and filled with the trans-blotting buffer. The transfer process was performed at a constant 
current of 300 mA for 1 hour with a cooling system. After the transfer, the PVDF membrane was stained with 
Ponceau S solution for 1 min and destained with 1% acetic acid until protein bands appeared. Then the PVDF 
membrane was washed in TBST solution until no protein band was visible. The PVDF membrane was then 
blocked by 5% non-fat milk for 1 hour at RT or overnight at 4 °C. After blocking, the membrane was washed 3 
times with TBST and incubated with a specific first antibody for 1 hour at RT with constant shaking. After the 
incubation with the first antibody, the membrane was intensively washed three times for 5 minutes each with 
TBST before a corresponding secondary antibody was added. After one-hour incubation, the membrane was 
again intensively washed, and an enhanced chemiluminescence (ECL) mixture containing 1 mL luminal solution 
and 10 μL coumaric acid was added to the PVDF membrane. The membrane was then placed in a film cassette 
and exposed to an X-ray film for an appropriate amount of time (30 sec to 1 min). 
 
3.1.6 Chromatography purifications of recombinant proteins 
The frozen resuspended E. coli pellet containing heterologously overexpressed recombinant proteins was first 
thawed and mixed with a small amount of DNAse and lysozyme (4 mg/g pellet). The mixture was then stirred on 
ice for 30 min to 1 hour, followed by ultra-sonication (three times for 30 sec each) to completely disrupt the cells 
and release proteins. The clear supernatant was taken out via centrifugation at 38,000 g for 30 min at 4 °C. 
For the purification of recombinant proteins fused with six additional histidine residues (6×His tag), the 
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supernatant was applied onto a pre-equilibrated nickel-nitrilotriacetate (Ni-NTA) column with a 1-2 mL bed 
volume of the Ni-NTA agarose. After the supernatant passed though the column, the column was washed with a 
20-column volume of an appropriate washing buffer. The bound proteins were then eluted using an appropriate 
elution buffer containing a gradient of imidazole concentrations (20-500 mM). The proteins in elution fractions 
were resolved via SDS-PAGE, and the purified proteins were checked with Coomassie blue staining. 
For the purification of recombinant GST-tagged proteins, the supernatant was applied onto a pre-equilibrated 
GSH-sepharose column with an appropriate volume of GSH-sepharose 4B resin. After all supernatant passed 
though the column, the column was washed with a 20-column volume of PBS. The GST-tagged proteins were 
then eluted using an appropriate elution buffer containing 10 mM reduced glutathione together wit 1 mM DTT. 
The proteins in elution fractions were resolved via SDS-PAGE, and the purified proteins were checked with 
Coomassie blue staining. 
To gain a high purity of the recombinant proteins, a gel filtration chromatography based on a 16/60 superdex200 
prep grade column connected to an ÄKTA FPLC system (Amersham Pharmacia Biotech) was used. The protein 
sample was concentrated to a volume of 1-2 mL, which can be loaded onto the column. The proteins were then 
separated based on their molecular weights on the superdex200 column at a flow rate of 1 mL/min. 
Protein-containing fractions were detected spectrophotometrically at 280 nm and collected, followed by 
SDS-PAGE analysis. The fractions containing target proteins were pooled and concentrated for further 
experiments. 
 
3.1.7 Protein concentration determination 
Protein concentrations were measured by using the Bradford method, which is based on the shift of the maximal 
absorbance of the Coomassie Brilliant Blue G-250 dye from 465 nm to 595 nm when the protein-dye complex is 
formed (Bradford 1976). To prepare a calibration curve for calculating protein concentrations, a series of BSA 
concentrations as standards was prepared. Five microliters of each standard was mixed with 495 μl 
double-distilled water (ddH2O). To each mixture, 125 μL of Bradford reagent (Bio-Rad) was added and 
immediately vortexed and incubated for 15 minutes at RT. The absorption at 595 nm of the respective standard 
sample was measured using a spectrophotometer. Then the calibration curve of absorption against the respective 
protein concentration was plotted. For the measurement of a sample, the same procedure was used and the 
protein concentration of the sample was be calculated according to the calibration curve. 
For the sample with a limited volume and a low protein concentration, the Bradford microassay was used. A 
calibration curve covering low protein concentrations (0-200 μg/mL) was prepared by using a 10 μL reaction 
system, in which 8 μL of the standard sample was mixed with 2 μL of Bradford reagent. Similarly, 8 μL of the 
sample to be measured was used following the same procedure. The absorption at 595 nm of the sample was 
measured on a NanoDrop spectrophotometer (Thermo Scientific) using only 1 μL of the reaction mixture. 
 
3.1.8 Cultivation of P. falciparum and isolation of the parasites 
Intraerythrocytic stages of P. falciparum were grown in continuous culture as described by Trager and Jensen 
Methods 
35 
(Trager et al., 1976), with slight modifications. Parasites were maintained at 1 to 10% parasitemia and 3.3% 
hematocrit in an RPMI 1640 culture medium supplemented with A+ erythrocytes, 0.5% lipid-rich bovine serum 
albumin (Albumax), 9 mM (0.16%) glucose, 0.2 mM hypoxanthine, 2.1 mM L-glutamine, and 22 mg/ml 
gentamicin. All incubations were carried out at 37 °C in 3% O2, 3% CO2, and 94% N2. Synchronization of 
parasites in culture to ring stages was carried out via treatment with 5% (w/v) sorbitol (Lambros et al., 1979). 
For experimental purposes, isolation and enrichment of P. falciparum parasites were performed. Trophozoite 
stage parasites were harvested by suspending red blood cells for 10 min at 37 °C in a 20-fold volume of saponin 
lysis buffer containing 7 mM K2HPO4, 1 mM NaH2PO4, 11 mM NaHCO3, 58 mM KCl, 56 mM NaCl, 1 mM 
MgCl2, 14 mM glucose, and 0.02% saponin, pH 7.4. After centrifugation at 1,500 g, the parasites pellet was 
washed with saponin lysis buffer followed by PBS. The parasite pellet can be kept frozen at -80 °C. 
 
3.2 Protein S-nitrosylation methods 
3.2.1 Preparation of P. falciparum cell extracts for protein S-nitrosylation analysis 
To identify S-nitrosylated proteins in P. falciparum, the parasite cell extracts were prepared directly from the 
harvested parasites, which had been untreated or treated with 100 or 400 μM GSNO for 1h or 4h in the cell 
culture. The preparation of parasite cell extracts was carried out under protection from light. A parasite pellet 
was suspended in an equal volume of lysis buffer containing 50 mM Tris, 1 mM EDTA, 0.2 mM neocuproine, 
and complete protease inhibitor (Roche, Germany), pH 7.4. Cells were disrupted with four freezing-thawing 
cycles and ultrasonication. The contaminating hemozoin was first removed via a centrifugation at 15,000 g for 
30 min at 4 °C, and then the clear supernatant was gained by an ultracentrifugation at 100,000 g for 30 min at 4 
°C. The protein concentration of the cell extracts was determined via the Bradford assay. A typical protein 
concentration in the cell extracts was 6-8 mg/mL. Cell extracts were immediately subjected to a biotin-switch 
assay for the detection of endogenous S-nitrosylated proteins. For detecting S-nitrosylated proteins in the cell 
extracts treated with GSNO, freshly prepared cell extracts (4 mg total protein) were incubated with 40 or 100 μM 
GSNO at 25 °C for 1 hour. The residual GSNO was removed by passing the cell extracts through a Zeba 
desalting column (Thermo Scientific), and the S-nitrosylated proteins were detected via the biotin-switch assay 
(see below). The cell extracts treated with 100 μM GSNO were used for the identification of S-nitrosylated 
proteins by mass spectrometry. 
 
3.2.2 Biotin-switch assay, detection of S-nitrosylated proteins, and purification of biotinylated proteins 
The biotin-switch assay was performed as previously described with modifications (Han et al., 2008; Forrester et 
al., 2009; Huang et al., 2010). P. falciparum cell extracts were diluted to 1 mg/mL with blocking buffer (8 M 
urea, 50 mM Tris, 1 mM EDTA, 0.1 mM neocuproine, pH 8.0) containing 200 mM methyl methanethiosulfonate 
(MMTS). The free cysteine thiols in cell extracts were blocked by MMTS via incubation at 50 °C for 30 min in 
the dark, with occasional vortexing. The reaction was stopped by adding three volumes of ice-cold acetone 
followed by protein precipitation at -20 °C for 30 min. After centrifugation at 5,000 g, the protein pellet was 
washed three times with 70% ice-cold acetone and completely dissolved in labeling buffer (4 M urea, 50 mM 
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Tris, 1 mM EDTA, 0.01 mM neocuproine, pH 8.0). The S-nitrosylated thiols were then switched to biotinylated 
thiols via incubation with 20 mM sodium ascorbate (NaAsc) and 0.2 mM iodoacetyl-PEG2-biotin (Pierce) for 1 
h at 25 °C in the dark with constant shaking. A control sample without NaAsc was prepared in parallel. The 
reaction was stopped via protein precipitation in acetone, and the protein pellet was washed three times to 
remove residual biotinylating reagents. 
To detect S-nitrosylated proteins, western blot analysis using anti-biotin antibodies was performed. Briefly, a 
protein pellet was dissolved in 0.2 mL labeling buffer and 2 μg of proteins per lane was subjected to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane, which was then blocked overnight at 4 °C with 5% 
non-fat milk in Tris-buffered saline Tween-20 (TBST). Signals corresponding to S-nitrosylated proteins tagged 
with biotin were visualized via protein immunoblotting using anti-biotin antibodies (Santa Cruz, diluted 1:1,000 
in 5% non-fat milk in TBST). 
To purify biotinylated proteins, the protein pellet was completely dissolved in 0.2 mL labeling buffer and diluted 
to 1 mL with pull-down buffer (50 mM Tris, 150 mM NaCl, pH 8.0). Samples were further dialyzed against 100 
mL pull-down buffer 3 times at RT. After dialysis, 150 μL of equilibrated SoftLink™ Soft Release avidin resin 
(Promega) was added and incubated with the samples overnight at 4 °C. The resin was collected and washed 
with 0.5 mL pull-down buffer six times in order to remove all unbound proteins. Biotinylated proteins were 
eluted by incubation of the resin with 0.5 mL pull-down buffer containing 5 mM biotin for 30 min at RT. The 
eluate was concentrated to 60 μL, and 15 μL were loaded into a 12% SDS-PAGE gel for silver staining. The rest 
was kept at -80 °C for the mass spectrometry analysis. 
 
3.2.3. Sample preparation for mass spectrometry 
Protein samples were present in 35-45 μL of buffer (50 mM Tris, 150 mM NaCl, 10 mM biotin) and had a 
concentration below the detection limit of a Bradford assay but were detectable via silver staining. Samples were 
diluted with 30 μL 16 M urea, 160 mM Tris pH 8.5; 3 μL of 100 mM TCEP (tris(2-carboxyethyl)phosphine) was 
added, and samples were incubated at RT for 20 min. Three microliters of 250 mM iodoacetamide (IAA) was 
added, and samples were incubated at RT for 20 min in the dark. Samples were diluted with 180 μL 100 mM 
Tris, pH 8.5, and trypsin was added (0.5 μg/μL). Samples were incubated at 37 °C overnight, and digestion was 
halted by adding 13.5 μL of 90% formic acid. Samples were spun for 20-30 min at 14,000 rpm and transferred to 
a new Eppendorf tube before pressure loading onto a microcapillary column. 
 
3.2.4. Multidimensional protein identification technology (MudPIT) 
The protein digest was pressure-loaded onto a fused silica capillary column containing 2.5 cm of Partisphere 
strong cation exchanger (Whatman, Clifton, NJ) followed by 2.5 cm of 10 µm Aqua C18 (Phenomenex, Ventura, 
CA) packed into a 250 µm inside diameter (i.d.) capillary (Polymicro Technologies, Phoenix, AZ) with a 1 µm 
frit. The column was washed for 60 min with buffer containing 95% water, 5% acetonitrile, and 0.1% formic 
acid. After washing, a 100-µm i.d. capillary with a 5-µm pulled tip packed with 15 cm 3-µm Aqua C18 material 
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(Phenomenex, Ventura, CA) was attached via a union, and the entire split column was placed in line with an 
Agilent 1100 quaternary high-performance liquid chromatography (HPLC) and analyzed using a modified 9-step 
separation similar to those described previously (Washburn et al., 2001). The buffer solutions used were 5% 
acetonitrile/0.1% formic acid (buffer A), 80% acetonitrile/0.1% formic acid (buffer B), and 500 mM ammonium 
acetate/5% acetonitrile/0.1% formic acid (buffer C). Step 1 consisted of a 75 min gradient from 0% to 100% 
buffer B. Steps 2-9 had the following profile: 10 min of X% buffer C, a 15 min gradient from 0% to 5% buffer B, 
and a 95 min gradient from 15% to 100% buffer B. The 10 min buffer C percentages were 10%, 20%, 30%, 40%, 
50%, 60%, 70%, and 100%, respectively, for the 9-step analysis. 
As peptides eluted from the microcapillary column, they were electrosprayed directly into an Orbitrap velos 
mass spectrometer (ThermoFisher, SanJose, CA) with the application of a distal 2.4 kV spray voltage. A cycle of 
one full-scan mass spectrum (400-1400 m/z) followed by 15 data-dependent tandem mass spectrometry (MS/MS) 
spectra at a 35% normalized collision energy was repeated continuously throughout each step of the 
multidimensional separation. Application of mass spectrometer scan functions and HPLC solvent gradients were 
controlled by the XCalibur data system. 
 
3.2.5. Analysis of tandem mass spectra 
Protein and modification identifications were done with Integrated Proteomics Pipeline-IP2 (Integrated 
Proteomics Applications, Inc., San Diego, CA. http://www.integratedproteomics.com) using ProLuCID, 
DTASelect2, Census, DeBunker, and Ascore. Spectrum raw files were extracted into ms1 and ms2 files from 
raw files using RawExtract 1.9.9 (http://fields.scripps.edu/downloads.php) (McDonald et al., 2004), and the 
tandem mass spectra were searched against a Plasmodium falciparum database (release date 01/10/12). In order 
to accurately estimate peptide probabilities and false discovery rates, we used a decoy database containing the 
reversed sequences of all the proteins appended to the target database (Peng et al., 2003). Tandem mass spectra 
were matched to sequences using the ProLuCID algorithm with 50 ppm peptide mass tolerance (Xu et al., 2006). 
ProLuCID searches were done on an Intel Xeon cluster running under the Linux operating system. The search 
space included all fully and half-tryptic peptide candidates that fell within the mass tolerance window with no 
miscleavage constraint. Modifications of: (i) +45.987722 on C (reversible label); (ii) +415.201515 on C 
(iodoacetyl-PEG2-biotin label); (iii) +146.081719 on C (fragment of biotin label); (iv) + 59.013305 on C 
(fragment of biotin label); and +57.02146 on C (iodoacetamide) were considered to be variable modifications. 
The validity of peptide/spectrum matches (PSMs) was assessed in DTASelect (Tabb et al., 2002; Cociorva et al., 
2007) using two SEQUEST (Eng et al., 1994) defined parameters, the cross-correlation score (XCorr), and a 
normalized difference in cross-correlation scores (DeltaCN). The search results were grouped by charge state (+1, 
+2, +3, and greater than +3) and tryptic status (fully tryptic, half-tryptic, and non-tryptic), resulting in 12 distinct 
sub-groups. In each one of these sub-groups, the distribution of Xcorr, DeltaCN, and DeltaMass values for (a) 
direct and (b) decoy database PSMs was obtained; then the direct and decoy subsets were separated by 
discriminant analysis. Full separation of the direct and decoy PSM subsets is not generally possible; therefore, 
peptide match probabilities were calculated based on a nonparametric fit of the direct and decoy score 
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distributions. A peptide confidence of 99.5% was set as the minimum threshold, and only peptides with a delta 
mass less than 10 ppm were accepted. The false discovery rate was calculated as the percentage of reverse decoy 
PSMs among all the PSMs that passed the 99.5% confidence threshold. After this last filtering step, we estimate 
that the peptide false discovery rate was below 1%. 
 
3.2.6 Preparation of recombinant plasmodial proteins 
Recombinant His-tagged P. falciparum glyceraldehyde 3-phosphate dehydrogenase (PfGAPDH), pyruvate 
kinase (PfPK), lactate dehydrogenase (PfLDH), and phosphoglycerate mutase (PfPGM) were overexpressed and 
purified as previously described (Kehr et al., 2011). The following recombinant His-tagged proteins were 
overexpressed and purified as described previously: recombinant wild type P. falciparum thioredoxin 1 
(PfTrx1-WT), cysteine-mutated PfTrx1C33S, PfTrx1C30S/C33S (Kanzok et al., 2000), PfTrx1C43S (Krnajski et al., 
2001), thioredoxin reductase (PfTrxR) (Kanzok et al., 2002), peroxiredoxin 6 (PfPrx6), peroxiredoxin 1a 
(PfPrx1a) (Akerman et al., 2003), and glutaredoxin 1 (PfGrx1) (Rahlfs et al., 2001). 
 
3.2.7 Protein immunoblotting analysis 
Recombinant PfGAPDH, PfPK, PfLDH, PfPGM, PfTrx1-WT, PfTrx1C33S, PfTrx1C30S/C33S, and PfTrx1C43S were 
reduced by incubation with 5 mM DTT for 30 min at RT, and the residual DTT was removed via gel filtration 
(ZebaTM, Thermo Scientific) at 4 °C. The reduced proteins (0.2 mg) were then incubated with different 
concentrations of GSNO in 0.5 mL buffer of 50 mM Tris, 1 mM EDTA, 0.2 mM neocuproine, pH 7.4 for 1 h at 
RT in the dark. The reaction was stopped by adding 1.5 mL ice-cold acetone followed by protein precipitation at 
-20 °C for 30 min and centrifugation. After washing, the protein pellet was resolved in blocking buffer with 200 
mM MMTS and subjected to a biotin-switch assay. Controls were performed without adding NaAsc into the 
assay. For detecting S-nitrosylated proteins, two microgram proteins were used in a western blot analysis, using 
anti-biotin antibody as mentioned before. Ponceau S staining of proteins was set as a loading control. 
 
3.2.8 Enzyme treatments and enzymatic assays 
Pre-reduced PfGAPDH, PfPK, and PfLDH were incubated with different concentrations of GSNO (0.1 mM to 1 
mM) in 50 mM Tris, 1 mM EDTA, 0.2 mM neocuproine, pH 7.4 at RT in the dark. At different incubation time 
points, aliquots were taken and assayed for the enzymatic activity. 
The PfGAPDH activity was measured as previously described (Kehr et al., 2011). Briefly, the assay mixture 
contained 40 mM triethanolamine, 50 mM Na2HPO4, 0.2 mM EDTA, pH 7.4, PfGAPDH (0.48 μg/mL), 2 mM 
NAD+, and 2 mM glyceraldehyde 3-phosphate (GAP, prepared from glyceraldehyde 3-phosphate diethyl acetal 
barium salt according the manufacturers’ instructions; Sigma Aldrich). The production of NADH catalyzed by 
PfGAPDH was monitored at 340 nm at 25 °C. 
To test whether GAP and NAD+ can protect PfGAPDH activity from inhibition by S-nitrosylation, PfGAPDH 
was incubated with 1 mM GAP or 2 mM NAD+ for 5 min at 25 °C prior to incubation with 0.2 mM GSNO. The 
PfGAPDH activity was then measured. The enzymatic activities of PfPK and PfLDH were determined as 
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previously described (Kehr et al., 2011). All enzyme activity assays were carried out in at least three 
independent experiments using a Hitachi U-2001 spectrophotometer. 
 
3.2.9. Denitrosylation assays 
S-nitrosylated proteins in P. falciparum cell extracts were generated by incubating parasite cell extracts (0.2 mg 
protein) with 1 mM GSNO in the buffer containing 50 mM Tris, 1 mM EDTA, and 0.2 mM neocuproine (pH 
7.4) at RT for 30 min in the dark. The residual GSNO was removed by passing the cell extracts through a Zeba 
desalting column (Thermo Scientific). Sixty micrograms of pre-reduced recombinant PfTrx1 was added to the 
cell extracts and incubated at 37 °C for 30 min in the dark for the denitrosylation. In another sample, 0.2 μM 
PfTrxR and 200 μM NADPH were added along with PfTrx1. For control samples, PfTrxR/NADPH alone or 1 
mM reduced glutathione were added to the cell extracts. After denitrosylation, proteins were precipitated and 
washed with acetone and then subjected to a biotin-switch assay. The residual S-nitrosylated proteins were 
detected via anti-biotin western blot analysis as described above. A western blot analysis of P. falciparum 
glutathione S-transferase (PfGST) in cell extracts was employed as a loading control. 
For denitrosylating PfGAPDH, PfGAPDH was first S-nitrosylated by incubating the 2 mg recombinant 
PfGAPDH with 1 mM GSNO in 0.5 mL buffer containing 50 mM Tris, 1 mM EDTA, and 0.2 mM neocuproine 
(pH 7.4) at RT for 30 min in the dark. After removing residual GSNO via gel filtration, 0.2 mg PfGAPDH (11 
μM) was taken out and incubated with a 2 or 5-fold molar excess of pre-reduced PfTrx1 and different PfTrx1 
cysteine mutants at 37 °C for 30 min in the dark for denitrosylation. The residual S-nitrosylated PfGAPDH was 
then analyzed via a biotin-switch assay followed by an anti-biotin western blot. 
In order to enzymatically study the denitrosylation of PfGAPDH, PfGAPDH was S-nitrosylated via incubation 
with 1 mM GSNO for 30 min at 25 °C. The residual GSNO was removed by desalting PfGAPDH using a Zeba 
desalting column. The GSNO-treated PfGAPDH was incubated with different-fold molar excess of recombinant 
wild type PfTrx1 (with or without 0.2 μM PfTrxR and 200 μM NADPH) and cysteine-mutated PfTrx1 variants. 
Aliquots were taken at different incubation time points to monitor PfGAPDH activity as described above. 
 
3.2.10 Transnitrosylation assays 
Briefly, S-nitrosylated PfTrx1-WT and PfTrx1C30S/C33S were generated by incubating respective recombinant 
proteins with 1 mM GSNO for 30 min at 25 °C. After residual GSNO was removed, 20 μM S-nitrosylated 
PfTrx1-WT and PfTrx1C30S/C33S were incubated with P. falciparum cell extracts (0.2 mg) in 0.5 mL buffer 
containing 50 mM Tris, 1 mM EDTA, and 0.2 mM neocuproine, pH 7.4 for 1 h at 25 °C in the dark. For the 
transnitrosylation of PfGAPDH, a 2 or 5-fold molar excess of S-nitrosylated PfTrx1-WT and PfTrx1C30S/C33S 
were incubated with 11 μM PfGAPDH for 30 min at 25 °C in the dark. After transnitrosylation, proteins were 
subjected to the biotin-switch assay. The resulting S-nitrosylated proteins in cell extracts and the S-nitrosylated 
PfGAPDH were detected via anti-biotin western blot analysis. To compare the transnitrosylation efficiency of 
PfTrx1 and GSNO, pre-reduced PfTrx1C30S/C33S was S-nitrosylated with a 50-fold molar excess of GSNO for 30 
min and then desalted to remove residual GSNO. In 300 μL buffer system (50 mM Tris, 1 mM EDTA, and 0.2 
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mM neocuproine, pH 7.4), 2.4 μg PfGAPDH was mixed with the same molar amounts of GSNO and 
S-nitrosylated PfTrx1C30S/C33S individually; 60 μL mixture was taken out every 5 min to measure the PfGAPDH 
activity. 
 
3.3 Proteasome methods 
3.3.1 Cloning of ubiquitin receptor domains of P. falciparum 
In order to clone putative PfUIM domains from a putative PfRpn10 subunit, a domain of PfRpn10 which 
contains two PfUIM domains was first amplified from a blood stage cDNA library of P. falciparum (3D7) by 
PCR using two primers (5’-GTTTTGAATTCATTTTTAAATAATAATG-3’ and 5’-ACTTGTTGTGTCTTTATTT 
TCTAATT-3’). The PCR-amplified fragment was purified with a QIAquick PCR Purification Kit (Qiagen) and 
ligated to a pGEM-T easy vector (Promega). The constructed plasmid was further transformed into E. coli XL-1 
blue cells. Colonies were inoculated into 3 mL LB medium supplemented with carbenicillin (100 μg/mL) and 
grown overnight. The plasmids were extracted from the cells, and inserts can be analyzed by digesting the 
plasmids with EcoRI. The plasmids with inserts at the right size were sent for sequencing for verification. 
The PfUIM1 domain, PfUIM2 domain, and the domain containing both PfUIMs (PfUIM1+2) were then 
individually amplified from the verified construct using different primers described in Table 2. After purification 
and cleavage of the PfUIM domains with respective restriction enzymes, the respective PfUIM domain was 
cloned into either a cleaved pQE30 vector or a cleaved pRSET expression vector. Both vectors add an 
N-terminal 6×His-tag to the recombinant protein. The plasmids containing right inserts were verified via 
sequencing analysis. 
 
Table 2. Primers used for cloning the putative PfUIM domains. 
Target domains Primers* 
PfUIM1 5’-ATATGGATCCGTTTTGAATTCATTTTTAAATAATAATG-3’ 
5’-ATATAAGCTT CATATGCTGACTTTCTTCCAAAG-3’ 
PfUIM2 5’-ATATGGATCC ACAACTAATAATAATGACTTACC-3’ 
5’-ATATAAGCTT TTTATTTTCTAATTTATTCTTTTCTG-3’ 
PfUIM1+2 5’-ATATGGATCCGTTTTGAATTCATTTTTAAATAATAATG-3’ 
5’-ATATAAGCTT TTTATTTTCTAATTTATTCTTTTCTG-3’ 
*The restriction enzyme cleavage sites of BamHI and HindIII were underlined. 
 
The putative Pru domain of a putative PfRpn13 subunit was amplified from the blood stage cDNA library of P. 
falciparum (3D7) by PCR using the primers 5’-ATATGGATCCGATTCAGCAAAGATACATTTACA-3’ and 
5’-ATATAAGCTTTTCGTCCTTCGAATCATCATAA-3’, which have restriction sites of BamHI and HindIII 
(underlined). After the PCR product (320 bp) was purified and digested with BamHI and HindIII, the cleaved 
PCR product was directly ligated into a pQE30 plasmid cleaved with the same restriction enzymes. The 
constructed plasmid was transformed into E. coli XL-1 blue cells and the E. coli colonies were inoculated in 3 
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mL LB medium supplemented with carbenicillin (100 μg/mL) and grown overnight. After the constructed 
plasmids were extracted from the cell and purified, they were digested with BamHI and HindIII for 1 h at 37 °C 
and analyzed by an agarose gel (1.5%) electrophoresis. The plasmids with inserts at the right size were sent to 
sequencing analysis for verification. 
 
3.3.2 Cloning of ubiquitin-like domains from putative PfRad23 and PfDsk2 
The ubiquitin-like (UBL) domain from the putative PfRad23 was amplified from a blood stage cDNA library of 
P. falciparum (3D7) by using PCR with two primers: ’-ATATGAATTCTTATTCCTTTTGATTATTTTTATTA 
ATAATTC-3’ and 5’-ATATGGATCCAAAATAAAAGTAAGAACACTACAAAAC-3’ with the cleavage sites 
of EcoRI and BamHI (underlined). Then the PCR product was purified and digested with EcoRI and BamHI, and 
directly ligated into a GST fusion protein expression vector (pGEX-4T) cleaved with the same restriction 
enzymes. The constructed plasmid was transformed into E. coli XL-1 blue cells, and the E. coli colonies were 
picked up and inoculated in 3 mL LB medium supplemented with carbenicillin (100 μg/mL) and grown 
overnight. After the constructed plasmids were extracted and purified, they were digested with EcoRI and 
BamHI for 1 h at 37 °C and analyzed by an agarose gel (1.5%) electrophoresis. The plasmids with inserts at the 
right size were sent to sequencing analysis for verification. 
For cloning another UBL domain from the putative PfDsk2, a similar cloning procedure was carried out. For the 
amplification of the fragment, the following primers were used: 5’-ATATGGATCCGTAATAAATGTATC 
TTTTAAAGTTAC-3’ and 5’-ATATGAATTCTTAATTACTTCTAACTAAATGCATAGTATT-3’ with the 
restriction sites for BamHI and EcoRI underlined. 
 
3.3.3 Heterologous expression and purification of ubiquitin receptor domains of P. falciparum 
The plasmids of PfUIM2/pQE30 and PfUIM1+2/pQE30 were individually transformed into E. coli M15 cells. 
Colonies were inoculated in the tubes containing 3 mL of sterile LB medium supplemented with the antibiotics 
kanamycin (50 μg/mL) and carbenicillin (100 μg/mL) and grown at 37 °C for about 10 h. Then the culture 
mixture was transferred into a flask containing 50 mL sterile LB medium supplemented with the two antibiotics, 
and the cells were grown in a shaking incubator at 37 °C overnight. The overnight pre-culture mixture was then 
transferred into 1 L sterile LB medium supplemented with the two antibiotics and grown at 37 °C on the shaking 
incubation. The culture was induced with 1 mM IPTG when an optical density (OD600) of the culture mixture 
reached 0.9. After induction, the cells continued to grow for 4 h at 37 °C and then were harvested via 
centrifugation at 10,000 g for 15 min at 4 °C. The E. coli cell pellet was resuspended with a resuspension buffer 
(50 mM sodium phosphate, 300 mM NaCl, pH 8.0) supplemented with protease inhibitors PMSF (100 μM), 
pepstatin (3 μM) and cystatin (80 nM), and stored at -20 °C. The purification of the recombinant domains were 
performed based on the Ni-NTA affinity purification followed by the gel filtration chromatography as described 
in 3.1.6. Two milliliter Ni-NTA resin was used to purify the recombinant PfUIM2 expressed in 1 L culture, 
whereas only one milliliter resin was used to purify the recombinant PfUIM1+2 expressed in 1 L culture. The 
proteins were finally stored at 4 °C in a buffer containing 25 mM HEPES/KOH, 5 mM MgCl2, 10% glycerol, pH 
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7.4. 
For the heterologous overexpression of PfUIM1 domain, the plasmid PfUIM1/pRSET was transformed into E. 
coli BL21 cells. The cells were inoculated in a tube containing 3 mL of sterile LB medium supplemented with 
100 μg/mL carbenicillin and grown at 37 °C for about 10 h. Then the culture mixture was transferred into a flask 
containing 50 mL sterile TB medium supplemented with 100 μg/mL carbenicillin, and the cells were grown in a 
shaking incubator at 37 °C overnight. The overnight pre-culture mixture was then transferred into 1 L sterile TB 
medium supplemented with 100 μg/mL carbenicillin, and cells were grown at 37 °C until its OD600 value 
reached 0.7. Then the cells continued to grow at RT. When the OD600 value reached 1.0, 0.5 mM IPTG was 
added to induce the expression of PfUIM1. After 20 h, the cells were harvested and resuspended in the 
resuspension buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) supplemented with protease inhibitors 
PMSF (100 μM), pepstatin (3 μM) and cystatin (80 nM). PfUIM1 was purified following the same procedure as 
described for the purification of PfUIM1+2. 
For the heterologous overexpression of the PfPru domain, the plasmid PfPru/pQE30 was transformed into E. coli 
M15 cells. Colonies were inoculated in the tubes containing 3 mL of sterile LB medium supplemented with the 
antibiotics kanamycin (50 μg/mL) and carbenicillin (100 μg/mL) and grown at 37 °C for about 10 h. Then the 
culture mixture was transferred into a flask containing 50 mL sterile TB medium supplemented with the two 
antibiotics, and the cells were grown at 37 °C overnight. The overnight pre-culture mixture was then transferred 
into 1 L sterile TB medium supplemented with antibiotics, and the cells were grown at 37 °C until its OD600 
value reached 1.3. Then the cells continued to grow at RT. When the OD600 value reached 1.6, 0.2 mM IPTG 
was added to induce the expression of PfPru. After 20 h, the cells were harvested and resuspended in a 
resuspension buffer (50 mM HEPES, 500 mM KCl, 20 mM imidazole, 10 % glycerol and 1% Triton X-100, pH 
8.0) supplemented with protease inhibitors PMSF (100 μM), pepstatin (3 μM) and cystatin (80 nM). The 
recombinant His-tagged PfPru domain was purified with the Ni-NTA affinity chromatography followed by gel 
filtration as described in 3.1.6. Half milliliter of Ni-NTA resin was used to purify PfPru expressed in 1 L culture. 
The purified and concentrated PfPru was stored at 4 °C in a buffer containing 50 mM Tris, 150 mM NaCl, pH 
8.0. 
 
3.3.4 Heterologous overexpression and purification of ubiquitin-like domains from putative PfRad23 and 
PfDsk2 
The plasmid constructs containing UBL domains from putative PfRad23 and PfDsk2 were individually 
transformed into E. coli BL21 cells. Colonies were inoculated in the tubes containing 3 mL of sterile LB medium 
supplemented with 100 μg/mL carbenicillin and grown at 37 °C for about 10 h. Then the culture mixture was 
transferred into a flask containing 50 mL sterile LB medium supplemented with 100 μg/mL carbenicillin and the 
cells were grown in a shaking incubator at 37°C overnight. The overnight pre-culture mixture was then 
transferred into 1 L sterile LB medium supplemented with 100 μg/mL carbenicillin. The culture was induced 
with 1 mM IPTG when an optical density (OD600 nm) of the culture mixture reached 0.9. After induction, the 
cells continued to grow for 4 h at 37 °C and were then harvested by centrifugation at 10,000 g for 15 min at 4 °C. 
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The E. coli cell pellet was resuspended with PBS supplemented with protease inhibitors (100 μM PMSF, 3 μM 
pepstatin and 80 nM cystatin), and stored at -20 °C. 
The purification of the recombinant GST-tagged UBL domains was carried out based on the GSH-sepharose 
purification followed by the gel filtration chromatography as described in 3.1.6. Two milliliters of 
GSH-sepharose 4B resin was used to purify the recombinant UBL domains expressed in 1 L culture. The 
proteins were finally stored at 4 °C in a buffer containing 25 mM HEPES/KOH, 5 mM MgCl2, 10% glycerol, pH 
7.4. 
Besides the full-length product, a truncated UBL domain of PfRad23 with a complete N-terminal GST tag can be 
co-purified. This truncated product cannot be separated from the full-length product via the chromatography 
purifications that we currently applied as well as by adding a C-terminal His-tag to the full-length product in 
order to purify the full-length GST-UBL by additional chromatography purification with Ni-NTA. 
 
3.3.5 In vitro ubiquitin- and UBL-binding assays 
Purified His-tagged P. falciparum ubiquitin receptor domains (18 μM) were mixed individually with 1.8 μM 
GST-tagged UBL domains (from the putative PfRad23 and PfDsk2) together with 20 μL (bed volume) 
pre-equilibrated Ni-NTA resin in 0.8 mL PBS buffer supplemented with 2 mg/mL BSA, 10 mM imidazole, 0.5% 
Triton-X100 (v/v). After incubation for 1 h at 4 °C with constant mixing, each incubation mixture was poured 
into a clean centrifuge tube (0.8 mL, Pierce) and centrifuged at 1,500 g for 1 min to discard the flow through. 
Then the Ni-NTA beads were intensively washed with 0.5 mL PBS seven times. The bound proteins were eluted 
with 0.8 mL PBS supplemented with 500 mM imidazole. The elution fraction was concentrated to 80 μL by a 
Vivaspin centrifugal concentrator with a molecular weight cut off of 3,000 Da. The sample was mixed with 20 
μL 5×SDS-PAGE loading buffer and heated at 95 °C for 4 min. Then 12 μL sample was loaded into a 12% gel 
and proteins were fractionated by the SDS-PAGE and probed with an anti-GST HRP conjugate (GE Healthcare). 
To test for ubiquitin-binding abilities, 4.5 μM purified His-tagged P. falciparum ubiquitin receptor domains was 
incubated with 5 μg of K48-linked polyubiquitin chains ranging from one to seven (Boston Biochem Inc.) in the 
Ni-NTA pull down assay. The ubiquitin chains were probed with an anti-ubiquitin antibody (sigma U5379, 
1:1,000 dilution in 5% non-fat milk), followed by a second anti-goat antibody (1:20,000 dilution in 5% non-fat 
milk) and developed by the ECL method. 
 
3.3.6 Preparation of P. falciparum cell extracts for purifications of the P. falciparum 26S proteasome 
P. falciparum (3D7) cultivated in 24 large culturing plates (45 mL) were collected while they were in 
trophozoite and early schizont stages, and the parasitemia reached 8-10%. To do this, parasites from every two 
large culturing plates were collected in a 50 mL Falcon separately and subjected to saponin lysis as described in 
3.1.8. After washing two times with PBS, two Falcons of parasites were pooled and subsequently incubated with 
10 mL PBS containing 1% formaldehyde (v/v) to cross-link the parasites for 10 min at RT. The cross-linking 
was stopped by centrifuging the parasites at 1,500 g for 10 min and washing the parasite pellet with 10 mL PBS 
containing 0.125 M glycine. After a centrifugation at 1,500 g for another 10 min, the parasite pellet was washed 
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twice with PBS and immediately used or kept at -80 °C. 
When the parasite pellet is to be used, the pellet was resuspended with an equal volume of a pre-cooled 
proteasome purification buffer (25 mM HEPES/KOH, 5 mM MgCl2, 10% glycerol, 1 mM DTT, 10 mM ATP and 
1 mM Na3VO4, pH 7.4). To avoid possible disruptions of the plasmodial 26S proteasome complex, a mild protein 
extraction method was used to prepare P. falciparum cell extracts. The resuspended parasites were first passed 
through a needle with a diameter of 0.55 mm in a syringe (B.Braun Sterican, Melsungen, Germany). Then the 
parasites were passed eight times through a needle with the diameter of 0.4 mm within the same syringe on ice to 
lyse the parasites. After a 30 min centrifugation at 100,000 g at 4 °C, the supernatant was taken out and 
subsequently passed though a 0.45-μm filter (Whatman) to remove residual cell debris and was collected in a 15 
mL Falcon. The protein concentration of the cleared cell extracts was measured via the Bradford assay. Typically, 
about 8.5 mg total proteins can be obtained in the parasites extracts generated from 24 large culturing plates of 
parasites. The cell extracts were kept on ice, protected from the light and immediately used in the purification of 
the plasmodial proteasome. 
 
3.3.7 Affinity purification of the P. falciparum 26S proteasome 
The P. falciparum 26S proteasome complex was purified by an adopted chromatography method based on the 
affinity of the plasmodial proteasome to the UBL domain of the putative PfRad23 (Besche et al., 2009; Scanlon 
et al., 2009). The cleared P. falciparum cell extracts (~8.5 mg) were incubated with 2 mg purified GST-tagged 
UBL domain (GST-UBL) together with 0.4 mL (bed volume) of GSH-sepharose (GE Healthcare) for 3 h at 4 °C 
with constant mixing. Then the suspension was poured into a 5 mL empty column, and the flow through was 
collected for analysis. The GSH-sepharose was intensively washed with 10 mL pre-cooled proteasome 
purification buffer containing 2 mM ATP. In the elution step, excess of His-tagged PfUIM2 was used to compete 
with the proteasomes in binding to the GST-UBL affinity matrix, therefore eluting the proteasome from the 
GSH-sepharose. For elution, the GSH-sepharose was carefully agitated with 0.5 mL proteasome purification 
buffer containing 2 mM ATP and 1 mg purified His-tagged PfUIM2 and incubated for 20 min at RT. The elution 
step was repeated, and the column was washed once with 0.5 mL buffer without the PfUIM2 to elute residual 
proteasomes. All elution fractions (1.5 mL) were combined and supplemented with 0.25 mL (bed volume) of 
Ni-NTA resin (Invitrogen), and incubated for 45 min with constant mixing at 4 °C to completely remove residual 
His-tagged PfUIM2. After the incubation, the mixture was poured into a clean centrifuge tube (0.8 mL, Pierce), 
and the flow through containing the purified proteasome was collected. Finally, the proteasome sample was 
concentrated by a Vivaspin centrifugal concentrator with a molecular weight cut-off of 3,000 Da to a final 
volume of approximately 100 μL. The purified proteasome samples were immediately used in the proteasomal 
activity measurements without freezing. The remaining samples were kept at -80 °C until used for the MS 
analysis. The mock purification with GST as the bait protein was carried out in the same procedure. 
 
3.3.8 Sample preparation for mass spectrometry 
Proteasome samples (10 μg) were diluted to 120 μL with 200 mM Tris, pH 8.5 and solid urea was added to 8 M 
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(57 μg).  Samples were reduced and alkylated by addition of 6 μL of 100 mM TCEP and incubated with 
shaking at RT for 20 minutes, followed by addition of 6 μL of 250 mM IAA, and incubated with shaking in the 
dark at RT for 20 minutes. One microgram (1 μg/μL) of endoproteinase-LysC was added and the reaction was 
allowed to proceed for 4 hours at 37 °C. Samples were diluted with 360 μL 100 mM Tris pH 8.5 and 2 μg of 
trypsin (1 μg/μL) was added. Samples were incubated with shaking at 37 °C for 18 hours and digestion was 
halted with the addition of 25 μL of 90% formic acid. Samples were spun for 20 min at 14,000 rpm and 
transferred to a new Eppendorf tube. 
 
3.3.9 Multidimensional protein identification technology (MudPIT) for proteasome sample analysis 
The protein digest was pressure-loaded onto a fused silica capillary column containing 2.5 cm of Partisphere 
strong cation exchanger (Whatman, Clifton, NJ) followed by 2.5 cm of 10 µm Aqua C18 (Phenomenex, Ventura, 
CA) packed into a 250 µm inside diameter (i.d.) capillary (Polymicro Technologies, Phoenix, AZ) with a 1 µm 
frit. The column was washed for 60 min with buffer containing 95% water, 5% acetonitrile, and 0.1% formic 
acid. After washing, a 100-µm i.d. capillary with a 5-µm pulled tip packed with 15 cm 3-µm Aqua C18 material 
(Phenomenex, Ventura, CA) was attached via a union, and the entire split-column was placed in line with an 
Agilent 1100 quaternary high-performance liquid chromatography (HPLC) and analyzed using a modified 9-step 
separation similar to those described previously (Washburn et al., 2001). The buffer solutions used were 5% 
acetonitrile/0.1% formic acid (buffer A), 80% acetonitrile/0.1% formic acid (buffer B), and 500 mM ammonium 
acetate/5% acetonitrile/0.1% formic acid (buffer C). Step 1 consisted of a 90 min gradient from 0% to 100% 
buffer B. Steps 2-9 had the following profile: 10 min of X% buffer C, a 15 min gradient from 0% to 5% buffer B, 
and a 95 min gradient from 15% to 100% buffer B. The 10 min buffer C percentages were 10%, 20%, 30%, 40%, 
50%, 60%, 70%, and 100%, respectively, for the 9-step analysis. As peptides eluted from the microcapillary 
column, they were electrosprayed directly into an Orbitrap Velos mass spectrometer (ThermoFisher, SanJose, 
CA) with the application of a distal 2.4 kV spray voltage. A cycle of one full-scan mass spectrum (400-1400 m/z) 
followed by 15 data-dependent MS/MS spectra at a 35% normalized collision energy was repeated continuously 
throughout each step of the multidimensional separation. Application of mass spectrometer scan functions and 
HPLC solvent gradients were controlled by the XCalibur data system. 
 
3.3.10 Analysis of tandem mass spectra of proteasome samples 
Protein identifications were done with Integrated Proteomics Pipeline-IP2 (Integrated Proteomics Applications, 
Inc., San Diego, CA. http://www.integratedproteomics.com) using ProLuCID (Xu et al., 2006) and 
DTASelect2.0 (Tabb et al., 2002; Cociorva et al., 2007). Spectrum raw files were extracted into ms1 and ms2 
files from raw files using RawExtract 1.9.9 (http://fields.scripps.edu/downloads.php) (McDonald et al., 2004), 
and the tandem mass spectra were searched against a Plasmodium falciparum database (release date 01/10/12). 
In order to accurately estimate peptide probabilities and false discovery rates, we used a decoy database 
containing the reversed sequences of all the proteins appended to the target database (Peng et al., 2003). Tandem 
mass spectra were matched to sequences using the ProLuCID algorithm. ProLuCID searches were done on an 
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Intel Xeon cluster running under the Linux operating system. The search space included all fully and half-tryptic 
peptide candidates that fell within the mass tolerance window with no miscleavage constraint. Modification of 
+57.02146 on C (iodoacetamide) was considered to be a static modification. 
The validity of peptide/spectrum matches (PSMs) was assessed in DTASelect2.0 using two SEQUEST defined 
parameters (Eng et al., 1994), the cross-correlation score (XCorr), and a normalized difference in 
cross-correlation scores (DeltaCN). The search results were grouped by charge state (+1, +2, +3, and greater than 
+3) and tryptic status (fully tryptic, half-tryptic), resulting in 8 distinct sub-groups. In each one of these 
sub-groups, the distribution of Xcorr and DeltaCN values for (a) direct and (b) decoy database PSMs was 
obtained; then the direct and decoy subsets were separated by a quadratic discriminant function which was used 
to compute a confidence score and achieve a user-specified false discovery rate. Full separation of the direct and 
decoy PSM subsets is not generally possible; therefore, peptide match probabilities were calculated based on a 
nonparametric fit of the direct and decoy score distributions. The false discovery rate was calculated as the 
percentage of reverse decoy PSMs among all the PSMs that passed the confidence threshold. Identified proteins 
were required to have minimum two peptides with a mass accuracy of up to 20 ppm. Under such filtering 
conditions, the estimated false discovery rate was below 1% at the peptide and protein level. 
 
3.3.11 Proteasome activity assay 
The three peptidolytic activities of the P. falciparum 26S proteasome were determined by a fluorogenic peptide 
cleavage assay using three specific peptide substrates: Suc-LLVY-AMC, Bz-VGR-AMC and Z-LLE-AMC 
(Enzo life Science). The assay is based on detection of the fluorophore 7-amino-4-methylcoumarin (AMC) after 
cleavage from the labeled substrates by the proteasome (Scanlon et al., 2009). The released AMC fluorescence 
can be dynamically quantified using a 380/460 nm filter in a fluorometer. Generally, a standard AMC calibration 
curve has to be generated, and then the specific activity of the proteasome on a particular substrate is determined 
by measuring its response against the standard AMC calibration curve.  
Briefly, appropriate amount of respective substrate was dissolved in DMSO to prepare a 10 mM stock solution of 
each substrate. To prepare a 100 μM substrate working solution, 20 μL of substrate stock solution was mixed 
with 980 μL assay buffer (50 mM Tris, 5 mM MgCl2, 1 mM DTT, pH7.5). In parallel, 1 mM AMC working 
solution was prepared with the same assay buffer. Due to the auto-hydrolysis of AMC-containing peptide 
substrates, it is necessary to create the standard AMC curve for each of the substrates in serial dilution of AMC 
in the presence of the substrate. For this purpose, the AMC/substrate standard solution containing 16 μM AMC 
and 100 μM of respective substrates was prepared by adding 16 μL of AMC working solution (1 mM) and 10 μL 
stock solution (10 mM) of the respective substrate to 974 μL assay buffer. For the preparation of the AMC 
calibration curve for each substrate, the serial dilutions of AMC according to Table 3 were prepared in duplicate 
in a 96-well black plate (Greiner Bio-One, Frickenhausen, Germany). After 30 min of incubation at 37 °C, the 
fluorescence of AMC of each well was read at 460 nm (excited at 380 nm) by a Tecan Infinite 200 fluorescent 
photometer. Then the AMC standard curve was produced by plotting the fluorescence intensity against the molar 
amount of AMC (Figure 13). 
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To measure the proteasomal activity, 5-10 μL of purified P. falciparum proteasome sample was mixed with 100 
μM of respective substrate in 100 μL of assay buffer with or without 10 μM MG132 or lactacystin (Enzo life 
Science). In parallel, control wells only containing the respective substrates were set as blanks. The AMC 
fluorescence was read immediately after all samples were prepared. After 30 min incubation at 37 °C, AMC 
fluorescence was read again. The increased fluorescence intensity (△F) of blanks was subtracted from the △F 
of the respective samples. Then the respective proteasomal activities of the purified proteasome samples were 
calculated according to the AMC standard curve. 
 
Table 3. Standard AMC concentrations with substrates in a 96-well plate used for creating AMC calibration curves*. 
 1 2 3 4 5 6 
A 16 μM AMC + 100 μM Suc-LLVY-AMC 16 µM AMC + 100 μM Bz-VGR-AMC 16 μM AMC + 100 μM Z-LLE-AMC 
B 8 μM AMC + 100 μM Suc-LLVY-AMC 8 μM AMC + 100 μM Bz-VGR-AMC 8 μM AMC + 100 μM Z-LLE-AMC 
C 4 μM AMC + 100 μM Suc-LLVY-AMC 4 μM AMC + 100 μM Bz-VGR-AMC 4 μM AMC + 100 μM Z-LLE-AMC 
D 2 μM AMC + 100 μM Suc-LLVY-AMC 2 μM AMC + 100 μM Bz-VGR-AMC 2 μM AMC + 100 μM Z-LLE-AMC 
E 1 μM AMC + 100 μM Suc-LLVY-AMC 1 μM AMC + 100 μM Bz-VGR-AMC 1 μM AMC + 100 μM Z-LLE-AMC 
F 0.5 μM AMC + 100 μM Suc-LLVY-AMC 0.5 μM AMC + 100 μM Bz-VGR-AMC 0.5 μM AMC + 100 μM Z-LLE-AMC 
G 0.25 μM AMC + 100 μM Suc-LLVY-AMC 0.25 μM AMC + 100 μM Bz-VGR-AMC 0.25 μM AMC + 100 μM Z-LLE-AMC 
H 0.125 μM AMC + 100 μM Suc-LLVY-AMC 0.125 μM AMC + 100 μM Bz-VGR-AMC 0.125 μM AMC + 100 μM Z-LLE-AMC 
* A total volume of the mixture in each well is 50 μL. 
 
 
Figure 13. AMC calibration curves with respect to the peptide substrates used in the proteasome activity assay. 
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4. RESULTS 
4.1 Protein S-nitrosylation in P. falciparum 
4.1.1 Detection and isolation of S-nitrosylated proteins in P. falciparum 
To detect S-nitrosylated proteins in P. falciparum, the biotin-switch assay coupled with anti-biotin western blot 
analysis was used. The biotin-switch assay involves the blocking of free protein thiols, specific reduction of 
S-nitrosothiols and subsequent biotinylation of the nascent thiols (Figure 14A). To ensure the unbiased 
identification of S-nitrosylated proteins, the sufficiency of thiol blockage and the specificity of the assay were 
tested for P. falciparum samples (Figure 14B). P. falciparum cell extracts were incubated with DTT (5 mM) to 
reduce and expose all protein thiols, which were then blocked with or without methyl methanethiosulfonate 
(MMTS, 200 mM) before biotinylation. The minimal anti-biotin immunoreactivity in MMTS-blocked cell 
extracts (Figure 14B, lane 8) compared to the strong immunoreactivity in unblocked cell extracts (Figure 14B, 
lane 1) indicated the minimization of false-positives by efficient blockage of free thiols. Additionally, the 
biotin-switch assay lacked the ability to recognize protein disulfides and protein S-glutathionylation, two major 
types of thiol-based redox modifications induced by hydrogen peroxide (H2O2) and oxidized glutathione 
(GSSG), respectively (Figure 14B, lanes 3, 2). 
 
Figure 14. Analysis of S-nitrosylated proteins in P. falciparum cell extracts. (A) Schematic diagram of the biotin-switch 
assay used for the analysis of S-nitrosylated proteins. (B) Evaluation of the biotin-switch assay and the detection of 
S-nitrosylated proteins in P. falciparum cell extracts. (C) A representative silver-stained gel shows the avidin-purified 
S-nitrosylated proteins from P. falciparum cell extracts treated with 100 μM GSNO. A control sample without reduction of 
S-nitrosothiols by NaAsc was included in parallel. MMTS: methyl methanethiosulfonate; GSSG: glutathione disulfide. 
NaAsc: sodium ascorbate. (Wang et al., 2013) 
 
After the specificity of the biotin-switch assay was verified, we first applied the assay to detect S-nitrosylated 
proteins in unstressed and intact parasites. For this experiment, trophozoite-stage P. falciparum parasites were 
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isolated, directly lysed, and the cell extracts were immediately subjected to the biotin-switch assay. A control 
sample without the reduction of S-nitrosothiols by ascorbate was produced in parallel. Western blots indicated a 
rather low abundance of endogenous S-nitrosylated proteins in P. falciparum (Figure 14B, lanes 6 and 7), which 
is consistent with observations in other organisms (Lindermayr et al., 2005; Lam et al., 2010; Murray et al., 
2011). Incubation of parasitized erythrocytes with GSNO, a naturally occurring NO donor that promotes SNO 
(Broniowska et al., 2013), did not significantly enhance the signals, which is likely due to the presence of high 
hemoglobin concentrations and multiple cell membranes surrounding the parasites (Sobolewski et al., 2005). 
Therefore we decided to determine targets of S-nitrosylation in P. falciparum cell extracts treated with GSNO 
(40 and 100 μM). As a result, anti-biotin immunoblotting signals were clearly observed (Figure 14B, lanes 4 and 
5), indicating that a group of S-nitrosylated proteins was specifically detected. 
The S-nitrosylated proteins in the P. falciparum cell extracts treated with 100 μM GSNO were pulled down by 
avidin and visualized in gels via silver staining. In parallel, a stringent control sample that omitted the reduction 
of S-nitrosothiols by ascorbate was set, representing biotinylated proteins derived from blocking-resistant thiols 
and non-specific avidin-binding proteins. As shown in the silver-stained gel, a number of bands belonging to 
isolated S-nitrosylated proteins emerged in the GSNO-treated cell extracts but not in the control sample, 
indicating that S-nitrosylated proteins were specifically isolated (Figure 14C). 
 
4.1.2 Identification of S-nitrosylated proteins in P. falciparum cell extracts 
The S-nitrosylated proteins isolated from the 100 μM GSNO-treated P. falciparum cell extracts were 
trypsin-digested and identified using a linear trap quadrupole (LTQ)-Orbitrap mass spectrometer. Only proteins 
for which at least two peptides were detected in at least two independent experiments were included in the target 
list. Proteins that were also abundantly detected in control samples (without reduction of S-nitrosothiols) were 
subtracted. Meeting these strict criteria, 267 S-nitrosylated annotated proteins (Appendix Table 1) and 52 
S-nitrosylated hypothetical proteins (Appendix Table 2) were identified as potential SNO targets in P. 
falciparum. In parallel, the MS/MS analysis revealed 37 S-nitrosylation sites from 34 proteins. Categorization of 
the identified proteins according to their gene ontology annotated in PlasmoDB (version 9.2) has revealed that 
S-nitrosylated proteins participate in a wide range of biological processes in P. falciparum and also differ in 
molecular functions (Figure 15). 
 
Figure 15. Functional classification of identified S-nitrosylated proteins in P. falciparum. The identified S-nitrosylated 
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proteins were categorized according to their gene ontology (GO) annotations in biological processes (A) and molecular 
functions (B). Only annotated proteins were used in the analysis, and the most predominant GO terms were shown using the 
program PatternLab for Proteomics (Kehr et al., 2011). (Wang et al., 2013) 
 
4.1.3 Glycolytic enzymes as targets for S-nitrosylation in P. falciparum 
Interestingly, all eleven enzymes contributing to glycolysis were identified as potential SNO targets (Appendix 
Table 1), indicating that glycolysis appears to be affected by S-nitrosylation. In order to reveal the effects of 
SNO on plasmodial glycolysis, S-nitrosylation on four glycolytic enzymes was characterized in more detail, 
including P. falciparum glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH), phosphoglycerate mutase 
(PfPGM), pyruvate kinase (PfPK), and lactate dehydrogenase (PfLDH). 
The enzymes were heterologously overexpressed in E. coli and purified to homogeneity. The pure proteins were 
incubated with different concentrations of GSNO and then subjected to the biotin-switch assay followed by 
anti-biotin western blot analysis. Consistent with the large-scale study, the glycolytic enzymes were all 
susceptible to in vitro S-nitrosylation by GSNO in a concentration-dependent manner, whereas P. falciparum 
thioredoxin reductase (PfTrxR) and glutathione S-transferase (PfGST), which were not identified as SNO targets 
in the study, were not S-nitrosylated in the assay (Figure 16A). Furthermore, the effects of S-nitrosylation on the 
enzymatic activities of PfGAPDH, PfPK, and PfLDH were tested. Interestingly, GSNO-induced S-nitrosylation 
resulted in a concentration and time-dependent inhibition of PfGAPDH activity (Figure 16B), whereas 
incubation with GSNO (up to 1 mM) did not significantly influence PfPK and PfLDH activities (data not 
shown). 
 
Figure 16. S-nitrosylation of glycolytic enzymes of P. falciparum. (A) Analysis of S-nitrosylation on PfGAPDH, PfPGM, 
PfPK, and PfLDH. Pre-reduced recombinant enzymes were incubated with different concentrations of GSNO at 25 °C for 1 
h and subjected to a biotin-switch assay with or without NaAsc (as a control). S-nitrosylated enzymes were detected by the 
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anti-biotin western blot analysis. Ponceau S staining shows equal amounts of protein loaded into each lane. P. falciparum 
glutathione S-transferase (PfGST) and thioredoxin reductase (PfTrxR), which were not identified as SNO targets, served as 
negative controls were indeed not S-nitrosylated under the conditions chosen; these results further underline the modification 
specificity of the assay. (B) Concentration and time-dependent inhibition of PfGAPDH activity by S-nitrosylation induced by 
GSNO. Enzymatic activity is given as the percentage of PfGAPDH incubated without GSNO. (C) Protection of PfGAPDH 
activity from GSNO by the substrate glyceraldehyde 3-phosphate (GAP) and the cofactor nicotinamide adenine dinucleotide 
(NAD+). PfGAPDH was incubated with 1 mM GAP or 2 mM NAD for 5 min prior to the treatment with 0.2 mM GSNO. 
Data are represented as mean ± standard deviation from at least three independent determinations. (D) Protection of 
PfGAPDH from GSNO-induced S-nitrosylation by preincubation with GAP and NAD+ as revealed by anti-biotin western 
blot analysis. (Wang et al., 2013) 
 
It is known that PfGAPDH uses its active site cysteine (Cys153) to metabolize its substrate glyceraldehyde 
3-phosphate (GAP) in the presence of the adjacently bound cofactor, nicotinamide adenine dinucleotide (NAD+) 
(Robien et al., 2006). To assess whether Cys153 is the target for S-nitrosylation, PfGAPDH was pre-incubated 
with GAP or NAD+ for 5 min before it was exposed to GSNO treatment. Indeed, pre-incubation with either 
substrate or cofactor markedly protected PfGAPDH from inhibition by GSNO (Figure 16C). In parallel, 
western blot analysis of S-nitrosylated PfGAPDH also showed a reduced level of S-nitrosylation of PfGAPDH, 
which had been pre-incubated with GAP or NAD+ (Figure 16D). The results indicate that GAP and NAD+ 
competed with GSNO at the active site, thus protecting PfGAPDH from S-nitrosylation. Therefore the results 
strongly suggest that Cys153 is the target site for S-nitrosylation in PfGAPDH. 
 
4.1.4 Redox-regulating proteins as targets for S-nitrosylation in P. falciparum 
Several thiol-based redox-regulating proteins have been identified as potential SNO targets in P. falciparum 
(Appendix Table 1). Several important redox-regulating proteins, including P. falciparum peroxiredoxin 6 
(PfPrx6), glutaredoxin 1 (Grx1) and peroxiredoxin 1a (PfPrx1a) were tested in an in vitro S-nitrosylation assay. 
As a result, all the tested proteins can be dose-dependently S-nitrosylated by GSNO (Figure 17). 
 
Figure 17. In vitro S-nitrosylation of recombinant P. falciparum PfPrx6, PfGrx1 and PfPrx1a. Pre-reduced recombinant 
proteins were incubated with different concentrations of GSNO at 25 °C for 1 h and subjected to a biotin-switch assay with 
or without NaAsc (as a control). S-nitrosylated proteins were detected via the anti-biotin western blot analysis. Ponceau S 
staining shows equal amounts of protein loaded in each lane. (Wang et al., 2013) 
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More importantly, P. falciparum thioredoxin 1 (PfTrx1, the major cytosolic thioredoxin), a ubiquitous protein 
disulfide oxidoreductase, was identified as a target of S-nitrosylation in P. falciparum. Similar to human Trx1 
(hTrx1), PfTrx1 contains a pair of active site cysteines in the conserved sequence Cys-Gly-Pro-Cys and a third 
cysteine (Cys43) (Krnajski et al., 2001). Importantly, it has been shown for hTrx1 that distinct responses of its 
different cysteine residues to nitrosylating stress direct denitrosylating and transnitrosylating activities of hTrx1 
in the regulation of SNO (Barglow et al., 2011; Wu et al., 2011). In order to explore possible regulatory roles of 
PfTrx1 in SNO, it is thus important to investigate susceptibilities of different cysteines of PfTrx1 to 
S-nitrosylation. 
For this purpose, recombinant wild type and different cysteine-mutated PfTrx1s were pre-reduced with DTT 
followed by GSNO treatments. The S-nitrosylation of these proteins was detected by using the biotin-switch 
assay coupled to western blot analysis. As shown in Figure 18, wild type PfTrx1 (PfTrx1-WT) was detected to 
be S-nitrosylated by high concentrations of GSNO (more than 200 μM). Mutation of the resolving active site 
cysteine (Cys33) to serine in PfTrx1 (PfTrx1C33S) showed an increased susceptibility to S-nitrosylation, as 
revealed by the S-nitrosylation of the mutant upon relatively low concentrations of GSNO (100 μM). 
Interestingly, PfTrx1 with both active site cysteines mutated to serine (PfTrx1C30S/C33S) was 
concentration-dependently S-nitrosylated by GSNO, implying that Cys43 is an important site for S-nitrosylation. 
This was further evidenced by the finding that a single mutation of Cys43 in PfTrx1 (PfTrx1C43S) completely 
abrogated S-nitrosylation of the protein, despite the fact that high concentrations of GSNO were used. 
Collectively, the results suggest that Cys43 of PfTrx1 is site-specifically targeted by S-nitrosylation, whereas the 
active site cysteines are not major sites of S-nitrosylation. The site-specific S-nitrosylation of PfTrx1 clues a 
potential of this protein in the regulation of SNO in P. falciparum. 
 
 
Figure 18. Characterization of the S-nitrosylation site in PfTrx1. Recombinant wild type PfTrx1 (PfTrx1-WT) and 
different PfTrx1 variants with cysteine mutated to serine were pre-reduced and incubated with different concentrations of 
GSNO for S-nitrosylation at 25 °C for 1 h. Proteins were then subjected to a biotin-switch assay with or without NaAsc (as a 
control) followed by anti-biotin western blot analysis. Ponceau S staining shows equal amounts of protein loaded into each 
lane. (Wang et al., 2013) 
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4.1.5 Denitrosylation by P. falciparum thioredoxin 1 
In order to understand how SNO is regulated in P. falciparum, we began to study denitrosylation by searching 
for a plasmodial homolog of GSNO reductase (GSNOR). However, bioinformatic analysis using the Basic Local 
Alignment Search Tool (BLAST) revealed that Plasmodium genomes lack the sequence encoding a putative 
GSNOR (data not shown). Considering the fact that P. falciparum also possesses a functional thioredoxin 
system and having learned about the site-specific response of PfTrx1 to S-nitrosylating stress, we hypothesized 
that PfTrx1 functions as a denitrosylase. To test this, we examined whether PfTrx1 is able to denitrosylate 
proteins at a biochemical level. A large variety of S-nitrosylated proteins was generated in P. falciparum cell 
extracts treated with GSNO and incubated with recombinant wild type PfTrx1 for denitrosylation. The residual 
S-nitrosylated proteins were then detected by the biotin-switch assay followed by anti-biotin western blot 
analysis. It was found that PfTrx1 dramatically reduced the levels of S-nitrosylated plasmodial proteins. 
Incubation of PfTrx1 along with PfTrx reductase (PfTrxR) and NADPH nearly eliminated all S-nitrosylation 
signals. This treatment was approximately equipotent to treatment with 1 mM GSH. On the contrary, incubation 
only with PfTrxR and NADPH showed no obvious denitrosylating effect, implying that PfTrxR has a catalytic 
effect in the PfTrx1-mediated denitrosylation by reducing PfTrx1 (Figure 19A). 
To investigate the denitrosylation mechanism in more detail, we assessed activities of PfTrx1 and its 
cysteine-mutated variants in the denitrosylation of PfGAPDH by using both protein immunoblotting and 
enzymatic assays. Recombinant PfGAPDH was incubated with 1 mM GSNO to generate S-nitrosylated 
PfGAPDH, which was then incubated with pre-reduced wild type PfTrx1 and different cysteine-mutated PfTrx1 
variants for denitrosylation. S-nitrosylation levels of PfGAPDH were analyzed with a biotin-switch assay 
followed by anti-biotin western blots (Figure 19B). We found that PfTrx1 harboring intact active site cysteines 
(PfTrx1-WT and PfTrx1C43S) significantly denitrosylated PfGAPDH with an efficiency comparable to 5 mM 
DTT. However, mutations of one or both active site cysteines in PfTrx1 markedly reduced its denitrosylating 
activity on PfGAPDH, though a slight denitrosylation was observed, which might be due to protein-protein 
transnitrosylation from S-nitrosylated PfGAPDH to PfTrx1. In the enzymatic assay, wild type PfTrx1 recovered 
the activity of S-nitrosylated PfGAPDH in a dose and time-dependent manner, whereas active site 
cysteine-mutated PfTrx1 variants did not (Figure 19C). The results clearly suggest that active site cysteines of 
PfTrx1 are mainly responsible for the denitrosylating activity of PfTrx1. Furthermore, we found that the 
presence of PfTrxR substantially promoted the PfGAPDH-denitrosylating activity of PfTrx1, reflected by the 
accelerated recovery of PfGAPDH activity (Figure 19D). This implied that an active site disulfide in PfTrx1 
was formed in the catalysis of PfGAPDH denitrosylation and in turn reduced by PfTrxR. This result indicates 
that denitrosylation by PfTrx1 is based on a dithiol-disulfide exchange mechanism (Krnajski et al., 2001). 
Collectively, the results clearly suggest a denitrosylating activity of PfTrx1 mediated by its active site cysteines. 
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Figure 19. In vitro denitrosylation of plasmodial proteins by PfTrx1. (A) Denitrosylation of a large variety of 
S-nitrosylated proteins in P. falciparum cell extracts by PfTrx1 together with or without a back-up system containing PfTrxR 
and NADPH. Incubation of GSH and PfTrxR/NADPH alone was set as positive and negative controls, respectively. 
Immunoblotting of P. falciparum glutathione S-transferase (PfGST) in cell extracts was used as a loading control. (B) 
Denitrosylation of PfGAPDH by PfTrx1. The molar ratio of PfTrx1 proteins to PfGAPDH in the denitrosylation assay 
system was 2:1 or 5:1. S-nitrosylated PfGAPDH without denitrosylation was set as a control. Ponceau S staining shows an 
equal amount of PfGAPDH loaded into each lane. (C) The enzymatic activity of S-nitrosylated PfGAPDH was restored by 
wild type PfTrx1 in both concentration and time-dependent manners but not by active site mutated PfTrx1 variants 
(PfTrx1C33S and PfTrx1C30S/C33S). (D) PfTrxR accelerated the denitrosylation of PfGAPDH-mediated by PfTrx1. The molar 
ratio of wild type PfTrx1 to PfGAPDH in the denitrosylation assay system was 1:1 or 2:1. Data are represented as mean ± 
standard deviation from at least three independent determinations. Incubation with PfTrxR/NADPH alone did not recover the 
PfGAPDH activity. (Wang et al., 2013) 
 
4.1.6 Transnitrosylation by P. falciparum thioredoxin 1 
Because PfTrx1 can be S-nitrosylated at Cys43, we further tested whether PfTrx1 has a transnitrosylating 
activity mediated by the S-nitrosylated Cys43 residue. Wild type PfTrx1 and the PfTrx1 variant with double 
mutated active site cysteines (PfTrx1C30S/C33S) were S-nitrosylated by GSNO and then incubated with P. 
falciparum cell extracts. Analyzed by the biotin-switch assay coupled with an anti-biotin western blot, a number 
of S-nitrosylated proteins in cell extracts emerged upon the incubation of S-nitrosylated wild type PfTrx1, 
indicating that numerous plasmodial proteins were transnitrosylated by PfTrx1 (Figure 20A). Compared to wild 
type PfTrx1, the similar immunoblotting pattern of S-nitrosylated proteins induced by S-nitrosylated 
PfTrx1C30S/C33S indicated that Cys43 is responsible for the transnitrosylating activity of PfTrx1. Additionally, by 
using PfGAPDH as a transnitrosylation substrate, we found that both wild type PfTrx1 and PfTrx1C30S/C33S were 
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able to transnitrosylate PfGAPDH in a dose-dependent manner (Figure 20B). Furthermore, it was found that 
PfGAPDH activity was more rapidly inhibited by the S-nitrosylated PfTrx1C30S/C33S than by the same molar 
amount of GSNO, indicating a higher efficiency of PfTrx1 in the protein transnitrosylation compared to the in 
vivo NO donor GSNO (Figure 20C). Taken together, the results strongly indicate a transnitrosylating activity of 
PfTrx1, which is mediated by its Cys43 residue. 
    
 
Figure 20. In vitro transnitrosylation of plasmodial proteins by PfTrx1. (A) Protein transnitrosylation in P. falciparum 
cell extracts by S-nitrosylated wild type PfTrx1 and active site cysteine-mutated PfTrx1 (PfTrx1C30S/C33S). Immunoblotting of 
PfGST in cell extracts was used as a loading control. (B) Transnitrosylation of PfGAPDH by S-nitrosylated PfTrx1 and 
PfTrx1C30S/C33S. The molar ratio of PfTrx1 proteins to PfGAPDH in the transnitrosylation assay system was 2:1 or 5:1. 
Incubation of 100 μM GSNO with PfGAPDH was used as a positive control. Ponceau S staining shows an equal amount of 
PfGAPDH loaded into each lane. (C) Comparison of the transnitrosylation efficiency of PfTrx1C30S/C33S with GSNO by using 
PfGAPDH as a substrate. Equal molar amounts of S-nitrosylated PfTrx1C30S/C33S and GSNO were individually incubated with 
PfGAPDH (molar ratio of both agents to PfGAPDH were 40:1, 52.5:1, and 100:1). A time-dependent inactivation of 
PfGAPDH was monitored to reflect the transnitrosylation efficiency. PfTrx1-WT-SNO, S-nitrosylated wild type PfTrx1; 
PfTrx1C30S/C33S-SNO, S-nitrosylated PfTrx1C30S/C33S; *, statistically significant difference P<0.05 (student t-test). (Wang et al., 
2013) 
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4.2 Characterization of the 26S proteasome network in P. falciparum 
4.2.1 Identification of intrinsic ubiquitin receptors in the P. falciparum 26S proteasome 
The intrinsic ubiquitin receptors of the eukaryotic 26S proteasome are critical for the substrate recognition at the 
26S proteasome. As introduced before, the eukaryotic 26S proteasomes mainly equip two distinct 
ubiquitin-binding entities for docking ubiquitin or ubiquitin-like molecules, i.e. the UIM domain and the Pru 
domain located at the 19S Rpn10 and Rpn13 subunits, respectively (Tomko et al., 2013). In order to understand 
the mechanism of substrate recognition at the plasmodial 26S proteasome, we aimed to identify and characterize 
the intrinsic ubiquitin receptors of the P. falciparum 26S proteasome. 
 
4.2.1.1 In silico searching of intrinsic ubiquitin receptors in the P. falciparum 26S proteasome 
In silico analysis based on the Basic Local Alignment Search Tool (BLAST) using human UIM and Pru domains 
as queries was carried out in order to search for putative ubiquitin receptors in the corresponding counterparts of 
the P. falciparum 26S proteasome. The human Rpn10 (S5a) has two UIM sequences which are separated by 
about 40 residues (Mueller et al., 2003). By using a BLAST analysis with the sequence of the S5a domain 
(amino acids 203-310) containing two UIMs, two putative P. falciparum UIMs (PfUIMs) were predicted in a P. 
falciparum homolog of Rpn10 (PF08_0109, putative PfRpn10) (Figure 21A). Sequence alignment of the 
predicted PfUIMs with human UIMs revealed that PfUIMs preserve the key residues that have been 
demonstrated to be essential for binding ubiquitin or ubiquitin-like molecules (Figure 21B). Additionally, we 
found that the putative plasmodial UIMs appear to be conserved in other Plasmodium species, with the second 
UIM (UIM2) being more conserved among Plasmodium species (Figure 21C). 
 
Figure 21. Identification of putative UIM domains in a P. falciparum homolog (PF08_0109) of S5a/Rpn10. (A) 
Sequence alignment of human S5a203-301 with PF08_0109 (putative PfRpn10). The amino acid sequences of two human 
UIMs are indicated. (B) Multiple sequence alignment of the identified putative P. falciparum UIMs (PfUIMs) with human 
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UIMs. The most conserved leucine/isoleucine, alanine and serine residues found in both human UIMs and putative PfUIMs 
were labeled with asterisks. (C) Multiple sequence alignment of PfRpn10181-294 with its counterparts in other Plasmodium 
species: PVX_088150 (P. vivax), PKH_011040 (P. knowlesi), PCHAS_122350 (P. chabaudi), PBANKA_122290 (P. berghei) 
and PY04193 (P. yoelii). The sequences of putative PfUIM domains that were subjected to cloning and heterologous 
overexpression are underlined. The conserved residues are labeled with gray color, with the intensity of the color indicating 
the degree of conservation of the residues. 
 
Furthermore, searching for the Pru domain in the P. falciparum genome with BLAST predicted a putative Pru 
domain at the N-terminus of a P. falciparum homolog of Rpn13 (PF14_0138, PfRpn13) (Figure. 22A). This 
putative Pru domain has a 58% sequence similarity with the human Pru domain, highly suggesting that a 
functional Pru domain is present in PfRpn13. The putative plasmodial Pru domain was also found to be 
conserved in the corresponding counterparts of other Plasmodium species (Figure 22B). 
 
 
Figure 22. Identification of putative Pru domain in a P. falciparum homolog (PF14_0138) of Rpn13. (A) Sequence 
alignment of the Pru domain of human Rpn13 with the N-terminal sequence of PF14_0138 (putative PfRpn13). (B) Multiple 
sequence alignment of the N-terminal sequence of PF14_0138 with its counterparts in other Plasmodium species: 
PVX_085750 (P. vivax), PKH_133360 (P. knowlesi) and YYC_02989 (P. yoelii). The sequence of the putative PfPru domain 
that was subjected to cloning and heterologous expression is underlined. The conserved residues are labeled with gray color, 
with the intensity of the color indicating the degree of conservation of the residues. 
 
4.2.1.2 Cloning, heterologous overexpressions and purifications of the putative ubiquitin receptor 
domains of P. falciparum 
The putative PfUIM domains, the domain containing both PfUIM1 and PfUIM2 (PfUIM1+2) as well as the 
PfPru domain were successfully amplified from a blood stage cDNA library using the specific primers 
described in the Methods. For the heterologous overexpression of His-tagged recombinant domains, the PfUIM2, 
PfUIM1+2, and PfPru domains were individually cloned into a pQE30 expression vector, and the PfUIM1 
domain was cloned into a pRSET vector in order to increase its expression yield (see Methods). Both expression 
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vectors render a His-tag to the N-terminus of the respective recombinant domains. The ubiquitin receptor 
domains were heterologously overexpressed in E. coli and purified via Ni-NTA affinity chromatography 
followed by gel filtration. The recombinant, His-tagged PfUIM1, PfUIM1+2, and PfPru were further verified via 
western blot analyses with anti-His antibodies (Figure 23). 
 
Figure 23. Ni-NTA purifications of recombinant ubiquitin receptor domains of P. falciparum. (A-D) SDS-PAGE 
analysis and Coomassie staining of the purified PfUIM1, PfUIM2, PfUIM1+2, and PfPru domains in imidazole elution 
fractions. The purified PfUIM1, PfUIM1+2, and PfPru were confirmed by the western blot analysis using an anti-His 
antibody. In the western blot analysis of Pru, a protein detected by the anti-His antibody at the size of 27 kDa is most likely a 
dimer of the recombinant PfPru. 
 
4.2.2 Identification of the ubiquitin-like domains from two putative UBL-UBA proteins in P. falciparum 
The ubiquitin receptors of the eukaryotic 26S proteasome have been reported not only to bind to (poly)ubiquitin 
but also to the ubiquitin-like (UBL) domains of several proteasomal substrate shuttle factors, i.e. the UBL-UBA 
proteins (Mueller et al., 2003; Husnjak et al., 2008). The best studied UBL-UBA proteins are Rad23 and Dsk2. 
By using the sequences of human Rad23 and Dsk2 as inquiries in the BLAST, we found that P. falciparum 
encodes two proteins (PF10_0114 and PF11_0142), which are highly homologous to human Rad23 and Dsk2, 
respectively (data not shown). Sequence alignments of the UBL domains from human Rad23 and Dsk2 with the 
corresponding N-terminal parts of the two proteins suggested putative UBL domains are conserved in the two 
plasmodial proteins (Figure 24). 
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Figure 24. Identification of putative UBL domains in PF10_0114 (putative PfRad23) and PF11_0142 (putative 
PfDsk2). (A) Sequence alignment of the UBL domains of human RAD23A and RAD23B with the N-terminal sequence of 
PF10_0114. (B) Sequence alignment of the UBL domain of human Dsk2 with PF11_014235-111. The conserved residues are 
labeled with gray color, with the intensity of the color indicating the degree of conservation of the residues. 
 
The putative UBL domains of PF10_0114 and PF11_0142 were individually amplified and cloned into a 
GST-fusion protein expression vector. The GST-fused UBL domains were heterologously overexpressed in E. 
coli and purified via GSH-sepharose 4B affinity chromatography followed by gel filtration (Figure 25). It 
should be noted that the GST-fused UBL domain of PF10_0114 forms a truncated product with intact GST tag 
during the heterologous expression, which can be revealed via western blot analysis using the anti-GST 
antibody. The truncated product could not be further separated from the full-length product via normal 
chromatographic purifications, possibly due to the fact that they form a stable heterodimeric complex via their 
GST parts. 
 
 
Figure 25. GSH-sepharose 4B purifications of recombinant GST-tagged UBL domains from the putative PfRad23 and 
PfDsk2. (A) SDS-PAGE analysis and Coomassie staining of the purified GST-tagged UBL domain from putative PfRad23 
(GST-UBL-PfRad23). The purified GST-UBL-PfRad23 can be confirmed via a western blot analysis using the anti-GST 
antibody. A truncated product with a complete GST tag can be co-purified and detected. (B) SDS-PAGE analysis and 
Coomassie staining of the purified GST-tagged UBL domain from putative PfDsk2 (GST-UBL-PfDsk2). 
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4.2.3 Verification of the identified P. falciparum ubiquitin receptor domains 
To verify the identified ubiquitin receptor domains, the in vitro binding of the ubiquitin receptors with UBL 
domains or ubiquitin were assessed in a Ni-NTA-based pull-down assay. First, equal molar amounts of 
His-tagged ubiquitin receptor domains together with Ni-NTA resin were used to pull down the GST-fused UBL 
domains of PfRad23 and PfDsk2. As a result, it was found that the recombinant PfUIM and PfPru domains can 
pull down the GST-fused ubiquitin-like domains derived from PfRad23 and PfDsk2, whereas an equal molar 
amount of recombinant His-tagged PfTrx1 cannot. In the control experiment, GST itself was hardly pulled down 
by PfUIMs and PfPru, thus indicating that the ubiquitin receptor domains directly interact with the plasmodial 
UBL domains in the assay (Figure 26A). 
Next, we incubated the identified ubiquitin receptor domains with a mixture of K-48 linked polyubiquitin chains 
containing mono-ubiquitin and polyubiquitin molecules up to hepta-ubiquitin (Ub1-7) in the pull down assay. In 
the control experiments, either the equal molar amount of His-tagged PfTrx1 or only Ni-NTA resin was 
incubated with the polyubiquitin chains. The pulled-down ubiquitin molecules were detected via western blot 
analysis using anti-ubiquitin antibodies. As a result, it was found that PfUIM2 and PfUIM1+2 domains 
successfully pulled down the polyubiquitin chains ranging from diubiquitin to hepta-ubiquitin, but not the 
mono-ubiquitin. In strong contrast, the PfUIM1 and PfPru domains did not pull down any ubiquitin molecules. 
Using a 3-fold molar amount of PfUIM1 and PfPru in the pull-down assay was still unable to pull down 
polyubiquitin chains (data not shown), indicating that they lack the ability to bind ubiquitin and polyubiquitin 
chains. No ubiquitin molecules were pulled down by the His-tagged PfTrx1 or only by the Ni-NTA resin 
(Figure 26B). 
Taken together, the in vitro binding assays confirmed the UBL domain-binding capabilities of all identified P. 
falciparum ubiquitin receptor domains. However, only the PfUIM2 domain pocesses the capability to bind 
high-molecular-weight ubiquitin chains, strongly suggesting that the PfUIM2 domain of PfRpn10 is the major 
site for the direct recognition of ubiquitin conjugates at the P. falciparum 26S proteasome. 
 
Figure 26. In vitro binding of the UBL domains and the K48-linked polyubiquitin chains by P. falciparum ubiquitin 
receptor domains. (A) The recombinant His-tagged PfUIM1, PfUIM2, and PfPru domains (18 μM) were individually used 
to pull down GST-tagged UBL domains or GST (1.8 μM) together with 25 μL Ni-NTA resin. The western blot analysis using 
an anti-GST antibody was used to detect GST or GST-tagged UBL domains. One microgram of the respective purified 
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GST-tagged UBL domains were loaded as positive controls (lane 1). Pull down of GST-tagged UBL domains with an equal 
amount of His-tagged PfTrx1 were set as control experiments (lane 5). (B) The recombinant His-tagged PfUIM1, PfUIM2, 
UIM1+2, and PfPru domains (4.5 μM) were individually used in the pull down of 5 μg K-48 linked polyubiquitin chains 
(Ub1-7). The western blot analysis using an anti-ubiquitin antibody was used to detect ubiquitin molecules. One microgram of 
polyubiquitin chains was loaded as a positive control. As negative controls, equal molar amounts of His-tagged PfTrx1 or 
only Ni-NTA resin (Null) were used in the pull-down assay. 
 
4.2.4 Affinity purification of the P. falciparum 26S proteasome 
To characterize the componential integrity and functionality of the P. falciparum 26S proteasome complexes, we 
developed an affinity purification method to isolate the P. falciparum 26S proteasome complex. The method is 
based on the interaction of the PfUIM2 domain with the GST-tagged UBL (GST-UBL) domain of PfRad23. The 
experimental design is shown in Figure 27A. Formaldehyde was used to cross-link the intact parasites before 
lysis in order to stabilize the assembly of the whole 26S complex and maximize the identification of putative 
proteasome-interacting proteins (PIPs) (Bousquet-Dubouch et al., 2009). 
 
Figure 27. Affinity purification of the P. falciparum 26S proteasome. (A) The experimental workflow of the affinity 
purification of the P. falciparum 26S proteasome is based on the interaction of PfUIM2 with the UBL domain of PfRad23. 
See Methods for experimental details. The scheme has been modified from (Besche et al., 2012) (B) The SDS-PAGE (12%) 
and silver staining analysis of the proteins in the purified P. falciparum 26S proteasome sample. A control sample from a 
mock purification by using GST was included in parallel. The presence of the 20S subunits in the purified proteasome 
sample was confirmed by a western blot analysis with an antibody against 20S alpha subunits. 
 
Analysis of the purified proteasome sample in a silver-stained gel revealed that a number of proteins emerged in 
the GST-UBL-based purification but not in the mock purification with GST itself (Figure 27B). Additionally, 
the presence of 20S subunits can be detected via western blot analysis using an anti-20S α-subunit antibody. A 
typical yield of the purified 26S proteasome sample was about 15 μg from 6 mg parasite extracts. Furthermore, 
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determined by the fluorogenic peptide cleavage assay, the specific chymotrypsin-like, trypsin-like, and PGPH 
activities of the purified P. falciparum 26S proteasome were shown to be 54.6±8.8 pmol/μg/h, 76.08±17.5 
pmol/μg/h, and 35.62±3.9 pmol/μg/h, respectively. The respective proteasomal activities were also shown to be 
inhibited by the human proteasome inhibitors MG132 and lactacystin (Figure 28). No proteasomal activities 
were detected in the control sample from the GST mock purification (data not shown). 
 
Figure 28. The proteasomal activities of the affinity purified P. falciparum 26S proteasome. The specific 
chymotrypsin-like, trypsin-like, and PGPH activities of the purified P. falciparum 26S proteasome were determined by using 
the fluorogenic proteasomal substrates Suc-LLVY-AMC, Bz-VGR-AMC, and Z-LLE-AMC in a peptide cleavage assay, 
respectively. Inhibitory effects of the human proteasome inhibitors MG132 and lactacystin (10 μM) were tested on the 
proteasomal activities of the purified P. falciparum 26S proteasome. Ten percent of the purified sample was used in each 
measurement. 
 
The proteins in the purified P. falciparum 26S proteasome samples from four independent GST-UBL-based 
purifications together with a control sample from a mock purification with GST were trypsin-digested and 
identified using a linear trap quadrupole (LTQ)-Orbitrap mass spectrometer (Table 4). Proteins that were 
abundantly detected in the control sample were subtracted. In total, 33 proteasomal proteins covering all 
putative subunits of the P. falciparum 26S proteasome were abundantly and reproducibly identified in the 
samples but not in the control, demonstrating the robustness of the purification method for isolating plasmodial 
26S proteasomes. The overall abundance of the identified 19S subunits appeared to be higher than that of the 
20S subunits. This is probably due to the fact that the affinity is generated to the 19S sub-complex, resulting in 
the capture of both single and double-capped 26S proteasomes. Besides, a putative plasmodial subunit of the 
proteasome activator complex (PA28) was also identified. No human 26S proteasome subunits were detected, 
indicating the specificity of the affinity purification method. 
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Table 4. Proteasomal components identified in the affinity purification of the P. falciparum 26S proteasome 
PlasmoDB 
Accession No. 
Descriptive name1 
Unique 
Peptides2 
Coverage %3 
19S RP   
Non-ATPase subunits   
PFB0260w Proteasome 26S regulatory subunit, putative (Rpn1) 55/43/28/19 38.3/32.6/24.7/25.1 
PF14_0632 26S proteasome regulatory subunit, putative (Rpn2) 48/34/23/18 38.5/31.9/27.2/26.5 
MAL13P1.190 Proteasome regulatory subunit, putative (Rpn3) 28/19/16/6 41/34.8/40.4/19.7 
PFC0785c Proteasome regulatory protein, putative (Rpn4/P27) 4/5/3 19.1/19.1/18.2 
PF10_0174 26s proteasome regulatory subunit p55, putative (Rpn5) 25/14/17/14 39/22.3/29.8/23.1 
PF14_0025 Proteosome subunit, putative (Rpn6) 22/19/15/11 27/24.2/23.9/15.3 
PF11_0303 26S proteasome regulatory subunit, putative (Rpn7) 13/18/7/4 31.6/25.4/18.1/15 
PFI0630w 26S proteasome regulatory subunit, putative (Rpn8) 17/14/11/7 49.1/36.1/34.3/31.4 
PF10_0298 26S proteasome regulatory subunit, putative (Rpn9) 16/11/5/5 34.9/30/17/16.5 
PF08_0109 Proteasome subunit alpha type 5, putative (Rpn10) 27/17/20/9 38.7/48.4/33.1/32.4 
MAL13P1.343 Proteasome regulatory subunit, putative (Rpn11) 17/15/13/13 50.8/45.7/42.8/51.1 
PFC0520w 26S proteasome regulatory subunit S14, putative (Rpn12) 5/3/3/2 15.8/8.9/8.9/8.9 
PF14_0138 26S proteasome regulatory subunit, putative (Rpn13) 7/3/4 43.1/19.8/24.9 
ATPase subunits   
PF13_0063 26S proteasome regulatory subunit 7, putative (Rpt1) 31/31/19/19 41.4/50.5/33.6/39.3 
PF10_0081 26S proteasome regulatory subunit 4, putative (Rpt2) 42/36/37/23 62.5/60.3/53.6/52.7 
PFD0665c 26S proteasome AAA-ATPase subunit, putative (Rpt3) 45/29/31/15 58.7/48/59.9/37.8 
PF13_0033 26S proteasome regulatory subunit, putative (Rpt4) 19/20/13/9 41.2/37.2/33.1/29.3 
PF11_0314 26S proteasome regulatory subunit 6a, putative (Rpt5) 55/49/44/30 60.4/60.1/65.4/64.5 
PFL2345c 26S proteasome regulatory subunit 8, putative (Rpt6) 30/25/27/19 46.9/49/49/40.5 
20S CP   
Alpha-subunits   
MAL8P1.128 Proteasome subunit alpha, putative (α1) 16/12/8/9 53.8/46.9/28.1/35.4 
PFF0420c Proteasome subunit alpha type 2, putative (α2) 14/12/13/8 52.8/43.8/52.8/43.8 
PF13_0282 Proteasome subunit, putative (α3) 15/10/11/6 59.8/51.2/42.3/45.1 
MAL13P1.270 Proteasome subunit, putative (α4) 23/19/10/10 38.6/45.6/37.8/44.4 
PF07_0112 Proteasome subunit alpha type 5, putative (α5) 15/15/11/12 39.5/46.5/35.5/37.1 
PF14_0716 Proteosome subunit alpha type 1, putative (α6) 15/8/10/9 43.7/25.2/43.7/42.5 
PFC0745c Proteasome component C8, putative (α7) 6/6/7/3 23.8/20.6/25.8/15.9 
Beta-subunits   
PFI1545c Proteasome precursor, putative (β1) 15/11/8/3 27.3/28/26.2/21.3 
PF13_0156 Proteasome subunit beta type 7 precursor, putative (β2) 3/2 13.3/4.1 
PFA0400c Beta3 proteasome subunit, putative (β3) 13/10/7/5 32.4/41.7/20.6/31.4 
PF14_0676 20S proteasome beta 4 subunit, putative (β4) 8/7/4/3 40/40/23.6/17.9 
PF10_0111 20S proteasome beta subunit, putative (β5) 7/4/4/2 27.3/15.9/15.1/12.5 
PFE0915c Proteasome subunit beta type 1, putative (β6) 8/5/8/4 32.9/18.3/32.5/18.8 
MAL8P1.142 20S proteasome beta subunit (β7) 30/25/14/16 44.2/44.2/38.1/45.3 
Proteasome activator   
PFI0370c Subunit of proteasome activator complex, putative, PA28 9/5/4/7 42.3/21.5/17.2/31.2 
1The descriptive names of the proteins were annotated in the PlasmoDB. The assignments of the subunits of the P. 
falciparum 26S proteasome complex were referred to the “Malaria Parasite Metabolic Pathways” 
(http://priweb.cc.huji.ac.il/malaria/). 2,3The number of unique peptides and the corresponding sequence coverage identified 
by the MS/MS analysis were given for each identified protein. Values from four independently conducted experiments were 
listed. 
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4.2.5 Identification of putative P. falciparum proteasome-interacting proteins (PIPs) 
Besides the proteasomal components, a number of additional plasmodial proteins were identified in the MS/MS 
analysis, indicating the co-purification of these proteins with the P. falciparum 26S proteasome (Table 5). It is 
well known in the mammalian and plant system that a variety of PIPs dynamically interact with the 26S 
proteasome (Bousquet-Dubouch et al., 2009; Saeki et al., 2009). Thus, we speculate that many of the co-purified 
proteins might be putative PIPs of the P. falciparum 26S proteasome. Supporting this, a large group of the 
co-purified proteins consist of many conserved proteins whose mammalian and plant counterparts have been 
reported to be PIPs in other affinity purifications of the eukaryotic 26S proteasomes. For example, the putative 
PfRad23 and PfDsk2, whose mammalian counterparts are well characterized proteasome interactors, were 
identified in at least three independent purifications. Additionally, several proteins that belong to the plasmodial 
UPS were identified in the purified proteasome sample, including the plasmodial polyubiquitin, one E1 enzyme 
and four E2 enzymes, and several deubiquitinases. Of great significance, a putative ubiquitin carboxyl-terminal 
hydrolase (PFE1355c) were abundantly and reproducibly identified with a large number of peptides and high 
sequence coverage in the MS/MS analysis, highly suggesting a specific interaction of the protein with the 
plasmodial 26S proteasome. Furthermore, a variety of proteins involved in the protein folding and quality 
control, protein translation, glycolysis, ribosomal function, and Plasmodium-specific processes were also 
identified to be co-purified with the plasmodial 26S proteasome. Many of the proteins have mammalian and 
plant counterparts that are validated PIPs or have been shown to be co-purified with the 26S proteasome by 
similar purification strategies or other biochemical approaches. These proteins include heat shock proteins, 
proteasome-assembling chaperones, T-complex proteins, elongation factors, some glycolytic enzymes, and 
ribosomal proteins (Table 5). These proteins appear to be present in high abundance among total co-purified 
proteins, indicating the effectiveness of the affinity purification method to co-isolated putative PIPs of the P. 
falciparum 26S proteasome. Of course, the interactions of the identified putative PIPs with the plasmodial 26S 
proteasome need to be validated in further investigations. 
 
Table 5. Co-purified proteins identified in the affinity purification of the P. falciparum 26S proteasome. 
PlasmoDB 
Accession No. 
Descriptive name1 
Peptides 
number2 
Coverage %3 
   
Ubiquitin and ubiquitin domain containing proteins   
PFL0585w Polyubiquitin※ 2 6.6 
PF10_0114 DNA repair protein RAD23, putative※ 2/2/2 5.6/5.9/5.6 
PF11_0142 Ubiquitin domain containing protein※ 4/4/4/2 18/18/22.2/17 
Ubiquitination enzymes   
PFL1245w Ubiquitin-activating enzyme e1, putative 5/5/2/10 5.1/5.9/2.3/16.1 
PFE1350c Ubiquitin conjugating enzyme 13, putative 3/7/5/4 24.3/63.8/52.6/52 
PFL0190w Ubiquitin conjugating enzyme E2, putative 4/5/3/4 18.4/18.4/18.4/18.4 
PFI0740c Ubiquitin conjugating enzyme, putative 2/3 35.8/35.8 
PF13_0301 Ubiquitin conjugating enzyme, putative 2/2/3 26.2//21.8/34.2 
Deubiquitinases   
PFE1355c Ubiquitin carboxyl-terminal hydrolase, putative※ 34/24/26/12 39.7/30.2/39.8/22.5 
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PlasmoDB 
Accession No. 
Descriptive name1 
Peptides 
number2 
Coverage %3 
MAL7P1.147 Ubiquitin carboxyl-terminal hydrolase, putative 2 1.2 
PFA0220w Ubiquitin carboxyl-terminal hydrolase, putative 2 1.5 
PF11_0177 Deubiquinating/deneddylating enzyme※ 2/5 7.7/14 
Protein folding and quality control   
PFF0940c Cell division cycle protein 48 homologue, putative※ 12/13/20/23 19.2/23.9/29.1/27.7 
PF14_0046 Conserved Plasmodium protein, unknown function▲ 18/12/11/19 42.1/42.1/45.5/53.9 
PF11_0055 Conserved protein, unknown function▲ 10/8/21/16 24.8/21/34/34.7 
PF11_0098 Endoplasmic reticulum-resident calcium 37/28/38/36 71.7/75.8/73.5/66.5 
 binding protein▲   
PFL1070c Endoplasmin homolog precursor, putative▲ 24/33/38/34 31.2/48.7/48.2/40.7 
PF07_0033 Heat shock protein 110※ 13/12/14/13 20.8/18.1/23.6/21 
MAL13P1.540 Heat shock protein 110, putative▲ 22/19/52/48 32.3/25.6/51.1/48.5 
PFI0875w Heat shock protein 70※ 172/119/238/197 83.6/70.2/88.8/75.9 
PF08_0054 Heat shock protein 70※ 47/47/59/51 55.1/53.3/67.7/58.3 
PF11_0351 Heat shock protein 70※ 17/16/44/32 30.6/26.5/49.6/41.9 
PF07_0029 Heat shock protein 90※ 51/76/58/61 45/56.5/52.8/49.9 
PF14_0359 HSP40, subfamily A, putative 14/4/9/9 35.1/18.2/30.7/28.1 
PF14_0324 HSP70/HSP90 organizing protein, putative  9/14/16/7 20.7/30.5/28.9/15.4 
PFF1050w Nascent polypeptide associated complex  11/8/4/5 56.5/47.8/37.5/48.9 
 alpha chain, putative※▲   
PF11_0164 Peptidyl-prolyl cis-trans isomerase, cyclophilin▲ 6/4/8/7 35.9/19.0/51.8/46.2 
MAL8P1.17 Protein disulfide isomerase▲ 17/21/25/25 37.1/42.4/50.7/49.9 
PFL1425w T-complex protein 1, gamma subunit, putative※ 12/11/9/12 27.7/28.4/20.5/22.1 
PFC0285c T-complex protein beta subunit, putative※ 5/16/4/12 15.2/29.1/13.3/21.4 
Protein translation    
PF14_0486 Elongation factor 2※ 38/37/39/33 45.3/41.7/47.4/34.6 
PF13_0304 Elongation factor 1-alpha※ 62/63/58/63 59.8/65.9/55.1/65.9 
PFI0645w Elongation factor 1-beta※ 17/13/12/11 55.8/51.1/43.1/50 
PF13_0214 Elongation factor 1-gamma, putative 11/13/14/14 18/24.6/23.8/20.9 
PFL0625c Eukaryotic translation initiation factor-3  10/15/7/7 10.8/14.7/9.7/9.8 
 subunit 10, putative   
PF14_0104 Eukaryotic translation initiation factor 2  10/10/6/7 26.2/23.4/18.3/22.2 
 γ-subunit, putative   
Glycolysis    
PFI0755c 6-phosphofructokinase※ 17/13/41/40 19.9/15.3/31/32 
PF10_0155 Enolase※ 25/32/36/38 53.8/58.3/57.2/61.7 
PF14_0425 Fructose-bisphosphate aldolase※ 28/30/14/18 55.3/58.3/48.5/45.3 
PF14_0598 Glyceraldehyde-3-phosphate dehydrogenase※ 34/31/43/33 57.6/48.1/68/66.5 
PF13_0141 L-lactate dehydrogenase 16/27/27/22 50.3/70.3/70.6/60.4 
PFI1105w Phosphoglycerate kinase 25/24/29/30 51/50.7/58.2/56 
PF11_0208 Phosphoglycerate mutase, putative  8/14/16/20 35.6/48.8/56.8/57.2 
PFF1300w Pyruvate kinase※ 27/22/26/38 39.5/41.9/39.3/58.1 
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Accession No. 
Descriptive name1 
Peptides 
number2 
Coverage %3 
Ribosome complex   
PFE0810c 40S ribosomal protein S14, putative   10/12/11/13 52.3/70.9/68.9/52.3 
PF11_0272 40S ribosomal protein S18, putative 12/8/11/13 51.3/38.5/46.2/46.2 
PF14_0448 40S ribosomal protein S2, putative  16/12/10/12 50/29/31.6/32 
PF10_0264 40S ribosomal protein S2B, putative 12/12/16/13 39.5/46/46/39.2 
PF14_0627 40S ribosomal protein S3, putative※ 13/14/12/15 42.5/44.8/40.7/40.7 
PFC1020c 40S ribosomal protein S3A, putative  14/11/18/17 44.3/38.5/34.7/38.9 
PF11_0065 40S ribosomal protein S4, putative 12/14/17/16 38.7/41.4/41/53.3 
PF13_0228 40S ribosomal protein S6, putative※ 20/13/17/19 37.9/27.8/32/40.5 
PF14_0083 40S ribosomal protein S8e, putative  15/13/13/10 64.7/46.8/50.5/33.9 
PFC0400w 60S acidic ribosomal protein P2, putative 23/17/12/13 75/65.2/65.2/75 
PF14_0141 60S ribosomal protein L10, putative  13/13/9/10 32/32/31.5/31.5 
PF10_0272 60S ribosomal protein L3, putative 13/19/15/19 26.9/33.9/30.1/33.4 
PFE0350c 60S ribosomal protein L4, putative 23/19/23/18 33.6/32.4/37/33.1 
PF14_0230 60S ribosomal protein L5, putative  12/13/10/9 35/38.1/38.4/34 
PF13_0213 60S ribosomal protein L6-2, putative  8/11/11/12 41.6/42.1/41.2/48.4 
PF11_0313 60S ribosomal protein P0※ 20/24/21/26 52.8/70.9/63.9/57 
PF11_0043 60S ribosomal protein P1, putative 22/13/21/19 69.5/72/69.5/69.5 
Proteinases and Plasmodium surface protein   
PFI1475w Merozoite surface protein 1  35/43/46/56 24.6/28.7/26.8/30.1 
PF14_0075 Plasmepsin IV  17/13/19/15 37.6/35.4/38.1/33.2 
MAL13P1.56 M1-family alanyl aminopeptidase  15/13/26/31 21.6/18.3/27/35.1 
PF14_0078 Plasmepsin III, histo-aspartic protease  11/18/21/17 25.1/40.4/45.7/29.3 
PF14_0077 Plasmepsin II 10/9/10/6 25.4/23.4/20.1/15.7 
1The descriptive names of the proteins were annotated in the PlasmoDB. 
2,3The number of peptides and the corresponding sequence coverage identified by the MS/MS analysis were given for each 
identified protein. Values from four independently conducted experiments were listed. 
▲Proteins predicted to have endoplasmic reticulum retention sequences. Refer to the “Malaria Parasite Metabolic Pathways” 
(http://priweb.cc.huji.ac.il/malaria/) 
※The proteins that have mammalian counterparts which were validated as PIPs or have been shown to be co-purified with 
eukaryotic 26S proteasomes (Wang et al., 2008; Besche et al., 2009; Bousquet-Dubouch et al., 2009; Bousquet-Dubouch et 
al., 2009; Scanlon et al., 2009). 
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5. DISCUSSION 
5.1 The S-nitrosoproteome of P. falciparum 
In this thesis, we carried out the first comprehensive analysis of protein S-nitrosylation (SNO) induced by the 
NO donor GSNO in the human protozoan parasite P. falciparum. Based on a biotin-switch assay coupled to 
proteomic analysis, 319 potential protein targets and 37 sites for S-nitrosylation have been identified. The 
identified proteins give an initial insight into the S-nitrosoproteome of P. falciparum. It should be noted that 
although the S-nitrosylated proteins were identified in cell extracts of asexual intraerythrocytic P. falciparum, 
many proteins are expressed throughout the complete life cycle of the parasites, including the mosquito stages. 
Thus, the data may also contribute to the understanding of SNO in the mosquito stages, when the parasites 
encounter severe oxidative/nitrosative stresses (Luckhart et al., 1998; Ascenzi et al., 2002; Peterson et al., 
2007). 
It is known that S-nitrosylated proteins are normally present in very low abundance in unstressed cells and are 
technically difficult to be directly detected and identified (Hess et al., 2005). Therefore, the biotin-switch assay 
was invented to be the most commonly used method to study SNO. To increase sensitivity and facilitate sample 
handling, the assay typically requires cell extracts that are directly treated by NO donors (100 μM to 1 mM) or 
are extracted from the cells treated with NO donors (100 μM to 1 mM). Accordingly, in this study 100 μM 
GSNO was used to facilitate the detection and identification of SNO targets in the P. falciparum cell extracts. To 
our knowledge, the direct quantification of cellular RNS/GSNO levels is technically difficult, and the 
quantitative information of GSNO or RNS concentration that the malaria parasites are exposed to is so far 
unclear (Kalyanaraman et al., 2012). However, Ostera G. and co-workers have detected RNS in both 
intraerythrocytic stages of the parasites and parasite gametocytes by using a specific fluorescent probe. Although 
no quantitative information of RNS was provided, they have observed that RNS are abundantly present around 
the food vacuole in the parasites, indicating that compartmentalized concentrations of intraparasitic RNS can 
probably be high (Ostera et al., 2008). Besides, from the view of host-parasite interaction, malaria parasites are 
exposed to extracellular NO originating mainly from the NO synthase of host immune cells or mosquito vectors 
(Ferrari et al., 2011; Marois 2011). It was determined that the NO concentration in the hemolymph of Anopheles 
albimanus infected with P. berghei (a rodent Plasmodium parasite) is about 17 μM, which is three times higher 
than that in uninfected mosquitoes (Herrera-Ortiz et al., 2011). Another study reported that in CBA/Ca mice 
infected with P. chabaudi (another rodent Plasmodium parasite), the NO concentration in serum was 120 μM 
when a peak parasitemia appears (Legorreta-Herrera et al., 2011). Furthermore, one study on malaria patients 
reported that the NO concentration in the plasma of patients infected with P. falciparum is about 7 μM 
(Lima-Junior et al., 2012), whereas another study reported the NO concentration in patients’ plasma to be about 
60 μM (Nahrevanian et al., 2006). These studies are indicative of the overall elevation of NO levels due to 
Plasmodium infection, suggesting that intraparasitic RNS/NO levels can dramatically increase when the 
parasites are directly exposed to an inflammatory level of ROS/RNS stress from the host immune response or 
near the parasitic origin where endogenous RNS are generated. 
The identified plasmodial S-nitrosoproteome shares a similar pattern of composition with the 
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S-nitrosoproteomes from other organisms. In accordance with S-nitrosoproteomes of higher eukaryotic 
organisms [dbSNO, http://dbsno.mbc.nctu.edu.tw], the P. falciparum S-nitrosoproteome possesses many 
conserved proteins whose mammalian and plant counterparts have been reported as canonical S-nitrosylation 
targets. These proteins are mainly gene transcription and translation factors, protein chaperones, ribosome 
proteins, proteasome subunits, cytoskeletal and antioxidant proteins, and miscellaneous metabolic enzymes. The 
specificity of S-nitrosylation on these proteins is most likely due to the evolutionary conserved structure of these 
proteins in P. falciparum and higher eukaryotes, indicating that SNO may play similar regulatory roles in 
corresponding pathways. 
 
5.2 Potential NO targets and affected pathways in P. falciparum 
The identified S-nitrosylated proteins involved in diverse cellular processes and biological pathways provide a 
molecular basis for further studies on how NO exerts its action in P. falciparum and – at high concentrations – 
mediates parasite killing. For example, S-adenosylmethionine synthetase (SAMS), a key enzyme involved in 
methionine and polyamine metabolism, was identified to be S-nitrosylated at a cysteine residue conserved in 
both P. falciparum (Cys113, see Appendix Table 1) and rat (Cys121) (Chiang et al., 1999; Perez-Mato et al., 
1999). It has been shown for rat SAMS that the acidic (Asp355) and basic (Arg357, Arg363) amino acids in the 
vicinity of Cys121 are critically involved in the deprotonation of the sulfur group of the cysteine and 
concertedly facilitate the GSNO-induced S-nitrosylation at Cys121 (Perez-Mato et al., 1999; Hess et al., 2005). 
Intriguingly, P. falciparum SAMS (PfSAMS) shares a sequence identity of 57% with rat SAMS and preserves 
the surrounding acidic/basic amino acids required for S-nitrosylation: Asp352, Arg354, and Gln360 (a 
conservative substitution of Arg363 in rat SAMS) (Chiang et al., 1999). Thus, S-nitrosylation may occur at 
Cys113 of PfSAMS due to the coordination of surrounding acidic/basic amino acids in the same manner. More 
importantly, S-nitrosylation of Cys121 has been shown to markedly inactivate rat SAMS and result in a 
reduction of the S-adenosylmethionine (SAM) level in rat hepatocytes (Perez-Mato et al., 1999). Regarding the 
similar metabolic function and the presence of the same S-nitrosylation site in PfSAMS compared to rat SAMS, 
it is reasonable to speculate that SNO may affect the SAM biosynthesis in P. falciparum by influencing PfSAMS 
activity. Because SAMS is a key precursor for polyamine biosynthesis, which is closely related to the 
proliferation of P. falciparum (Clark et al., 2010), SNO on PfSAMS may correlate with the growth arrest of 
Plasmodium parasites caused by NO, which has been observed in several studies (Taylor-Robinson 1997; 
Balmer et al., 2000). Of course, this hypothesis needs to be substantiated by further experiments. 
Of particular interest, a series of essential proteases involved in the cascade of hemoglobin digestion were 
identified as potential SNO targets (Appendix Table 1). It is well known that hemoglobin digestion in the 
parasites’ food vacuole is essential for Plasmodium parasites, providing a main source of amino acids during 
parasite growth (Goldberg 2005). Given that intraparasitic RNS are abundantly present around the food vacuole 
where many of these hemoglobinases reside (Ostera et al., 2008), nitrosative stress-derived S-nitrosylation has a 
high likelihood of occurrence on these hemoglobinases. Indeed, the cysteine protease falcipain has been 
demonstrated to be substantially inactivated by 10 μM of NO donors due to S-nitrosylation of its active site 
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cysteine (Venturini et al., 2000). The susceptibility of falcipain to NO has been linked to the growth inhibition of 
parasites under NO donor treatments (Venturini et al., 2000; Nahrevanian 2006). Thus, it is likely that SNO 
influences hemoglobin digestion via modulating hemoglobinases, thereby being relevant to the inhibitory effects 
of NO on the proliferation of the parasites. 
Glycolytic enzymes of P. falciparum appear to undergo multiple thiol-based redox regulations. We have shown 
previously that nine enzymes in the glycolysis pathway can be modified by GSH via S-glutathionylation in vivo 
(Kehr et al., 2011). Moreover, PfPK, PfLDH, PfGAPDH, and PfHK (hexokinase) are regulated by the 
thioredoxin superfamily in P. falciparum (Sturm et al., 2009). Strikingly, in this study we identified all eleven 
glycolytic enzymes of P. falciparum as potential SNO targets, suggesting that the glycolysis pathway is highly 
susceptible to redox modulation by NO. The importance of glycolysis to P. falciparum is highlighted by the fact 
that the uptake and consumption of glucose by parasitized erythrocytes is increased by a factor of ~100 
compared to normal erythrocytes (Roth 1990). Additionally, because of the absence of a pyruvate 
dehydrogenase complex in mitochondria, P. falciparum becomes critically dependent upon glycolysis for energy 
production (Ralph 2005). Hence, perturbation of glycolysis may render detrimental effects on the proliferation 
of parasites as suggested before (van Schalkwyk et al., 2008). We confirmed that four glycolytic enzymes, PfPK, 
PfLDH, PfPGM, and PfGAPDH were readily S-nitrosylated via protein immunoblotting analysis (Figure 16A). 
Furthermore, PfGAPDH was found to be significantly inhibited by S-nitrosylation at its conserved active site 
cysteine (Cys153) (Figure 16B and C). GAPDH is a central glycolytic enzyme responsible for the 
NAD+-dependent phosphorylation of glyceraldehyde-3-phosphate to the product, 1,3-bisphosphoglycerate, a key 
step in the glycolytic pathway (Robien et al., 2006). Thus, inhibition of PfGAPDH via SNO may indicate an 
inhibitory role of NO in the regulation of glycolysis in the parasite. Furthermore, it has been reported that 
reversible inactivation of GAPDH under oxidative stress may protect the enzyme from over-oxidation and 
re-route the metabolic flux from glycolysis to the pentose phosphate pathway (PPP), which is a critical process 
for generating reducing equivalents in the form of NADPH (Ralser et al., 2007). Similarly, the reversible 
inactivation of PfGAPDH via S-nitrosylation is presumably also an early signaling event that redirects the 
carbohydrate flux to the PPP in order to generate more NADPH, which can be used to cope with oxidative and 
nitrosative stress in the parasites. For example, the plasmodial TrxR-Trx system may utilize NADPH to recover 
PfGAPDH activity via denitrosylation (Figure 19). In this way, S-nitrosylation of PfGAPDH may serve as a 
signaling switch to contribute to the parasitic tolerance to nitrosative stress. 
 
5.3 Regulation of SNO in P. falciparum 
Intracellular GSH, an abundant antioxidant tripeptide, detoxifies nitrosative stress by reacting with RNS 
(Broniowska et al., 2013). This results in the formation of GSNO, which can be denitrosylated back to GSH by 
GSNOR as shown in higher eukaryotic cells (Benhar et al., 2009). Although GSNOR seems to be conserved 
from bacteria to humans, a plasmodial homolog of GSNOR has not been identifiable in the genome of P. 
falciparum so far. The lack of GSNOR in the parasites may render RNS detoxification more dependent upon the 
thioredoxin system. Indeed, we have previously reported that PfTrx1 can efficiently reduce GSNO to GSH at a 
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biologically relevant rate (Kanzok et al., 2000), suggesting that PfTrx1 might compensate for GSNOR to reduce 
GSNO in vivo. More importantly, we proved in this study that PfTrx1 functions as a general denitrosylase that 
can efficiently denitrosylate a large variety of proteins (Figure 19A), suggesting that PfTrx1 may protect 
proteins from NO stress. For example, the PfTrx1 system was demonstrated to be able to denitrosylate 
PfGAPDH and efficiently recover its glycolytic activity (Figure 19B, C, and D), indicating a role for the 
PfTrx1 system in protecting glycolysis from nitrosative stress. The active site cysteines were demonstrated to be 
responsible for the denitrosylating activity of PfTrx1, consistent with the denitrosylation mechanism of Trx in 
higher eukaryotic organisms (Wu et al., 2011). Considering the fact that PfTrx1 is generally located in the 
parasites’ cytosol and ubiquitously expressed in asexual and sexual stages of P. falciparum and also in parasite 
ookinetes (Kehr et al., 2010; Turturice et al., 2013), denitrosylation mediated by PfTrx1 may represent an 
important defense mechanism against nitrosative stress throughout the life cycle of Plasmodium parasites. 
Whereas PfTrx1 mediates denitrosylation via active site cysteines, we demonstrate that PfTrx1 itself can be 
site-specifically S-nitrosylated at Cys43, which in turn mediates the transnitrosylating activity of PfTrx1 (Figure 
18 and Figure 20). A number of proteins appear to be targets of transnitrosylation by PfTrx1. In contrast to 
denitrosylation, transnitrosylation by Trx has been reported to transduce NO stress and mediate NO signaling in 
cells (Wu et al., 2011; Nakamura et al., 2013). It is thus plausible that PfTrx1 plays dual roles in the regulation 
of SNO, which is closely associated with its site-specific response to NO stress. Based on these findings, we 
proposed a redox status-based model for PfTrx1 in protein denitrosylation and transnitrosylation (Figure 29): 
under normal conditions the reduced PfTrx1 is predominantly present in the parasites (Kanzok et al., 2000; 
Krnajski et al., 2001; Kanzok et al., 2002). The model of denitrosylation by reduced PfTrx1 may represent a 
general mechanism by which reduced PfTrx1 protects the parasites from RNS/NO stress. This protective 
mechanism may explain, at least in part, the parasitic tolerance to nitrosative stress generated either 
endogenously or exogenously (Luckhart et al., 1998; Ostera et al., 2008); however, upon extreme NO stress or 
along with an increase in ROS/RNS stress together with a gradual loss of the recycling of reduced PfTrx1, 
PfTrx1 could be S-nitrosylated at the non-active-site cysteine (Cys43) to a significant extent, turning the overall 
role of PfTrx1 from denitrosylation to transnitrosylation for transducing NO stress/signaling. The 
transnitrosylation model of PfTrx1 is probably of more physiological relevance during parasite transmission 
between mosquito vectors and hosts, as the parasites are directly exposed to the host immune response in which 
inflammatory levels of NO are clearly involved (Ascenzi et al., 2002; Ali et al., 2010). For example, during the 
initial invasion of the mosquito midgut, the Plasmodium parasite ookinetes temporarily suffer NO stress 
generated by the mosquito NOS (Ali et al., 2010). Although specific denitrosylation and transnitrosylation 
substrates of PfTrx1 are yet to be discovered, the model may give a first insight into possible regulatory 
potentials of PfTrx1 in the interplay of NO and the Plasmodium parasites within a specific redox milieu. It will 
be of great interest to identify and characterize denitrosylation and transnitrosylation substrates of PfTrx1 in P. 
falciparum in order to reveal specific pathways regulated by PfTrx1 upon nitrosative stress. 
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Figure 29. Proposed redox-based regulation of S-nitrosylation by PfTrx1. Upon mild to moderate nitrosative stress, the 
predominantly reduced PfTrx1 in cells mainly acts as a denitrosylase by catalyzing the denitrosylation of S-nitrosylated 
biomolecules via its active site cysteines. In this process, its active site cysteines are oxidized to a disulfide, which can be 
re-reduced by PfTrxR in the presence of NADPH. When parasite cells encounter severe and continuous oxidative/nitrosative 
stress (e.g. drug treatment) or local NO stress is severely enhanced (e.g. under NO burst generated from host iNOS), the 
reduction of oxidized PfTrx1 by PfTrxR can be compromised. Under these conditions, Cys43 of PfTrx1 can be S-nitrosylated 
to a significant extent and transnitrosylate other proteins, thus mediating NO stress. In addition to the processes shown in this 
scheme, S-nitrosylation of Cys43 in reduced PfTrx1 might also occur as well as transnitrosylation from S-nitrosylated 
proteins to PfTrx1. ROS, reactive oxygen species; RNS, reactive nitrogen species. (Wang et al., 2013) 
 
5.4 Mode of substrate recognition at the P. falciparum 26S proteasome 
The recognition of the proteasomal substrates is a key component of the UPS and represents the initial signaling 
event that triggers downstream proteasomal functions. It has been well established in eukaryotes that the UPS 
employed three different classes of ubiquitin receptors for recognizing ubiquitinated substrates, including the 
intrinsic ubiquitin receptors harbored by the proteasome itself, the UBL-UBA shuttle factors that contain both 
ubiquitin-like (UBL) and ubiquitin-associated (UBA) domains, and the CDC48-based complexes, which are 
primarily involved in the endoplasmic reticulum-associated degradation (ERAD) pathway (Tomko et al., 2013). 
In this study, we focused on the intrinsic ubiquitin receptors of the P. falciparum 26S proteasome, aiming to 
decipher the mechanistic context of the recognition of ubiquitin substrates by the plasmodial 26S proteasome. 
By taking advantage of current knowledge on eukaryotic ubiquitin receptors, we identified two PfUIM domains 
and a PfPru domain from the putative PfRpn10 and PfRpn13 subunits, respectively. All identified ubiquitin 
receptor domains were successfully cloned, heterologously overexpressed, and purified. 
In an in vitro binding assay, the recombinant PfUIM domains were proved to bind UBL domains from putative 
PfRad23 and PfDsk2, which are plasmodial homologs of UBL-UBA shuttle factors. This result indicates that 
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both PfUIM domains may be involved in receiving proteasomal substrates carried by the UBL-UBA shuttle 
factors, for example, the PfRad23 and PfDsk2. However, only the PfUIM2 domain was found to be able to bind 
K48-linked polyubiquitin chains rather than mono-ubiquitin, whereas the PfUIM1 domain completely lacked the 
ubiquitin-binding capability under the same experimental conditions. Consistent with our results, three UIM 
domains have been found in Arabidopsis but only the N-terminal UIM1 domain of Arabidopsis is able to bind 
ubiquitin chains (Fu et al., 1998; Fatimababy et al., 2010). 
Structural analyses of complexes of human UIMs with mono-ubiquitin or diubiquitin have revealed several 
structural determinants that affect their affinity. Although PfUIM1 preserves the key hydrophobic residues at the 
center of the ubiquitin-interacting surface, a strictly conserved N-terminal region of UIM1 (206FGVDPS211 in 
human S5a) is missing from the PfUIM1 sequence (Zhang et al., 2009). This region has been shown to be 
involved in the binding interface of S5a with diubiquitin. Lack of this region in PfUIM1 might be an explanation 
for its inability in binding ubiquitin chains. Of course, it cannot be ruled out that PfUIM1 has a weak 
ubiquitin-binding affinity that was not detected by the pull-down assay used in this study. Furthermore, both 
human UIMs (hUIM1 and hUIM2) have been reported to bind either mono-ubiquitin or polyubiquitin chains, 
with hUIM2 having a greater affinity over hUIM1 (Wang et al., 2005). The higher binding affinity of hUIM2 
could be attributed to an N-terminal region (P276-T282 in S5a) of hUIM2, which is important in forming a more 
compact and extensive binding interface with ubiquitin (Zhang et al., 2009). Within this region, a key 
methionine residue (M281 in S5a) is involved in stabilizing the N-terminal patch of hUIM2 and its substitution 
by alanine dramatically reduces the polyubiquitin-binding ability of hUIM2 (Zhang et al., 2009). Although no 
structural information of PfUIM2 was obtained, the sequence alignment of hUIM2 and PfUIM2 showed that 
PfUIM2 may also preserve such an N-terminal region in which the conserved methionine (M257 in PfRpn10) 
residue is located. 
Another intriguing finding of this study is that, similar to PfUIM1, the PfPru domain was found to bind UBL 
domains of PfRad23 and PfDsk2 but not K48-linked polyubiquitin chains. In fact, the ubiquitin chain-binding 
properties of eukaryotic Pru domains vary significantly across species. Human Pru domain has been shown to 
strongly bind mono-ubiquitin and diubiquitin with dissociation constant (Kd) values of 300 nM and 90 nM, 
respectively (Husnjak et al., 2008). However, the S. cerevisiae Pru domain (ScPru) has a markedly reduced 
affinity to mono-ubiquitin with a Kd value of 65 μM, and the Arabidopsis Pru domain has only a weak affinity to 
ubiquitin chains (Husnjak et al., 2008; Fatimababy et al., 2010). Although the PfPru domain is highly 
homologous to the human Pru domain, several key residues that are important for mammalian Pru domains for 
binding ubiquitin have been non-conservatively substituted in the PfPru domain. These conserved residues in 
the human Pru domain include Phe76, Asp78, and Phe98, which are replaced by Thr60, Lys61, and Asn81 in the 
PfPru domain, respectively (Schreiner et al., 2008). It has been shown that individual mutations of these 
conserved residues in human Rpn13 drastically decreased the affinity of the human Pru domain to K48-linked 
polyubiquitin chains (Husnjak et al., 2008; Schreiner et al., 2008). Therefore, the inability of PfPru in binding 
ubiquitin chains might be attributed to the lack of several key residues that are essential for the Pru domain to 
bind ubiquitin. 
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Collectively, the current data clearly suggest divergent roles of the identified ubiquitin receptor domains in the 
recognition of ubiquitin substrates. Based on the binding affinity, a model of substrate recognition mediated by 
the ubiquitin receptors at the P. falciparum 26S proteasome was proposed (Figure 30). All identified ubiquitin 
receptor domains might be involved in receiving proteasomal substrates delivered by the UBL-UBA shuttle 
factors (mainly PfRad23 and PfDsk2). Considering the fact that the PfUIM2 domain appears to be highly 
conserved among Plasmodium species and has been shown to directly bind K-48 polyubiquitin chains, the 
PfUIM2 domain probably plays a major role in the direct recognition of polyubiquitinated substrates at the P. 
falciparum 26S proteasome. 
 
            
 
Figure 30. A proposed model of recognitions of polyubiquitinated substrates by the identified ubiquitin receptor 
domains in P. falciparum. The arrow heads indicate the possible recognition sites for polyubiquitin chains or UBL domains 
of substrate shuttle factors, the putative PfRad23 and PfDsk2. UBL: ubiquitin-like domain; Ub: ubiquitin; UIM: 
ubiquitin-interacting motif; Pru, pleckstrin-like receptor for ubiquitin. 
 
5.5 The P. falciparum 26S proteasome complex 
The notion of utilizing the binding affinity between UIM and UBL domains in the purification of 26S 
proteasomes have been approved by the purifications of mammalian 26S proteasomes from mouse muscle tissue 
and human embryonic kidney cells (Besche et al., 2009; Scanlon et al., 2009). Based on the affinity of PfUIM2 
domain to the UBL domain of PfRad23, here we successfully adopted the affinity purification method to isolate 
the P. falciparum 26S proteasome complex from the parasite cell extracts. The use of PfUIM2 was due to the 
fact that it was shown to have the strongest affinity to both UBL domains and ubiquitin chains. To our 
knowledge, before this work there was no purification method available to purify the P. falciparum 26S 
proteasome. Li et al. reported that they have partially enriched the P. falciparum proteasome by using an anion 
exchange chromatography coupled to a size-exclusion chromatography (Li et al., 2012). Another pull down 
assay using an anti-GFP (anti-green fluorescent protein) antibody has immunoprecipitated nearly 30 
proteasomal components associated with the GFP-tagged Rpn6 subunit from the P. falciparum whole extracts 
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(Muralidharan et al., 2011). However, such antibody-based purification methods require in vivo genetic 
modifications on a proteasomal subunit, which may have already perturbed the subunit associations (Wang et al., 
2007). In great contrast, our affinity-based purification method offers a simple and robust method to isolate the 
intact P. falciparum 26S complex together with many proteasome-interacting proteins. Additionally, in vivo 
formaldehyde cross-linking was included to stabilize the assembly of the whole 26S complex as well as weak 
and transient interactions of some interactors with the plasmodial proteasome. Indeed, the use of a cross-linking 
strategy significantly increased the peptide recovery of the plasmodial 20S subunits and the number of 
co-purified proteins, compared to our preliminary tests without cross-linking. 
The established purification method has allowed us to take the first insight into the integral composition of the P. 
falciparum 26S proteasome complex. The MS/MS analysis of the purified proteasome samples has revealed all 
putative subunits of the P. falciparum 26S proteasome. It is acknowledged that high throughput liquid 
chromatography-MS/MS data frequently suffer from a lack of reproducibility and identify very low abundant 
proteins. However, most of the P. falciparum proteasomal subunits were reproducibly and abundantly identified 
from four independent purifications, suggesting that they are indeed proteasomal components and were 
selectively co-purified within a complex. Interestingly, in the MS/MS analysis the number of observed peptides 
and sequence coverage for the plasmodial Rpn13 subunit appeared to be typically low, indicating a low 
abundance of Rpn13 among the co-purified proteasomal subunits. Consistently, similar results have been 
reported in several affinity purifications of 26S proteasomes from other organisms (Besche et al., 2009; 
Bousquet-Dubouch et al., 2009; Scanlon et al., 2009). These results are reminiscent of a recent finding that only 
one Rpn13 copy is present in a double-capped eukaryotic 26S proteasome, meaning a non-stoichiometric 
occupancy of Rpn13 in the majority of the 26S proteasome population (Berko et al., 2014). This could be a 
reasonable explanation for the low abundance of Rpn13 observed in the purified proteasome samples. Therefore, 
our data not only support this notion but also highly suggest a similar asymmetric integrity in the P. falciparum 
26S proteasome. Besides, a plasmodial homolog of a proteasomal activator PA28 (in human PSMD10) was 
reproducibly identified, indicating its association with the plasmodial proteasome. In eukaryotes, three isoforms 
of PA28 subunits have been found. They form a heteroheptamer or hexamer complex that can attach to either 
one or both outer α-rings of the 20S CP, thus activating the peptidolytic activities of the 20S CP (Jung et al., 
2013; Tomko et al., 2013). Besides, hybrid proteasomes with one 19S RP and one PA28 complex at opposite 
ends of the 20S CP (19S-20S-PA28) have also been identified (Hendil et al., 1998; Tanahashi et al., 2000). 
Accordingly, PA28 has been observed to be co-purified in other affinity-based purifications of eukaryotic 
proteasomes (Besche et al., 2009; Scanlon et al., 2009). Although the role of the PA28 complex has not been 
studied in P. falciparum, the identification of plasmodial PA28 subunits suggests that 19S-20S-PA28 
proteasomes may exist in the parasites and that their role in the plasmodial 20S CP activation might be also 
conserved. 
Three major peptidolytic activities of eukaryotic proteasomes have been detected in the purified proteasome 
samples, indicating that our purification method is able to isolate plasmodial proteasomes in an active form. 
When compared to the reported values of proteasomal activities, the activities of the purified plasmodial 
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proteasome determined in the eluted fractions was generally lower, although the measured chymotrypsin-like 
activity was comparable to the one of 26S proteasomes purified from human erythrocytes (a product of Enzo 
Life Science, PW8720). However, it should be mentioned that the reported values of eukaryotic proteasomal 
activities vary significantly depending on the purification method and the assay components. Due to the 
existence of different forms of proteasomes in eukaryotes (e.g. free 20S proteasomes, single or double-capped 
26S proteasomes and hybrid proteasomes) and the inherently labile association between the 20S and the 19S 
subcomplexes (Tomko et al., 2013), different purification methods may result in a distinct composition of the 
isolated proteasomes. For example, conventional purifications of 20S proteasomes using multi-centrifugal 
procedures or affinity purifications via targeting the 20S subunits usually obtained a higher percentage of 20S 
proteasomes, which results in that the apparent proteasomal activities appear to be generally higher 
(Bousquet-Dubouch et al., 2009). In comparison, affinity purifications of 26S proteasomes via targeting to the 
19S subunits may result in a certain extent of loss of the 20S due to the reasons that a certain amount of 20S 
may not associate with the 19S or they dissociate from the 19S during the purification procedure. Furthermore, 
it has been shown that affinity purifications of eukaryotic 26S proteasomes usually co-purify a number of 
additional proteins (Besche et al., 2009; Scanlon et al., 2009; Tai et al., 2010), which will be taken into account 
when calculating the proteasomal activities in the elution fractions. Besides the factor of purification method, 
different assay components appear to significantly influence proteasomal activities. For example, in some 
studies the proteasomal activities were measured within a buffer containing a proteasome-activating agent 
(SDS), which we did not use in our assays (Shibatani et al., 1995; Scanlon et al., 2009). Therefore, low 
proteasomal activities observed in the purified plasmodial proteasome samples may be due to the 
aforementioned factors, or even due to the origin itself. 
 
5.6 Putative proteasome-interacting proteins (PIPs) in P. falciparum 
Apart from proteasomal components, the affinity purification method has concomitantly purified a number of 
plasmodial proteins, which could be candidates of PIPs for the P. falciparum 26S proteasome. Supporting this, 
the most abundantly identified proteins have predicted roles either in the UPS or related to protein metabolism 
processes. In addition, supportive evidence could be seen in purifications of eukaryotic proteasomes from other 
organisms, in which a large portion of the co-purified plasmodial proteins have counterparts that have been 
validated as PIPs or found to be co-purified with eukaryotic proteasomes. However, it is possible that some 
proteins were co-purified not via binding to the plasmodial proteasome but via binding to the UBL domain of 
PfRad23 and eluted together with the proteasome. Another possibility is that some co-purified proteins are 
ubiquitinated substrates that were captured when they transiently bound to the proteasome for degradation. 
However, ubiquitinated substrates are unlikely to contribute to the majority of the co-purified proteins, because 
they are supposed to be removed by the excess eluting protein, the PfUIM2 domain which has been proved to 
bind polyubiquitin chains efficiently. Of course, it cannot be ruled out that some ubiquitinated substrates that 
were not completely trapped by PfUIM2 were left and identified. 
 
Discussion 
76 
5.6.1 Putative PIPs in the plasmodial UPS system 
We noticed that several proteins belonging to the plasmodial UPS components were co-purified. This is in 
consistent with the results of other affinity purifications of eukaryotic proteasomes that UPS components are 
usually purified with the proteasome (Besche et al., 2009; Scanlon et al., 2009). Notably, the PfRad23 and 
PfDsk2 were identified, suggesting their interactions with the plasmodial proteasome and supporting the role of 
PfRad23 and PfDsk2 in transporting proteasomal substrates to the proteasome (Figure 30). Of greater 
significance, the affinity purification method has reproducibly co-purified two plasmodial deubiquitinases 
(DUBs), a deubiquinating/deneddylating enzyme, known as PfUCH54 (PFE1355c), and a putative ubiquitin 
carboxyl-terminal hydrolase (PF11_0177). The PfUCH54 has been characterized to be the plasmodial homolog 
of human Uch37, which is a validated proteasome-bound deubiquitinase (see Introduction) (Artavanis-Tsakonas 
et al., 2006). Structural analysis has revealed that Uch37 utilizes its C-terminal region to bind to a 
Uch37-binding motif at the C-terminus of Rpn13, therefore being associated with the 19S complex to perform 
its ubiquitin-trimming functions (Yao et al., 2006). Consistently, PfUCH54 was reported to preserve a 
C-terminus homologous to the one of Uch37 (Artavanis-Tsakonas et al., 2006). Furthermore, a putative 
C-terminal Uch37-binding motif could also be recognized in PfRpn13 based on sequence homology analysis 
(data not shown). Thus, it is most likely that the PfUCH54 associates with the plasmodial proteasome via 
binding to PfRpn13. Similar to the case of PfRpn13, a low abundance of the identified PfUCH54 was observed 
in the purified proteasome samples, which might be a supportive indication of the association between 
PfUCH54 and PfRpn13. Interestingly, different from its mammalian counterparts, PfUCH54 has been found to 
additionally have a deneddylating activity (Artavanis-Tsakonas et al., 2006). As there is limited information 
about the neddylation in the proteasomal degradation (Rabut et al., 2008), the significance of the deneddylating 
activity of PfUCH54 at the plasmodial proteasome remains unclear and is worth being further investigated. 
In contrast to PfUCH54, another putative ubiquitin carboxyl-terminal hydrolase with a predicted molecular 
weight of 70.7 kDa was among the most abundant co-purified proteins, strongly indicating its association with 
the plasmodial proteasome. Homology analysis of this protein strongly suggests that it is a plasmodial homolog 
of an important deubiquitinase known as Ubp6 in yeast or USP14 in human (unpublished work), and especially 
it has a putative N-terminal UBL domain, which is a key structural feature shared by Ubp6/USP14 homologs 
(Hu et al., 2005). Mechanistic studies have revealed that Upb6/USP14 docks at the 19S via its UBL domain, 
which in turn activates its ubiquitin-trimming activities (Hu et al., 2005). Thus, the co-purification of the 
plasmodial counterpart of Ubp6/USP14 highly suggests this uncharacterized protein is a proteasome-bound 
deubiquitinase in P. falciparum. 
Importantly, human Uch37 and USP14 can be specifically targeted by small-molecular-weight inhibitors (Lee et 
al., 2010; D'Arcy et al., 2011). It has been shown that the inhibition of these proteasome-bound DUBs can 
significantly affect proteasomal functions and may have promising therapeutic implications in cancer and 
neurodegenerative diseases (Hanna et al., 2006; Lee et al., 2010; D'Arcy et al., 2011). Consistently, in our 
preliminary tests, human Uch37/USP14 inhibitors have been shown to have potent antimalarial activities against 
intraerythrocytic stages of P. falciparum (data not shown). Further biochemical characterizations of these 
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plasmodial DUBs would be of great interest for developing Plasmodium-specific inhibitors, aiming to offer 
novel antimalarial strategies. 
 
5.6.2 Other putative PIPs 
Many co-purified plasmodial proteins with the plasmodial proteasome are not directly involved in the UPS 
pathway. Among the identified proteins are a number of abundant cellular proteins, such as heat shock proteins 
(HSPs), elongation factors, glycolytic enzymes, and ribosomal proteins. Due to the large quantity of these 
proteins present in cells, it is difficult to completely prevent their nonspecific purification. However, it should be 
emphasized that these proteins were significantly enriched in the GST-UBL-based affinity purifications but not 
in the GST-based mock purification, indicating they were selectively isolated via certain interactions either with 
the plasmodial proteasome or directly with the UBL domain of PfRad23. In good agreement with our results, 
affinity purifications of eukaryotic proteasomes from other organisms have co-isolated many homologs of the 
plasmodial proteins identified in our study (Wang et al., 2008; Besche et al., 2009; Bousquet-Dubouch et al., 
2009; Besche et al., 2012). Although the proteasomal network has hardly been explored in P. falciparum, 
knowledge on PIPs identified in higher eukaryotic organisms could help when interpreting the co-isolation of 
some plasmodial proteins with the plasmodial 26S proteasome. 
To date, extensive studies have shown that protein chaperones play important roles in modulating proteasomal 
functions. Several HSP70 members have been reported to be associated with the yeast 26S proteasome (Guerrero 
et al., 2006; Wang et al., 2008). Furthermore, in higher eukaryotes it has been shown that HSP70 members can 
facilitate the delivery of aggregation-prone substrates for proteasomal degradation by interacting with the 26S 
proteasome via adaptor proteins (Luders et al., 2000; Wiederkehr et al., 2002). Furthermore, HSP90 family 
members have been suggested to play roles in the proteasomal structural integrity and assembly through their 
interactions with eukaryotic 26S proteasomes (Imai et al., 2003). The identification of plasmodial HSP70/90 
members as abundant co-purified proteins suggests that the identified plasmodial HSPs may preserve such roles 
in Plasmodium. Besides heat shock proteins, two subunits of plasmodial T-complex protein 1 (TCP-1) were 
identified. In eukaryotes the TCP-1 complex is known as a heterooligomeric molecular chaperone that assists in 
folding some cytosolic proteins such as actin and tubulin (Valpuesta et al., 2002). In accordance with our results, 
co-purification of TCP-1 subunits in affinity purifications of human 26S proteasomes has been reported (Wang et 
al., 2008). Additionally, a study based on a comparative proteome analysis has confirmed a direct interaction of 
the TCP-1 complex with the 26S proteasome of goldfish (Horiguchi et al., 2006). 
Importantly, the plasmodial homolog of cell division cycle protein 48 (CDC48) was identified to be abundantly 
co-purified with the plasmodial 26S proteasome. It is well acknowledged that in eukaryotes the 26S proteasome 
has an important application in degrading aberrant and misfolded proteins from the ERAD pathway, in which 
CDC48 is a major player (Wolf et al., 2012). It is generally thought that CDC48 forms complexes with several 
cooperators to extract and shuttle aberrant proteins from the ER to the 26S proteasome for degradation, thus 
linking ERAD and UPS pathways (Wolf et al., 2012). In this regard, CDC48 has been known as a validated PIP 
and indeed has been abundantly co-purified in several affinity-based purifications of eukaryotic proteasomes 
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(Besche et al., 2009; Scanlon et al., 2009). Recently, it was found that eukaryotic CDC48 directly binds to the 
20S in the place of 19S to form a CDC48-20S complex (Barthelme et al., 2013). It is thus likely that hybrid 
CDC48-20S-19S proteasomes may exist and can be co-isolated with 26S proteasomes. Furthermore, direct 
association of CDC48 with the 60S ribosome has been reported to play a role in extracting aberrant nascent 
polypeptides for proteasomal degradation (Defenouillere et al., 2013). Thus, it is also possible that the 
identification of plasmodial CDC48 was partially due to its association with plasmodial 60S ribosomal subunits, 
which were also abundantly co-purified. 
In addition to CDC48, a number of co-purified proteins with predicted ER-retention sequences have been 
identified. Most of them have validated or predicted functions in protein folding and quality control. A human 
counterpart of the identified plasmodial α-chain subunit of nascent polypeptide associated complex has been 
reported to be a putative PIP (Bousquet-Dubouch et al., 2009). Together with our results, the findings have a 
strong indication that proteasomal functions are tightly correlated with protein folding and quality control at the 
ER in eukaryotes, including P. falciparum. Similarly, plasmodial elongation factors were found to be among the 
most abundantly co-purified proteins. This agrees well with several reports that eukaryotic elongation factors 
can interact with both ubiquitinated substrates and the proteasome, therefore mediating the proteasomal 
degradation of co-translationally damaged proteins (Gonen et al., 1996; Schmidt et al., 2005). Based on our 
results, we speculate on a similar role for the co-purified plasmodial elongation factors in linking the pathways 
of protein synthesis and degradation in P. falciparum. 
Some Plasmodium-specific proteins were co-purified, including merozoite surface protein 1 (MSP1) and several 
plasmepsins. Although they have been largely enriched in the GST-UBL-based purifications, there is currently 
no clue indicating their associations with the proteasome complex. As these plasmodial proteins were predicted 
to be potential ubiquitinylation targets and the in vivo polyubiquitination of plasmepsin II has been detected in P. 
falciparum, it is possible that these proteins may be proteasomal substrates that were trapped during the 
purification process (Ponts et al., 2011). 
In conclusion, in this work we successfully isolated, for the first time, the P. falciparum 26S proteasome 
together with a number of putative PIPs via a novel affinity-based purification method. The established method 
has been proved to be a simple and efficient tool that can be applied in further investigations on the structure and 
function of the P. falciparum 26S proteasome. More importantly, the co-purified putative PIPs may shed light on 
a profound network orchestrated by the plasmodial proteasome in malaria parasites. Further validations of the 
putative PIPs and investigations on their essentiality in the parasite growth would have great significance for 
providing novel antimalarial agents targeting the plasmodial UPS or related pathways. 
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Appendix Table 1. S-nitrosylated proteins identified in P. falciparum cell extracts 
No. 1Protein name 
PlasmoDB 
Accession No. 
Mol. 
mass 
(kDa) 
2Coverage % 3SNO site 
     Cellular redox homeostasis     
1 Peroxiredoxin 6 (Prx6) PF08_0131 25.2 12.7 / 30.5 / 14.1 K.CCILPSVDNADLPK.L 
2 Glutaredoxin 1 PFC0271c 12.4 21.6 / 36.9   
3 Glutathione peroxidase-like thioredoxin peroxidase PFL0595c 24 18.5 / 12.7   
4 Glutathione reductase PF14_0192 56.5 6.4 / 9.2 / 9.2   
5 Peroxiredoxin 1a (Prx1a) PF14_0368 21.8 15.4 / 15.4   
6 Thioredoxin, putative PF14_0545 11.7 37.5 / 37.5 / 37.5   
     Cytoskeleton     
7 Actin I PFL2215w 41.9 24.7 / 16.2 / 21.8   
8 Actin II PF14_0124 42.6 7.2 / 7.2 / 7.2   
9 Alpha tubulin 1 PFI0180w 50.3 6.0 / 9.3 / 11.0 R.CVFVDLEPTVVDEVR.T 
10 Profilin, putative PFI1565w 19 31.0 / 35.7 / 39.8   
11 Tubulin beta chain PF10_0084 49.8 20.2 / 14.4 / 17.5   
     DNA and RNA metabolism and processing     
12 Adenosine deaminase, putative PF10_0289 42.5 17.7 / 15.8 / 17.7   
13 AP endonuclease, putative PFC0250c 72.4 5.4 / 4.5 / 5.2   
14 ATP-dependent DNA helicase, putative PF13_0330 54.6 6.0 / 8.7   
15 ATP-dependent RNA helicase, putative PFC0955w 86.6 5.0 / 2.9   
16 ATP-dependent RNA helicase, putative PFI0860c 94.1 3.4 / 3.4 R.NTVSEECTYSTNER.T 
17 Carbamoyl phosphate synthetase PF13_0044 273.4 2.1 / 1.6 / 1.9 K.VTINNSNNSISNNENVETNLNCVSER.A 
18 Cytidine triphosphate synthetase PF14_0100 98.5 6.8 / 5.1   
19 DEAD box helicase PFB0445c 52.2 5.5 / 9.6   
20 DNA/RNA-binding protein Alba, putative PF08_0074 27.3 16.9 / 32.7 / 22.2 R.CGSTVITDQYVSGQDNSEHVVQEK.T 
21 DNA/RNA-binding protein Alba, putative PF10_0063 12 43.0 / 20.6 / 43.0   
22 DNA/RNA-binding protein Alba, putative MAL13P1.233 25 10.1 / 10.1    
23 GMP synthetase PF10_0123 63.9 6.5 / 6.5 / 6.5   
24 Histone H2A variant, putative PFC0920w 16.5 12.1 / 12.0   
25 Histone H3 PFF0510w 15.4 22.1 / 14.7 / 21.2   
26 Histone H4 PF11_0061 11.5 41.7 / 43.7 / 33.0   
27 Hypoxanthine phosphoribosyltransferase PF10_0121 26.4 15.2 / 20.8   
28 Inosine-5'-monophosphate dehydrogenase PFI1020c 56.2 6.7 / 6.1 / 10.6   
29 Lsm6 homolog, putative PF13_0142 8.8 35.1 / 35.1 / 33.8   
30 MIF4G domain containing protein PF11_0086 381.9 3.4 / 4.4 / 2.3 K.SIDALTENENNKNDAECSDSTTVK.N 
31 Minchromosome maintenance complex subunit PF13_0291 105.7 4.7 / 4.5   
32 Minchromosome maintenance complex subunit, putative PF07_0023 94.2 4.4 / 11.3 / 5.1   
33 Minchromosome maintenance complex subunit, putative PFE1345c 109.8 7.5 / 10.0 / 7.2   
34 Minchromosome maintenance complex subunit, putative PF13_0095 115.2 4.7 / 2.3 / 3.7   
35 Minchromosome maintenance complex subunit, putative PFL0580w 85.9 6.1 / 4.0   
36 Nucleoside diphosphate kinase PF13_0349 17 19.5 / 20.8   
37 Polyadenylate-binding protein, putative PFL1170w 97.2 11.8 / 18.9 / 12.2 K.FCFINYADAESAK.N 
38 Pre-mRNA splicing factor, putative PF10_0217 62.1 4.5 / 4.1   
39 Proliferating cell nuclear antigen PF13_0328 30.6 24.8 / 24.5 / 8.8   
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No. 1Protein name 
PlasmoDB 
Accession No. 
Mol. 
mass 
(kDa) 
2Coverage % 3SNO site 
40 Purine nucleoside phosphorylase PFE0660c 26.9 11.4 / 7.3 / 18   
41 Ribonucleoside-diphosphate reductase, large subunit PF14_0352 96.9 4.8 / 3.5   
42 RNA-binding protein, putative PF10_0068 29.5 19.1 / 19.1 / 23.6   
43 RNA-binding protein, putative PFI1435w 33.6 14.5 / 14.5 / 14.5   
44 RNA-binding protein, putative MAL8P1.40 32.4 16.1 / 14.3 / 9.8   
45 RNA-binding protein, putative PFI1175c 23 12.4 / 21.3 / 14.4   
46 RNA-binding protein, putative PF08_0086 117.1 4.2 / 5.3 / 2.7   
47 RNA-binding protein, putative PF10_0028-a 29.8 18.7 / 7.7   
48 RNA-binding protein, putative PF10_0028-b 30.1 18.5 / 7.7   
49 RNA-binding protein, putative PFF0250w 85.6 10.6 / 4.5   
50 RNA-binding protein musashi, putative PFI0820c 45.1 10.1 / 9.8 K.CNEAVASSPSTR.R 
51 rRNA-associated RNA-binding protein, putative PF13_0315 57.1 17.1 / 11.0 / 10.6   
52 SNF2 helicase, putative PFF1185w 315.6 1.7 / 2.1 / 1.7   
53 Splicing factor, putative MAL13P1.120 100.9 5.0 / 5.3   
     Glycolysis     
54 6-Phosphofructokinase PFI0755c 159.5 2.8 / 4.5 / 6.3 K.SLGCMSELQTSR.L 
55 Enolase PF10_0155 48.7 43.3 / 25.6 / 31.2   
56 Fructose-bisphosphate aldolase PF14_0425 40.1 31.7 / 29.3 / 22.5   
57 Glucose-6-phosphate isomerase PF14_0341 67.4 9.3 / 9.3 / 7.3   
58 Glyceraldehyde-3-phosphate dehydrogenase PF14_0598 36.6 38.3 / 41.8 / 48.4   
59 Hexokinase PFF1155w 55.3 8.5 / 7.1 / 15.6   
60 L-Lactate dehydrogenase PF13_0141 34.1 27.2 / 34.2 / 32.3   
61 Phosphoglycerate kinase PFI1105w 45.4 45.7 / 49.8 / 56.2   
62 Phosphoglycerate mutase, putative PF11_0208 28.8 18.0 / 21.6 / 30.0   
63 Pyruvate kinase PFF1300w 55.7 27.2 / 22.5 / 27.8   
64 Triosephosphate isomerase PF14_0378 27.9 15.3 / 17.3 / 27.0   
     Methionine and polyamine metabolism     
65 Adenosylhomocysteinase,S-adenosyl-L-homocysteine hydrolase PFE1050w 53.8 14.8/ 14.0 / 20.7   
66 Ornithine aminotransferase PFF0435w 46.1 32.1 / 23.4 / 29.5   
67 S-Adenosylmethionine decarboxylase/ornithine decarboxylase PF10_0322 168.2 1.8 / 2.3 R.GTYEDTGMVNCVDVIYK.N 
68 S-Adenosylmethionine synthetase PFI1090w 44.8 26.6 / 27.4 / 24.9 K.VSIDEQSPDIAQCVHENR.S 
     Mitosis     
69 Centrin-1 PFA0345w-a 16.4 32.6 / 32.6 / 32.6   
70 Centrin-1 PFA0345w-b 19.6 27.4 / 27.4 / 27.4    
71 Centrin-2 PF14_0443 19.3 43.5 / 24.4 / 20.2   
72 Centrin-3 PF10_0271 20.9 16.8 / 16.8   
     Nucleosome assembly     
73 Chromatin assembly factor 1 protein WD40 domain, putative PFA0520c 50.7 7.8 / 10.8 / 10.8   
74 Chromatin assembly protein (ASF1), putative PFL1180w 31.5 9.5 / 12.1 / 8.4   
75 Chromodomain-helicase-DNA-binding protein 1 homolog, putative PF10_0232 381.3 1.7 / 2.4 / 0.9   
76 Nucleosome assembly protein PFI0930c 31.8 32.3 / 32.3 / 32.3   
77 Nucleosome assembly protein PFL0185c 40.5 6.3 / 6.1   
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No. 1Protein name 
PlasmoDB 
Accession No. 
Mol. 
mass 
(kDa) 
2Coverage % 3SNO site 
Pathogenesis / Evasion / Protein export / Antigen     
78 Antigen 332, DBL-like protein PF11_0506 689.3 11.1 / 10.4 / 8.9   
79 Asparagine-rich antigen PF08_0060 254.8 3.5 / 2.6 / 2.9   
80 Asparagine-rich antigen PF11_0111 173.9 2.2 / 2.2 / 3.7   
81 Early transcribed membrane protein 5 PFE1590w 19 13.3 / 21.0 / 13.3    
82 High molecular weight rhoptry protein 2 PFI1445w 162.7 4.5 / 2.8   
83 High molecular weight rhoptry protein 3 PFI0265c 104.9 5.7 / 7.5 / 7.2   
84 Liver stage antigen 3 PFB0915w 175.7 3.3 / 2.4 / 2.4   
85 Macrophage migration inhibitory factor PFL1420w 12.8 29.3 / 42.2 / 52.6   
86 Mature parasite-infected erythrocyte surface antigen PFE0040c 168.3 19.3 / 16.9 / 15.6   
87 Merozoite capping protein 1 PF10_0268 43.9 10.4 / 24.9 / 18.1   
88 Merozoite surface protein 1 PFI1475w 195.7 14.1 / 12.7 / 10.9   
89 Plasmodium-exported protein (PHISTb) PFL0050c 77.1 5.2 / 5.7 / 5.7   
90 Plasmodium-exported protein (PHISTb) PFE1600w 60.2 4.9 / 4.9 / 4.9   
91 Rhoptry protein, putative PF14_0637 169.3 4.7 / 3.8 / 4.4   
92 Rhoptry-associated membrane antigen MAL7P1.208 103.6 2.0 / 3.5   
93 Rhoptry-associated protein 1 PF14_0102 90.1 8.2 / 5.8 / 4.2   
94 Surface protein, Pf113 PF14_0201 112.6 5.9 / 5.8   
95 Translocon component PTEX150 PF14_0344 112.4 8.2 / 5.9 / 5.9   
     Pentose-phosphate shunt     
96 6-Phosphogluconate dehydrogenase, putative PF14_0520 53 6.6 / 8.8 / 9.8   
97 Glucose-6-phosphate dehydrogenase-6-hosphogluconolactonase PF14_0511 107 4.8 / 3.2 / 3.2   
98 Transketolase PFF0530w 75.8 3.9 / 3.9   
     Protein folding     
99 10 kD chaperonin PFL0740c 11.2 52.4 / 52.4 / 32   
100 Activator of Hsp90 ATPase, putative PFC0270w 41.6 6.6 / 6.0   
101 Co-chaperone GrpE, putative PF11_0258 35 20.3 / 32.9 / 26.9   
102 Cochaperonin PF13_0180 29.1 53.5 / 40.3 / 45.7 K.FSPFSNESCEFTYQNAK.Y 
103 Cyclophilin, putative PFE1430c 23.2 16.2 / 16.2   
104 DnaJ protein, putative PF14_0700 52.5 28.2 / 31.1 / 30.8 R.NQEEGSTNCSNVVEEEMTLEK.C 
105 DnaJ protein, putative PF13_0036 38.9 10.6 / 12.4   
106 Endoplasmin homolog precursor, putative PFL1070c 95 24.2 / 15.6 / 22.8   
107 FK506-binding protein (FKBP)-type peptidyl-propyl isomerase PFL2275c 34.8 11.2 / 7.9   
108 Heat shock protein 40, putative PFB0595w 37.4 11.3 / 7.3 / 18.3   
109 Heat shock protein 60 PF10_0153 62.6 23.8 / 34.3 / 27.4   
110 Heat shock protein 70 PFI0875w 72.4 49.5 / 46.9 / 50.0   
111 Heat shock protein 70 PF08_0054 73.9 33.4 / 33.4 / 41.2   
112 Heat shock protein 70 PF11_0351 73.3 33.3 / 33.3 / 34.7   
113 Heat shock protein 70, putative MAL13P1.540 108.2 8.0 / 7.2 / 6.4   
114 Heat shock protein 90 PF07_0029 86.2 32.6 / 36.1 / 39.6   
115 Heat shock protein 90, putative PF11_0188 108.5 7.3 / 6.6 / 4.5   
116 Heat shock protein 90, putative PF14_0417 107 3.3 / 5.4   
117 Hsp70 interacting protein, putative PFE1370w 51.1 8.7 / 12.4 / 15.5 R.DCTEALNLNIDSANAYK.V 
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PlasmoDB 
Accession No. 
Mol. 
mass 
(kDa) 
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118 Hsp70/Hsp90 organizing protein, putative PF14_0324 66.1 16.7 / 15.1 / 12.1   
119 Nascent polypeptide associated complex alpha chain, putative PFF1050w 20.6 56.0 / 56.0 / 57.1   
120 Peptidyl-prolyl cis-trans isomerase PFC0975c 19 11.1 / 19.3 / 19.9  K.RSVVITDCGEL. 
121 Peptidyl-prolyl cis-trans isomerase,cyclophilin PF11_0164 21.7 27.7 / 27.7 / 34.4   
122 Prefoldin subunit 2, putative PF14_0167 16.7 38.8 / 46.9 / 55.8   
123 Prefoldin subunit, putative PFE0595w 13.7 38.7 / 47.9 / 39.5   
124 Prefoldin subunit, putative PFI0220w 15.3 22.5 / 32.6   
125 Protein disulfide isomerase MAL8P1.17 55.5 27.3 / 23.8 / 27.3   
126 Small heat shock protein, putative PF13_0021 25.2 23.2 / 23.7 / 14.2   
127 T-complex protein 1 epsilon subunit, putative PFC0900w 59.2 8.4 / 10.1 / 6.2   
128 T-complex protein beta subunit, putative PFC0285c 59.1 13.7 / 25.0 / 11.7   
129 TCP-1/cpn60 chaperonin family, putative MAL13P1.283 58 14.4 / 12.5 / 13   
130 TCP-1/cpn60 chaperonin family, putative PF11_0331 60.3 7.9 / 8.5   
131 TCP-1/cpn60 chaperonin family, putative PFC0350c 59.6 4.6 / 6.9   
132 Tubulin-specific chaperone a, putative PFA0460c 19.6 13.9 / 13.9   
     Proteolysis / hemoglobin degradation     
133 Aminopeptidase P PF14_0517 88.5 15.7 / 10.3 / 11.4   
134 Dipeptidyl aminopeptidase 1 (DPAP1) PF11_0174 80.4 20.0 / 17.6 / 20.9 K.TSPNLTTCGSSQPNK.N 
135 Cysteine proteinase falcipain 2a PF11_0165 55.9 10.5 / 14.9 / 14.7   
136 Cysteine proteinase falcipain 2b PF11_0161 55.8 10.6 / 14.9 / 14.7 K.LITLSEQELVDCSFK.N 
137 Cysteine proteinase falcipain 3 PF11_0162 56.7 4.9 / 8.1   
138 Falcilysin PF13_0322 138.9 5.8 / 4.0 / 5.2   
139 Falstatin PFI0580c 47 8.0 / 8.0   
140 Insulinase, putative PF11_0189 173.6 1.9 / 1.9   
141 M17 leucyl aminopeptidase PF14_0439 67.8 9.8 / 12.2 / 10.2   
142 M1-family alanyl aminopeptidase MAL13P1.56 126.1 12.4 / 9.9 / 12.1   
143 Plasmepsin II PF14_0077 51.5 8.4 / 5.5    
144 Plasmepsin III,histo-aspartic protease PF14_0078 51.7 10.4 / 4.7 / 8.0   
145 Plasmepsin IV PF14_0075 51 13.6 / 11.1 / 7.6   
146 Serine repeat antigen 5 PFB0340c 111.8 14.3 / 18.3 / 17.5   
     Protein transport     
147 Adapter-related protein, putative PFI0200c 161.4 2.1 / 2.4    
148 Endoplasmic reticulum-resident calcium binding protein PF11_0098 39.4 47.5 / 24.2 / 40.2   
149 GTP-binding nuclear protein ran/tc4 PF11_0183 24.9 33.2 / 33.2 / 44.4   
150 Karyopherin alpha PF08_0087 61.2 9.7 / 7.9 / 5.5   
151 Karyopherin beta PFE1195w 127.4 5.7 / 9.5 / 4.1   
152 Rab GTPase 18 PF08_0110 23.2 12.9 / 12.9   
153 Rab GTPase 7 PFI0155c 23.8 23.3 / 17.0   
154 Ran binding protein 1, putative PFD0950w 33.2 22.9 / 32.5 / 28.2 K.VVANHYIYPNESYCK.L 
     Protein post-translational modification     
155 cAMP-dependent protein kinase regulatory subunit PFL1110c 50.8 6.1 / 10.7 / 10.7   
156 Dolichyl-phosphate-mannose protein mannosyltransferase PF10_0104 25.7 20.2 / 21.1   
157 Protein kinase, putative PFI1280c 367 1.1 / 1.0   
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158 Protein phosphatase 2c PF11_0396 105.4 25.1 / 18.0 / 18.0   
159 Serine/threonine protein kinase, FIKK family MAL8P1.203 171.8 4.9 / 2.0 / 4.0   
160 Serine/threonine protein phosphatase MAL13P1.274 76.9 4.4 / 4.4   
     Signal transduction     
161 14-3-3 protein, putative MAL8P1.69 30.2 48.9 / 34.7 / 50.8 K.EASNCAQEAYQK.A 
162 Calmodulin PF14_0323 16.9 27.5 / 48.3 / 44.3   
163 GTP binding protein, putative MAL7P1.122 45.2 9.9 / 9.4 / 9.9   
164 Parasitophorous vacuolar protein 1 PF11_0302 52 12.2 / 17.0   
165 Phosphoinositide-binding protein, Putative PF07_0017 118.8 8.8 / 8.7 / 3.8   
     Transcription     
166 Basic transcription factor 3b, putative PF14_0241 19.4 23.4 / 18.1   
167 High mobility group protein MAL8P1.72 11.5 38.4 / 38.4 / 24.2   
168 Histone acetyltransferase GCN5 PF08_0034 170.9 2.3 / 2.9 / 1.8   
169 Minchromosome maintenance (MCM) complex subunit PF14_0177 111.5 3.6 / 6.2 / 8.1   
170 Transcription factor with AP2 domain(s), putative PFL1900w 299.4 4.6 / 3.3 / 5.2 K.NEEVNYIINEVDSSNDCK.N 
171 Transcription factor with AP2 domain(s), putative PF10_0075 182.7 4.9 / 4.6 / 4.5   
172 Transcription factor with AP2 domain(s), putative PFF0670w 485.6 2.5 / 1.3 / 1.4   
173 Transcriptional coactivator ADA2 PF10_0143 300.3 1.2 / 1.9 K.INENECTSNDIEEDIK.S 
174 Transcriptional regulator, putative PFE0870w 132.7 4.1 / 4.1 / 4.1   
     Translation     
175 40S ribosomal protein S12, putative PFC0295c 15.4 43.3 / 21.3 / 29.1 K.LITTLCAEK.N 
176 40S ribosomal protein S16, putative PF08_0076 16.3 16.0 / 16.0   
177 40S ribosomal protein S21e, putative PF11_0454 9.1 50.0 / 50.0 / 50.0   
178 40S ribosomal protein S2B, putative PF10_0264 29.9 17.5 / 9.9 / 21.3   
179 40S ribosomal protein S8e, putative PF14_0083 25.1 25.7 / 18.8 / 18.8   
180 60S acidic ribosomal protein P2, putative PFC0400w 11.9 36.6 / 36.6 / 57.1   
181 60S ribosomal protein L12, putative PFE0850c 18.1 20.6 / 28.5 / 26.1   
182 60S ribosomal protein L40/UBI, putative PF13_0346 14.6 29.7 / 29.7 / 29.7   
183 60S ribosomal protein P0 PF11_0313 35 19.9 / 19.6 / 16.1   
184 Cysteinyl-tRNA synthetase, putative PF10_0149 79.5 3.5 / 3.5   
185 Elongation factor 1 (EF-1), putative PFC0870w 17.7 12.8 / 26.3   
186 Elongation factor 1-alpha PF13_0305 49 31.2 / 35.9 / 28.4   
187 Elongation factor 1-beta PFI0645w 32 16.7 / 27.5 / 22.8   
188 Elongation factor 1-gamma, putative PF13_0214 47.8 5.8 / 6.3 / 9.0   
189 Elongation factor 2 PF14_0486 93.5 11.4 / 15.4 / 13.2 R.ETVTEESTITCLGK.S 
190 Eukaryotic initiation factor 5a, putative PFL0210c 17.6 32.3 / 19.9 / 38.5 K.SVLVSVLSACGQEK.I 
K.YEDICPTSHNMDVPVVK.R  
191 Eukaryotic translation initiation factor 2 gamma subunit putative PF14_0104 51.2 4.9 / 4.9   
192 Eukaryotic translation initiation factor 3 subunit, putative MAL7P1.81 37.3 7.6 / 7.6   
193 Eukaryotic translation initiation factor 3 subunit 7, putative PF10_0077 63.1 6.4 / 6.4 / 6.4   
194 Eukaryotic translation initiation factor 3 subunit 8, putative PFL0310c 116 5.1 / 3.9   
195 Eukaryotic translation initiation factor, putative MAL8P1.83 31 16.9 / 19.2   
196 Glutamate-tRNA ligase, putative PF13_0257 101.4 4.4 / 3.1 / 4.2   
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197 Glycine-tRNA ligase, putative PF14_0198 104.3 3.1 / 2.8 / 4.4    
198 Helicase 45 PF14_0655 45.3 13.1 / 26.6 / 29.9   
199 Isoleucine-tRNA ligase, putative PF13_0179 151.3 3.5 / 2.3 / 2.4   
200 Leucyl-tRNA synthase PFF1095w 170.2 2.8 / 4.8 / 3.4   
201 Lysine-tRNA ligase, putative PF13_0262 67.6 10.3 / 7.2 / 10.3   
202 Methionine-tRNA ligase, putative PF10_0340 104.2 7.4 / 5.1 / 8.9   
203 Phenylalanyl-tRNA synthetase beta chain, putative PF11_0051 72.5 7.7 / 4.2   
204 Seryl-tRNA synthetase, putative PF07_0073 62.5 5.6 / 7.1   
205 Translation initiation factor IF-2, putative PFF0345w 112.4 4.7 / 1.8 / 3.3   
206 tRNA binding protein, putative PF14_0401 46.4 5.7 / 9.2   
     Ubiquitin-dependent protein catabolic process     
207 26S proteasome AAA-ATPase subunit RPT3, putative PFD0665c 44.7 10.7 / 7.9   
208 26S proteasome regulatory subunit 4, putative PF10_0081 49.8 8.0 / 11.8   
209 26S proteasome regulatory subunit 6a, putative PF11_0314 49.5 8.2 / 17.5 R.ACASQTNATFLK.L 
210 26S proteasome regulatory subunit, putative PF14_0632 132.8 1.2 / 2.5   
211 Cell division cycle protein 48 homologue, putative PFF0940c 92.4 24.9 / 20.0 / 23.2 K.TAGFSGADLAELCQR.A 
212 DNA repair protein RAD23, putative PF10_0114 44.4 36.8 / 20.6 / 23.1 K.ESIDNICAMGFEK.E 
213 Polyubiquitin PFL0585w 42.8 10.1 / 10.1 / 10.1   
214 Proteasome regulatory protein, putative PFC0785c 26.5 15.6 / 22.2   
215 Proteasome regulatory subunit, putative MAL13P1.343 35.2 8.0 / 11.3   
216 Proteasome subunit alpha type 2, putative PFF0420c 26.5 20.4 / 20.4 / 15.7   
217 Proteasome subunit alpha type 5, putative PF08_0109 55.1 8.7 / 5.8 / 5.8   
218 Proteasome subunit alpha type 5, putative PF07_0112 28.4 19.9 / 15.2   
219 Proteasome subunit beta type 1, putative PFE0915c 27.3 18.3 / 11.2 / 11.2   
220 Proteasome subunit, putative MAL13P1.270 27.2 15.4 / 15.4 / 11.2   
221 Proteasome subunit alpha type 1, putative PF14_0716 28.8 30.7 / 17.3 / 11.4   
222 Skp1 family protein, putative MAL13P1.337 18.8 17.3 / 17.3 / 17.3   
223 Small ubiquitin-related modifier, putative PFE0285c 11.1 21.0 / 19.0    
224 Ubiquitin carboxyl-terminal hydrolase a, putative PFD0680c 98.5 3.2 / 3.2 / 5.2    
225 Ubiquitin carboxyl-terminal hydrolase isozyme L3 PF14_0576 26.9 10.8 / 10.8   
226 Ubiquitin-conjugating enzyme 13, putative PFE1350c 17.4 25.0 / 25.0   
227 Ubiquitin-conjugating enzyme, putative PF13_0301 22.9 6.4 / 13.9   
228 Ubiquitin regulatory protein, putative MAL8P1.122 27.5 12.6 / 9.7   
229 Ubiquitin-specific protease, putative PFI0225w 207.6 2.5 / 1.8 / 1.8   
     Miscellaneous     
230 4-Methyl-5(B-hydroxyethyl)-thiazol monophosphate biosynthesis enzyme PFF1335c 20.3 20.1 / 13.8 / 21.7   
231 Acyl-CoA synthetase PFE1250w 76.9 5.9 / 5.2   
232 Adenylate kinase PF10_0086 27.6 37.6 / 26.0 / 26.4   
233 ATP synthase beta chain, mitochondrial precursor, putative PFL1725w 58.4 8.4 / 13.3 / 11.4   
234 Bifunctional dihydrofolate reductase-thymidylate synthase PFD0830w 71.7 5.9 / 5.9   
235 Bromodomain protein, putative PF10_0328 55.9 8.6 / 6.4   
236 Cg4 protein PF07_0033 100 14.8 / 14.2 / 17.9   
237 Clustered-asparagine-rich protein PFL1745c 51.5 4.9 / 4.5 / 9.7   
238 Coronin-binding protein, putative PFF1110c 91.1 4.1 / 4.7   
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239 Cytoplasmic translation machinery-associated protein, putative PFL2150c 39.7 8.1 / 10.7 / 14.9   
240 Cytosolic glyoxalase II PFD0311w 30.5 10.6 / 10.6   
241 Dihydrolipoamide acyltransferase, putative PFC0170c 51 10.3 / 15.0 / 17.0   
242 Ethanolamine kinase, putative PF11_0257 49.9 7.8 / 9.0   
243 Gamma-glutamylcysteine synthetase PFI0925w 124.5 3.3 / 2.8   
244 Glutamate dehydrogenase, putative PF08_0132 160.4 2.1 / 3.1   
245 Glycerol-3-phosphate dehydrogenase, putative PFL0780w 41.2 7.6 / 6.5   
246 Glycophorin binding protein PF10_0159 95.8 2.3 / 4.0    
247 Haloacid dehalogenase-like hydrolase, putative PF10_0325 32.8 9.4 / 12.5 / 9.4   
248 Mannose-6-phosphate isomerase, putative MAL8P1.156 117.7 3.9 / 2.7   
249 MORN repeat protein, putative PF10_0306 41.5 28.3 / 33.0 / 29.4   
250 MYND finger protein, putative PFF0105w 29.4 8.7 / 14.3 / 31.3 K.YVLISCDINNEIK.E  
R.ICSTEIYGDAFLSK.T  
251 Myo-inositol 1-phosphate synthase, putative PFE0585c 69.1 9.8 / 10.6 / 15.6   
252 NADP-specific glutamate dehydrogenase PF14_0164 52.5 11.9 / 18.9 / 9.4    
253 Nucleic acid binding protein, putative PF11_0332 31.7 8.8 / 8.8   
254 Phosphatase, putative PF14_0036 35.2 14.4 / 8.3   
255 Phosphatidylinositol-4-phosphate-5-kinase PFA0515w 200 3.1 / 2.0 / 2.1   
256 Phosphoethanolamine N-methyltransferase MAL13P1.214 31 51.1 / 42.5 / 38.3   
257 Pyrroline carboxylate reductase MAL13P1.284 28.4 16.8 / 17.9 / 17.9 K.YTVMNAVEAACEK.S 
258 QF122 antigen PF10_0115 131.6 3.3 / 5.4 / 5.3   
259 Receptor for activated c kinase PF08_0019 35.7 18.9 / 19.2 / 18.9   
260 Replication factor A-related protein, putative PFI0235w 56.2 9.3 / 7.2   
261 Serine hydroxymethyltransferase PFL1720w 49.8 13.8 / 9.3 / 12.4   
262 SNO glutamine amidotransferase family protein PFF1025c 33 16.6 / 9.3   
263 Translationally controlled tumor protein homolog, putative PFE0545c 20 21.6 / 21.6 / 26.9 K.DVFTNDEVCSDSYVQQDPFEVPEFR.E 
264 Vacuolar ATP synthase subunit a PF13_0065 68.6 11.0 / 6.9 / 12.8   
265 Vacuolar ATP synthase subunit b PFD0305c 55.8 11.7 / 19.2 / 14.6   
266 Vacuolar ATP synthase subunit g, putative PF13_0130 14.2 20.3 / 29.3/ 20.3   
267 Zinc finger protein, putative PF13_0313 70.3 7.3 / 4.9 / 4.6   
 
 
1 Proteins identified with at least two peptides from at least two independent experiments were considered S-nitrosylated proteins and listed here. Proteins enriched in the avidin pull-down assay due 
to any reason except S-nitrosylation were excluded by the control samples that omitted ascorbate treatment. 
2 Each value represents the percentage of sequence coverage in one of the three independently conducted experiments. For more detail, please refer to the main text. 
3 S-nitrosylation (SNO) sites were assigned by the characteristic mass shift (+415.20 Da) of the peptides observed in the MS/MS data due to irreversible S-biotinylation of cysteine residues (formerly 
S-nitrosylated), indicated by the biotinylation reagent (EZ-Link Iodoacetyl-PEG2-Biotin) used in our biotin switch assay. The SNO-targeted cysteine residues are highlighted. 
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Appendix Table 2.  S-nitrosylated hypothetical proteins identified in P. falciparum cell extracts 
 
No. 1PlasmoDB Accession 
No. 
Mol. mass 
(kDa) 
2Coverage % 3SNO site 
1 MAL8P1.95 36.3 15.2 / 15.2 / 22.5  
2 PF14_0257 33.0 32.7 / 34.2 / 41.6  
3 PF07_0087 29.3 12.7 / 18.4 / 18.4  
4 PFL0280c 39.0 7.2 / 17.1 / 12.9  
5 PF14_0390 26.3 19.4 / 19.4 / 19.4  
6 PFF0835w 53.0 8.1 / 8.3 / 12.1  
7 PF11_0218 184.9 9.3 / 9.2 / 9.6  
8 PF11_0069 30.7 21.4 / 25.2 / 21.4  
9 MAL13P1.237 42.2 18.5 / 17.2 / 18.5  
10 PF07_0042 350.7 0.9 / 3.7 / 2.3  
11 PFF0220w 334.4 3.5 / 2.2 / 3.4  
12 PF14_0329 28.9 15.9 / 21.0 / 16.7  
13 PFC0235w 135.7 10.4 / 8.9 / 6.5  
14 PF14_0046 34.7 22.2 / 16.5 / 23.5  
15 PFI1270w 24.7 12 / 16.1 / 16.1  
16 PFB0145c 237.7 1.3 / 2.3 / 1.3  
17 PFC0760c 403.0 0.9 / 2.0 / 1.4  
18 PFB0125c 158.8 4.6 / 5.1 / 3.3  
19 PF14_0487 176.2 1.8 / 6.1 / 4  
20 PF10_0361 192.7 1.8 / 4.2 / 3  
21 PF14_0228 183.6 3.0 / 3.9 / 4.0 K.NQTNDYSYAIAELDCR.Q 
22 MAL13P1.336 78.6 7.2 / 7.2 / 5.1  
23 PF07_0016 218.4 1.8 / 1.8 / 1.8  
24 PF14_0558 174.1 5.8 / 2.7 / 3.9  
25 MAL13P1.295 235.1 2.8 / 1.6 / 1.6  
26 PF11_0055 49.3 7.3 / 9.7 / 9.7  
27 PF08_0081 76.9 5.5 / 3.8  
28 PF14_0586 37.0 15.2 / 9.3  
29 PFI0705w 28.4 11.2 / 12.4  
30 MAL7P1.204 196.6 4.8 / 2.2  
31 PF11_0413 52.6 10.3 / 6.5  
32 PF13_0099 23.2 18.0 / 21.5  
33 PFE1485w 225.5 2.3 / 2.4  
34 PFF0325c 280.4 1.5 / 2.7  
35 PF10_0166 36.4 9.7 / 9.7  
36 PF14_0546 76.0 5.5 / 7.0  
37 MAL7P1.98 17.8 24.8 / 24.8  
38 PFE0500c 297.6 1.9 / 1.7  
39 PF14_0649 295.8 1.7 / 1.3  
40 PFL0350c 311.4 1.5 / 1.2  
41 MAL7P1.77 60.6 8.4 / 12.1  
42 PF07_0056 159.5 2.1 / 3.2  
43 MAL7P1.202 145.5 2.0 / 3.3  
44 PF14_0138 29.5 9.9 / 9.9  
45 PFF0575c 374.9 0.8 / 1.2  
46 PFL1930w 691.4 0.5 / 1.2  
47 PF14_0783 12.6 33.9 / 33.9 K.DGNELTLLTCDNAEIK.C 
48 PF13_0186 27.4 8.5 / 8.5  
49 PFL2355w 44.8 6.1 / 6.1  
50 PFL1815c 192.8 2.3 / 1.0 K.SNSECVQGQNMNEQNNEMVYNK.Q 
51 PF11_0206 208.6 2.3 / 2.3  
52 PF07_0101 260.8 1.2 / 1.4 K.YCVEDITLYEVQK.E 
  
1 Only those proteins identified with at least two peptides from at least two independent experiments were considered S-
nitrosylated proteins and listed here.  Proteins enriched in the avidin pull-down due to any reason than S-nitrosylation were 
excluded by subtracting the proteins identified in the control samples that did not receive ascorbate treatment.  
2 Each value represents the percentage of sequence coverage in one of the three independently conducted experiments. For 
more detail, please refer to the main text. 
3 S-nitrosylation (SNO) sites were assigned by the characteristic mass shift (415.20 Da) of the peptides due to irreversible S-
biotinylation of cysteine residues (formerly S-nitrosylated), indicated by the biotinylation reagent (EZ-Link Iodoacetyl-
PEG2-Biotin) used in our biotin switch approach. The identified SNO-targeted cysteine residues are highlighted. 
